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Abstract
Polymersomes are potentially multifunctional soft materials constructed by the selfassembly of amphiphilic block copolymers in aqueous medium. While much research has
focused on controlling the assembly and encapsulation properties of polymersomes, their
surface functionalization has been relatively unexplored. This is important because it
plays a critical role in determining their properties such as toxicity and biodistribution
behavior. The work described in this thesis involves the development of a biocompatible
and

biodegradable

polymersome

systems

based

on

poly(ethylene

oxide)-b-

polycaprolactone (PEO-PCL) block copolymers with azide surface groups as a novel
scaffold for various biomedical applications. The surface functionalization of these
polymersomes with polyester dendrons bearing alkyne focal points with different
peripheral groups, such as amines and guanidines, as well as a small molecule rhodamine
dye is accomplished and their conjugation yields are compared to each other. Moreover,
dendritic and non-dendritic polymersome-based MRI contrast agents, with the highest
currently reported longitudinal relaxivity for a polymersome system, are developed by
decorating PEO-PCL polymerosomes' surfaces with both non-dendritic and dendritic
Gd(III)-based contrast agents. In addition, PEO-PCL polymersomes were employed to
develop a multifunctional system with the potential to interfere with the viral infection
process at two levels. In addition to their use as materials for functionalizing the surfaces
of nanomaterials, dendrimers and their assemblies have been widely used as drug
delivery vehicles. In order to enable a new level of control over drug release, backbone
photodegradable dendrimers and dendrons are synthesized by incorporation of a
monomer unit based on o-nitrobenzyl esters and 2,2-bis(hydroxymethyl)propionic acid. It
is shown that these dendrimers undergo effective photolysis to release only small
molecules upon irradiation with UV light. Finally, these dendrons are incorporated into
amphiphilic Janus dendrimer structures and their self-assembly to dendrimersomes
followed by their photodegradation are discussed.
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Chapter 1
1 Biodegradable Polymersomes and Dendrimers in
Biomedical Applications*

1.1 Introduction to Macromolecules
The word macromolecule is a Greek-Latin hybrid word that contains two contradictory
terms. It refers to a small mass (Greek: molecula, diminutive of moles = mass) that is
large (Large: makros).1 Thus, they are simply large molecules. According to the
International Union of Pure and Applied Chemistry (IUPAC), a macromolecule is
defined as
"a molecule of high relative molecular mass, the structure of which essentially
comprises the multiple repetition of units derived, actually or conceptually, from
molecules of low relative molecular mass."
Macromolecules are either natural, such as proteins, DNA, and polysaccharides, or
synthetic, such as synthetic rubbers, fibers and dendrimers, with molecular weights
(MWs) of several thousands to millions. Humankind has used naturally occurring
macromolecules since the early days of civilization. For instance, proteins in meat and
polysaccharides in grain are essential constituents of food, and a high MW resin called
Amber was used in old Greece as jewelry. On the other hand, the first synthetic and
semisynthetic macromolecules, such as nitrocellulose in 1869, were prepared without any
insight to their chemical structure. It was not until 1920s when scientists began to obtain
knowledge about the structures of macromolecules, and soon after, fully synthetic
macromolecules such as polychloroprene, polystyrene, and nylon 6.6 were discovered
and commercialized.1

*

This chapter contains work that is press: Nazemi, A.; Gillies, E. R. “Dendrimer Bioconjugates: Synthesis
and Applications" in "Bioconjugates for Biomedical Applications” Narain, R. Ed., John Wiley and Sons,
Hoboken, New Jersey, In Press. Nazemi, A.; Gillies, E. R. Braz. J. Pharm. Sci. In Press. See CoAuthorship statement for specific contributions from each author.

2
Compared to traditional small molecules with single molar masses, synthetic
macromolecules display molar mass distributions. Among the different techniques
developed to measure these molar mass distributions,1 mass spectroscopy techniques
such as matrix-assisted laser desorption/ionization mass spectroscopy (MALDI-MS) and
size exclusion chromatography (SEC) have found widespread applications in chemistry
and materials science laboratories. Compared to mass spectroscopy, which is an absolute
method for molar mass determination, most SEC requires a correlation of the measured
properties of standards with molar masses that have been independently determined with
those of the sample. Because of the presence of the above-mentioned molar mass
distribution in most synthetic macromolecules, their molar mass is often calculated
around an average value. Depending on the statistical method that is applied to calculate
the average molar mass, different average values can be defined, among which number
average molar mass, Mn, and weight average molar mass, Mw, are most commonly used.
Mathematical expressions for Mn and Mw are shown in Figure 1.1. In these equations, Ni
is defined as the number of moles of each macromolecule species and Mi as the molar
mass of that species. Another term widely used in macromolecular science is
polydispersity index (PDI), which is calculated as Mw/Mn. PDI indicates the distribution
of individual molar masses in a batch of polymer sample. It has a value of greater than 1.
However, as the polymer chain lengths become more uniform, the PDI approaches 1.

Figure 1.1. Mathematical equations for Mw and Mn.
Among various natural and synthetic macromolecules, of particular interest to this
thesis are biodegradable polymers, block copolymers (BCPs), and dendritic architectures.
In the following sections, these families of macromolecules will be briefly introduced and
recent advancements in their self-assembly behaviors and their use in biomedical
applications will be highlighted.
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1.1.1 Biodegradable Polymers
During the past few decades, the field of synthetic polymers has progressed to such an
extent that synthetic polymers are essential in daily life. This mainly stems from their low
cost, reproducibility in production, and their resistance to physical aging.2 However,
when they are intended to be used for a limited period of time, such as in surgery,
pharmacology, or agriculture, such resistance becomes problematic. In all these timelimited applications, elimination of the artificial materials after use is desirable. For such
applications, biodegradable polymers have been emerged as an important class of
materials. These are defined as materials that can degrade by the action of living
organisms. Biodegradable polymers have found use in applications ranging from bulk
commercial materials such as biodegradable plastics to highly specialized drug delivery
vehicles. Mainly, they include polyesters such as polycaprolactone (PCL), poly(D/Llactic acid) (PDLLA), poly(L-lactic acid) (PLLA), and poly(glycolic acid) (PGA) (Figure
1.2). In addition to these commonly used biodegradable polymers, other backbones such
as

polyamides,

polyanhydrides,

polyphosphazenes,

polydisulfides,

polyacetals,

poly(ortho ester)s, and other polyesters derived from diacids and diols have been used as
biodegradable polymers. These biodegradable polymers have found widespread
biomedical applications in materials such as stents and sutures,3 tissue engineering,4-9 and
drug delivery vehicles.10,11

Figure 1.2. Chemical structures of the most common polyesters.

1.1.2 Block Copolymers
BCPs are macromolecules containing two or more chemically distinct homopolymer
blocks that are linked together. As shown in Figure 1.3, BCPs can be classified into a
number of architecturally different categories. Linear BCPs contain two or more polymer
chains in sequence. On the other hand, a star BCP is composed of more than two linear
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BCPs attached at a common branch point. Architecturally similar to star BCPs, when
polymers containing at least three homopolymers are attached at a common branching
point, are called mixed-arm star BCPs.

Figure 1.3. Representation of various BCP architectures.
BCPs exhibit many interesting properties, one of which is their ability to phase
separate both in thin films and in solution. This property stems from the inherent
immiscibility of the chemically different polymer blocks. As a consequence of phase
separation, BCPs form nanoscopic patterns in thin films,12 while self-assembling into a
wide range of morphologies in solution.13 To better control these processes, BCPs with
well-defined structures, specific chain lengths, and low PDIs are required. A great deal of
control over these parameters has been achieved by the development of various living
polymerization techniques including certain classes of ionic polymerization,14-16 atomtransfer radical polymerization (ATRP),17,18 reversible addition-fragmentation chaintransfer polymerization (RAFT),19 nitroxide-mediated polymerization,20 and ring-opening
metathesis polymerization (ROMP). 21,22 These advanced techniques allow for the precise
tailoring of BCPs architecture and composition.

1.1.3 Block Copolymer Self-Assembly in Solution
As described above, one of interesting properties of BCPs is their ability to undergo selfassembly in solution as a result of the inherent immiscibility of the polymer blocks.
Amphiphilic BCPs are composed of both hydrophilic and hydrophobic polymer blocks.
In aqueous solution, well-defined amphiphilic BCPs undergo self-assembly in order to
minimize energetically unfavorable hydrophobe–water interactions.13 The resulting
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morphologies obtained from self-assembly include spherical micelles,23 helical rods,24
toroids,25 vesicles,26,27 macroscopic tubes,28 and multicompartment cylinders.29 These
morphologies are a result of the inherent molecular curvature of the BCPs.30 More
specifically, for an amphiphilic diBCP suspended in aqueous solution it's been shown that
the resulting self-assembled morphology is dictated by the hydrophilic volume fraction of
the BCP (fhydrophilic).31 In aqueous medium, polymers with fhydrophilic between 20 % and 42
% are expected to form vesicles. BCPs with fhydrophilic between 42 % and 50 % are
expected to form worm-like assemblies while ones with fhydrophilic > 50 % are expected to
form spherical micelles.
Two morphologies that have been extensively studied are polymeric micelles and
vesicles. In micelles (Figure 1.4a), the hydrophobic portions of the BCP aggregate with
each other to avoid contact with water, while the hydrophilic portions are directed
towards water. When compared to micelles formed by surfactants, micelles formed by
BCPs show significant improvements in their thermodynamic stability with a lower
critical micelle concentration.32 The diameters of polymeric micelles typically fall in the
range of 10-100 nm.33 In addition to polymeric micelles, another morphology that has
received great interest in recent years is BCP vesicles, often called “polymersomes”
(Figure 1.4b).

Figure 1.4. Cartoon representation of a) polymer micelles, b) polymersomes.
Polymersomes are morphologies with membranes that resemble those of liposomes,
vesicles obtained from phospholipids. This self-assembled structure consists of
hydrophilic blocks directed towards the external and internal aqueous solution, and
hydrophobic blocks that repel water and thus form the interior of the membrane. In
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comparison with phospholipid vesicles, polymersomes have been shown to have several
improved properties. Based on the fact that the MWs of the polymers are usually several
times greater than those of phospholipids, polymersome membranes are thicker, which
results in higher stability and lower permeability than common phospholipid bilayers.34
In addition, chemical versatility of the BCP syntheses creates endless opportunities to
tune the polymersome properties. While micelles can only encapsulate hydrophobic
drugs in the core, polymersomes are capable of entrapping hydrophobic drugs within
their membrane as well as encapsulating hydrophilic species in their aqueous core.
Polymeric micelles and vesicles have been prepared by a variety of different methods.
The method of preparation often depends on solubility and other properties of the
constituent BCPs. The easiest method for the preparation BCP micelles and vesicles is
the direct dissolution of BCPs in water.34,35 In addition, film rehydration methods have
also been widely used for assembly formation.36,37 In this method, the BCP is first
dissolved in a volatile organic solvent. The solvent is then removed under a stream of air
or nitrogen. After subjecting to vacuum to remove most of the organic solvent, the
resulting film is hydrated by pure water or buffer solution. The assemblies are normally
formed upon stirring/sonication. In a method known as "solvent switch", "phase
inversion", or "nanoprecipitation", a solution of polymer in an organic solvent which is
miscible with water (such as ethanol or tetrahydrofuran) and is a good solvent for both
blocks, is diluted or injected into water or buffer solution. The organic solvent is then
normally removed by dialysis.38,39 Alternatively, these assemblies can be formed by oil in
water emulsion procedures.40,41 In this approach, the BCP is dissolved in a volatile
organic solvent that is immiscible with water, and this solution is then injected into a
rapidly stirring aqueous media. The organic solvent is then left to evaporate. Solvent-free
techniques such as electroformation have also been employed for the preparation of
assemblies.42

1.1.4 Other Macromolecular Architectures: Dendrimers
In addition to the above-mentioned polymers and BCPs, dendritic architectures including
hyperbranched polymers (HBPs) and dendrimers are another major class of
macromolecules. This class of macromolecules is characterized by their three-
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dimensional globular architecture. Structurally, HBPs are comprised of dendritic units,
linear units, and terminal groups (Figure 1.5a). An important characteristic of HBPs is
that these structural units are randomly distributed along their backbone.43 In other words,
they possess an irregular dendritic structure. Compared to HBPs with irregular structures,
and linear polymers and BCPs with molar weight distributions, dendrimers are
structurally perfect dendritic structures with a single or very narrow molar weight
distribution (Figure 1.5b). Dendrimers comprise three structural regions: a) a core, b)
layers of branching repeat units comprising the backbone, where each layer typically
results from one stage of growth and is termed a “generation”, and c) end groups on the
peripheral layer. Alternatively, when dendrimers are prepared from a monovalent core
moiety (focal point), a wedge-like structure typically called a “dendron” results (Figure
1.5c).

Figure 1.5. Schematics of a) a hyperbranched polymer; b) a dendrimer; c) a dendron.
The iterative synthesis of dendrimers can generally be categorized into two strategies,
the divergent approach and the convergent approach. In the divergent approach,44-48 the
dendrimer is grown outwards from the core by the repetition of coupling and activation
steps. This approach is the preferred one for the large scale preparation of dendrimers
because the quantity of dendrimer sample increases with each generation and the removal
of excess reagents by techniques such as precipitation, distillation, or ultrafiltration is
facilitated by their differences in mass. However, the exponentially increasing number of
coupling reactions required for each subsequent generation means that the number of side
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reactions or incomplete couplings also increases, ultimately leading to incomplete
branching and flawed structures that are nearly impossible to separate from the target
molecule.
In the convergent approach,49 growth initiates from what will become the dendrimer
periphery and progresses towards the core. When the desired generation is reached, the
resulting “dendrons” are coupled to a core molecule. As this approach only involves a
small number of coupling reactions at each generation, the molecules that result from
incomplete couplings can often be separated from the desired molecules as they are
sufficiently different in structure. This affords dendrimers with higher structural
homogeneity and monodispersity than the divergent approach. Nevertheless, the
couplings become increasingly challenging due to steric hindrance as the dendrons
approach higher generations. Furthermore, although the molar mass increases with each
generation, the excesses of dendrons used in the couplings, incomplete couplings and
losses associated with the purification generally result in a decrease in the overall mass of
material at each step, making this approach less attractive on a large or industrial scale.
Due to their iterative syntheses and highly branched structures, dendrimers and
dendrons possess several properties that are unique relative to traditional polymers. As
mentioned above, while most syntheses of linear and HBPs lead to a range of molecules
differing in MWs, the iterative syntheses of dendrimers leads to molecules with a single
or very narrow range of MWs. Furthermore, while linear or HBPs can theoretically be
grown infinitely, the growth of dendrimers is mathematically limited. This is due to the
exponential increase in the number of monomer units with each generation, while the
volume available for these units increases with the cube of the dendrimer radius. Finally,
one of the most important differences in the context of bioconjugate chemistry is that
while linear polymers have only two end groups, dendrimers have an exponentially
increasing number of end groups. This results in the properties of dendrimers being
dominated by these end groups at high generations, and also provides many sites for the
conjugation of functional moieties. Based on these unique properties, dendrimers and
dendrons have found widespread applications in biomedical research.50-53
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Over the past few decades, tremendous progress has been made in the optimization of
dendrimer syntheses and a diverse array of backbones are now readily accessible. Some
of the more commonly used backbones include the poly(amido amine) (PAMAM)
“Starburst” (Figure 1.6a), polyester (PE) dendrimers based on 2,2-bis(methylol)propionic
acid (Figure 1.6b), poly(propylene imine) (PPI) (Figure 1.6c), and poly(L-lysine) (PLL)
(Figure 1.6d).

Figure 1.6. Readily accessible dendrimer backbones: a) PAMAM; b) PE; c) PPI; d) PLL.
Many of these dendrimers are now available from commercial supplies.

10

1.1.5 Amphiphilic Janus Dendrimers and Their Assemblies
In addition to conventional dendrimers with uniform compositions as shown above, there
also exists a unique class of dendrimers known as "Janus dendrimers". These are
dendrimers with well-defined but asymmetric architectures of two chemically distinct
dendrons on opposite sides with different chemical compositions, peripheral groups, or
polarities. They are also known as surface-block dendrimers, diblock dendrimers,
codendrimers, diblock co-dendrimers, or bow-tie dendrimers.54
As shown in Figure 1.7, three main approaches have been proposed for the synthesis
of Janus dendrimers.54

Figure 1.7. Schematic representation of main methods for the synthesis of Janus
dendrimers.
In the simplest approach, two dendrons with complementary functional groups at their
focal points are reacted with each other to obtain the desired Janus dendrimer (Figure
1.7a). In the second method, one of the dendrons is first reacted with a multifunctional
core molecule and then the second dendron is grafted to the remaining functionality
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(Figure 1.7b). In the final approach, the focal point of one of the dendrons is used for the
divergent growth of the second dendron (Figure 1.7c). This method has not been found as
popular as the previous two approaches. It should be noted that as the purification of
macromolecules is often a difficult and tedious task to perform, highly efficient reactions
need to be employed for the synthesis of Janus dendrimers. Despite the difficulty in the
synthesis of Janus dendrimers compared to symmetrical dendrimers, Janus dendrimers
with various backbones such as benzyl ether, phenylene, phosphorous, PAMAM, 3,3'diaminobenzidine (DAB), lysine, ester, etc., have been synthesized via the abovementioned methods (Figure 1.8).54 The difficulties in their syntheses can certainly
account for the relatively limited number of examples of Janus dendrimers in comparison
to conventional symmetrical dendrimers.

Figure 1.8. Examples of Janus dendrimers based on a) ether/amide linkages; b) benzyl
ether and PAMAM dendrons.
Similar to amphiphilic BCPs, when constituents of Janus dendrimers are hydrophilic
and hydrophobic dendrons, they are called "amphiphilic Janus dendrimers (AJDs)". To
date, AJDs with a variety of dendritic backbones have been synthesized54 and their selfassembly behaviours have been studied, resulting in the formation of different
morphologies ranging from nano-aggregates55 to vesicles,56,57 multilamellar aggregates,57
button structures,58 and ribbons.59,60 More recently, Percec and coworkers have
synthesized a total number of 107 AJDs, with different backbones and generation
numbers, and screened their self-assembly behaviour in water.61,62 It was shown that such
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macromolecules were able to form structures including vesicles (named as
dendrimersomes), cubosomes, disks, tubular vesicles, and helical ribbons. The authors
concluded that dendrimersomes not only exhibit stability and mechanical strength of
polymersomes, but also have the advantages of superior size uniformity, ease of
formation, and chemical modification.61 A cartoon representation of a dendrimersome is
shown in Figure 1.9.

Figure 1.9. Schematic representation of a dendrimersome.
In a follow up study by the same group, it was observed that dendrimersome size and
stability were inversely proportional to the membrane thickness, meaning that
dendrimersomes with thinner membrane were larger and more stable. They attributed this
observation to the increased degree of interdigitation of the membrane-forming
hydrophobic dendron, which resulted in the shrinkage of the membrane thickness and its
higher stability.

1.2 Macromolecules for Biomedical Applications
For living cells to function, nature employs macromolecules and finds intelligent ways of
regulating their self-assembly behaviour to impart specific chemical and structural
functions. To mimic such systems, improve the biological functions of organs and
tissues, and cure diseases, researchers have prepared a wide range of synthetic
macromolecules with similar/improved features and established the field of
nanobiotechnology. Synthetic macromolecules, both in their molecular and selfassembled structures, have been the focus of intense research for a wide range of
biomedical applications during the past few decades.10,11,63-65 These include applications
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in tissue engineering,4-9 sutures,3 bone fixation devices and vascular grafts,66 drug
delivery systems,10,11,67,68 and diagnostics.69-71 In the following sections, recent advances
made in the biomedical applications of BCPs and their assemblies, and dendrimers will
be highlighted.

1.2.1 Block Copolymer Assemblies for Drug Delivery
Over the past several decades, many advances have been made in the development of
therapeutics to treat human diseases. However, many current drugs and new drug
candidates still suffer from significant limitations. For example, the low aqueous
solubilities of hydrophobic drugs are major obstacles for their administration. One of the
ways to overcome solubility problems is the use of excipients. However this can result in
undesirable side effects, such as when Cremophor EL or ethanol are used for the
solubilization of paclitaxel (TAX).72 An additional challenge encountered is the rapid
elimination of drug molecules from the blood stream, which limits their therapeutic
efficacy and increases the required dose. Moreover, many drugs exhibit a lack of
specificity for their therapeutic target. For example, many anti-cancer drugs not only
affect cancer cells but also kill non-cancerous and healthy cells causing severe side
effects. These challenges have motivated significant interest in the development of drug
delivery systems, where the incorporation of a drug into a polymeric system can enhance
its solubility, prolong its circulation time, and enhance its specificity for its target.
Among the various structures obtained by engineering BCP self assembly, which were
described earlier, polymeric micelles and vesicles are among the extensively investigated
systems. Therefore, the recent advances made in their applications as drug careers will be
discussed in this section.
There are several considerations that need to be taken to an account in the application
of self-assembled materials for in vivo drug delivery. Generally, delivery materials need
to avoid uptake by reticuloendothelial system (RES) and have prolonged circulation time
in the blood.73 One of the factors to control this property is the corona-forming
hydrophilic polymer block composition. A few examples of synthetic hydrophilic blocks
that have been used to achieve this property include poly(ethylene oxide) (PEO),74 poly
(acrylic acid),26 poly(acryloylmorpholine),75 poly(2-methyl-2-oxazoline) (PMOXA),76
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and polyvinylpyrrolidone.75 Although these hydrophilic blocks give so called "stealth"
properties to the assemblies, PEO has been found to be the most effective candidate due
to its excellent biocompatibility and minimal protein adsorption.75,77-79 In addition, the
size of the delivery vehicle also plays an important role in determining its circulation
time. It's been found that particles with diameters less than 200 nm can overcome the
clearance by RES.80 Furthermore, the lower size limit for the particles in order to avoid
renal clearance and thus rapid urinary excretion has been shown to be 5.5 nm.81 Particles
with diameters larger than 100 nm are found to accumulate mostly in liver and spleen.82
To minimize the side effects of drugs, it is preferable that drug delivery vehicles
selectively accumulate in the therapeutic sites. This is often achieved through selective
targeting. For cancerous tumors, there are two main targeting mechanisms, namely
passive and active targeting. Due to the tendency of tumor cells for rapid growth, it has
been shown that solid tumor tissues generally possess unusual characteristics such as
hypervasculature and incomplete vascular architecture which result in their leaky
behaviour.83 Because of these properties, tumor blood vessels show high permeability to
macromolecules and nano-sized particles.83 Additionally, because of the immature
lymphatic capillaries in cancer tissues, their lymphatic drainage system fails to operate as
in normal tissue.83 As a result, the uptaken nanoparticles are retained for prolonged
periods of time in tumor cells. This effect, known as the enhanced permeability and
retention (EPR) effect, is the basis for the passive tumor targeting by polymeric systems.
On the other hand, in active targeting, biologically specific interactions between the
diseased cells and the delivery vehicles are sought. This includes interactions such as
antigen-antibody binding. In this case, because of the overexpression of tumor-associated
antigens on tumor cells, specific antibodies that interact with those antigens can be
chosen and engineered onto the surface of the assembled materials.84 Other active
targeting mechanisms involving the binding of small molecules such as folate85 or
peptides such as RGD86 to receptors overexpressed in cancerous tissue have also been
explored.
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1.2.1.1

Polymeric Micelles for Drug Delivery

Polymeric micelles have been prepared using a wide range of BCP compositions.
Readers are referred to several comprehensive review articles published in this
context.11,83,87-89 With the advances made in this field, several BCP micellar drug delivery
systems have reached clinical trials. For instance, doxorubicin (DOX)-BCP micelles,
TAX-BCP micelles, and cisplatin BCP micelles are all in the Phase II of clinical trials. 88
It should be noted that hydrophobic drugs can either be physically entrapped within the
hydrophobic core of BCP micelles or chemically conjugated to the hydrophobic polymer
block and the drug release mechanism is mainly dependent on the type of encapsulation.
It has been proposed that in the case of covalently bound drug, bulk degradation of
polymer matrix or surface degradation is the main pathway of release, while for the
physically entrapped drug, diffusion plays the main role for drug release.83 Kataoka and
coworkers90 incorporated DOX at the core of BCP micelles composed of poly(ethylene
oxide-b-benzyl L-aspartate) by physical entrapment and showed that drug release occurs
very slowly from the micelles. In fact, it was found that even after 100 hours (h) only a
small percentage of the encapsulated DOX was released from the micelles. This was
suggestive of the stability of such micelle-drug complex. In an example of covalently
linked micelle-drug conjugate, Hruby and coworkers91 prepared micelle-DOX
bioconjugates via a pH-sensitive hydrazone linkage. In this study, poly(ethylene oxide-ballyl glycidyl ether) BCP was first functionalized with hydrazide groups by first reacting
the allyl side chains of the polymer with methyl sulfanylacetate and then treating the
resulting product with hydrazine hydrate. The resulting hydrazide groups of the polymer
were then reacted with the ketone moiety of DOX, to provide a hydrazone linkage and
yield a drug-containing BCP with approximately 3 wt.% drug loading. It was shown that
micelles formed from this BCP were able to release 43% of their drug upon incubation at
pH 5.0 for 24 h, while incubation at pH 7.4 resulted in 16% drug release. This illustrates
the importance of a labile linkage between drugs and micelles for the release of
covalently-constructed micelle-drug bioconjugates.
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1.2.1.2

Polymersomes for Drug Delivery

Unlike BCP micelles, owing to their aqueous core and hydrophobic membrane,
polymersomes can potentially be multifunctional. They are capable of encapsulating
hydrophilic drugs in their cores and entrapping hydrophobic species within their
membranes. Given the multifunctional capabilities of polymersomes and advances made
in the area of polymer synthesis, polymersomes composed of a wide range of BCPs have
been prepared and studied. These include polymer-polymer, polymer-polypeptide,
polymer-polysaccharide, and polypeptide-polysaccharide BCPs. Readers are referred to
several review articles published in this context for more details.30,79,92-95 Owing to their
aqueous core, they have not only been investigated as drug careers, but have also been
used as vehicles for proteins, DNA, and imaging agents. For the sake of space, only a few
examples of these systems will be discussed in this section.
Discher and coworkers have elegantly used polymersomes composed of a blend of
PEO-b-poly(lactic acid) and PEO-polybutadiene (PBD) to encapsulate both DOX and
TAX. In this system, DOX was loaded into the aqueous cores of the polymersomes while
TAX was entrapped within their hydrophobic membranes. The authors showed that when
used in vivo, this system demonstrated a higher maximum tolerated dose and increased
tumor shrinkage and maintenance compared to the case when both drugs were
administered as free drugs.96 In another example, Zhong and coworkers used a dually
responsive polymersome for protein delivery.97 Polymersomes were comprised of
poly(ethylene glycol)-S-S-poly(2-(diethyl amino)ethyl methacrylate) diBCP. In this BCP,
the poly(2-(diethyl amino)ethyl methacrylate block is the hydrophobic block that can be
protonated under mildly acidic conditions, resulting in disintegration of polymersomes.
Moreover, the disulfide bond ensures the responsiveness of polymersomes under
intracellular-mimicking reductive environments. This BCP self-assembled into
polymersomes of 55-67 nm, which were able to efficiently encapsulate proteins such as
bovine serum albumin (BSA) and cytochrome C. The authors showed that while protein
release was minimal at neutral pH and 37 °C, the release rate was significantly enhanced
at pH 6.0 due to disintegration of the polymersomes. Interestingly, it was found that the
fastest protein release occurred under intracellular-mimicking reductive environments (10
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mM dithiothreitol, pH 7.4). These polymersomes were able to efficiently deliver
cytochrome C protein to MCF-7 cells upon hours of incubation with the cells and induced
increased apoptosis of the cells. Thus, polymersomes are promising delivery vehicles for
future protein therapies, which currently suffer from delivery difficulties.
To demonstrate the potential of polymersomes for gene delivery, Li and coworkers98
synthesized poly[(n-butyl methacrylate)-b-(N-acryloylmorpholine)] amphiphilic BCPs,
self-assembled them into polymersomes, and used them for DNA delivery in gene
therapy. Compared to the traditional polyethylenimine as a DNA complexing agent,
these polymersomes exhibited improved plasmid DNA condensing efficiency, DNase I
degradation protection, and cellular uptake

by renal tubular epithelial and human

hepatocellular carcinoma cell lines. Moreover, compared to polyethylenimine, these
polymersomes were not cytotoxic and showed high serum stability, making them
promising candidates for DNA delivery. In addition to their use for drug delivery
purposes, polymersomes have also been employed for the encapsulation of various types
of imaging agents. Some examples include the encapsulation of near infrared (NIR)emissive porphyrin-based fluorophores,99 hydrophilic lanthanide complexes,100 and
membrane-entrapped superparamagnetic iron oxide nanoparticles.101

1.2.2 Dendrimers for Biomedical Applications
Whether prepared by a convergent or divergent approach, dendrimers are still much more
costly than conventional polymers. This means that over the longer term, the applications
of dendrimers will almost certainly be limited to high value added products. One area that
meets this criterion is biomedical materials, where the cost of a material is less important
than its performance. In addition, very well-defined materials are typically required by
regulatory agencies to approve their use in the human body. For this, the structural
homogeneity of dendrimers that results from their iterative syntheses is a distinct
advantage over other classes of synthetic macromolecules. As a result, the biomedical
applications of dendrimers are starting to be widely investigated. The following
subsections will discuss recent advances made in applications of dendrimers as drug
careers, imaging agents, and multivalent carbohydrate scaffolds (glycodendrimers). A
focus will be to explore how bioconjugation chemistry can be used to covalently attach
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biologically relevant molecules to dendrimers. It will explore how the specific
conjugation chemistries are determined based on the application, the chemical
functionalities available on the molecules of interest and those on the dendrimer’s focal
point or periphery.

1.2.2.1

Dendrimer-Drug Conjugates

Among the currently studied drug delivery systems, dendrimers have emerged as an
attractive class of materials, mainly because of their well-defined structures. In addition,
they possess many peripheral groups for drug conjugation and their nanoscale sizes can
lead to enhanced blood circulation times and selective accumulation in tumors via the
EPR effect.
As reviewed recently in the context of chemotherapeutics,51,52 drugs can be
incorporated into dendrimers either by covalent conjugation to the periphery or by
noncovalent encapsulation within the backbone of the dendrimer. Both classes of delivery
systems have been demonstrated to be more effective than the free drug in certain
laboratory studies and each approach is associated with its own advantages and
disadvantages. However, control over the drug:dendrimer ratio in a noncovalent system
can present challenges and noncovalently incorporated drugs are often released too
rapidly under physiological conditions. This has limited their in vivo efficacy thus far.
With the use of optimized chemical reactions, the covalent attachment of drugs to
dendrimers benefits from superior control over the ratio of drug:dendrimer in the
resulting conjugate. Moreover, the problem of the burst release observed for physically
entrapped drugs upon injection can be mitigated to a great extent by covalently attaching
drugs to dendrimers. In selecting the appropriate bioconjugation chemistry for dendrimerdrug conjugates, there are some important considerations. In order to achieve a controlled
release of the drug from a dendrimer-drug bioconjugate, the linker stability under various
physiological conditions is crucial. The lability of a given linker in a specific
microenvironment plays an important role in the specificity and the rate of drug release.
For example, to obtain selective and controlled release of drug in cancerous tissues or
within the endosomes and lysosomes of cells, which are known to be more acidic than
healthy tissues, an acid-labile linkage such as an ester or hydrazone can prove
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effective.102 In addition, the released drug derivative needs to be identical to, or as active
as the original drug in order to be effective.103
The review of various dendrimer-drug conjugates is out of the scope of this thesis. For
this purpose, readers are directed to several comprehensive reviews published in the
literature.52,104 Here, to illustrate the importance of the linkage type in pharmacological
behavior of drugs, one example will be discussed. In this example, Kono and coworkers
prepared PAMAM-DOX-PEO conjugates via both amide (Figure 1.10a) and hydrazone
(Figure 1.10b) linkages and observed that the conjugates containing hydrazone linkages
exhibited seven times higher cytotoxicity to HeLa cancer cells than the conjugates
containing amides. This result highlights the importance of the more labile hydrazone
linkage for the treatment of the cancerous cells. However, both conjugates showed lower
cytotoxicity to the same cell line when compared to free DOX.105

Figure 1.10. PAMAM-DOX conjugates with a) amide and b) hydrazone linkages

1.2.2.2

Dendrimer-Carbohydrate Conjugates

Carbohydrates are the most abundant group of natural products found on the earth. Aside
from their important roles in supplying energy to cells and structural support to plants,
carbohydrates are implicated in a vast array of biological processes. These include
hormonal activities, fertilization, embryogenesis, neural development, and many other
cellular processes such as cell-cell recognition, cell proliferation, cellular transport, viral
infection, bacterial adhesion, and tumour cell metastasis.106 Thus, it is not surprising that
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the efficient synthesis of saccharides and their incorporation into various systems to
obtain specific biological effects has attracted much attention in the past few decades.
One such example is the tremendous effort that has been devoted to enhancing the
multivalency of carbohydrates by incorporating them onto multivalent architectures such
as dendrimers. It is known that multivalent interactions are prevalent in biology, such as
in the adhesion of viruses and bacteria to cell surfaces and in the binding of cells to other
cells.107 Many of these processes involve the interactions of carbohydrates with protein
receptors called lectins. While the interactions of individual carbohydrate ligands with
lectins is often weak, multivalency provides a means of significantly increasing the
strength of the interaction.107
A wide variety of nanoscale materials such as linear and HBPs, nanoparticles, and
polymer assemblies can be used as backbones to present carbohydrates in a multivalent
manner,108-111 but the well-defined nature of the dendrimer backbone provides
advantages. For example, the number of carbohydrate ligands present on a given
molecule can be precisely determined, allowing advancements in the fundamental
understanding of carbohydrate-lectin interactions. In addition, the product monodispersity
and reproducibility in its synthesis is advantageous for the development of a clinical
therapeutic. A wide range of saccharides including mannose, galactose, glucose, lactose,
maltose,

xylose,

N-acetylneuraminic

acid

(Neu5Ac)

(sialic

acid),

and

other

oligosaccharides have been conjugated to various dendrimer peripheries via different
linkages such as amide, hydrazide, amine, thioether, thriourea, and triazole linkages.112
Unlike dendrimer-drug conjugates, in which fine-tuned lability of the linkage is essential
for controlled release of the drug, carbohydrates typically do not need to be released from
the dendrimer periphery in order to exhibit activity. Thus, although the linkages can have
modest effects on the binding affinities of multivalent carbohydrates, the choice of
linkage is determined primarily by synthetic requirements. In this section, the conjugation
of Neu5Ac, which is relevant to this thesis, to the peripheries of various dendrimer
backbones will be discussed and the biological properties of the resulting bioconjugates
will be briefly introduced. This discussion provides representative examples of the
different conjugation chemistries that can be for coupling of dendrimers with
carbohydrates.
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1.2.2.2.1

Dendrimer-N-Acetylneuraminic Acid Conjugates

Neu5Ac is the most abundant sialic acid found in mammalian cells. This negatively
charged molecule is found in complicated glycans on mucin and in glycoproteins that are
embedded in cell membrane. It is known that all types of influenza viruses interact with
Neu5Ac residues on the host cell surface through their trimeric lectin hemagglutinin
(HA), and this is followed by endocytosis of the virus into the cell.107 Monovalent
Neu5Ac can inhibit this interaction at millimolar concentrations, but there is significant
interest in the development of multivalent Neu5Ac derivatives in order to obtain higher
binding affinity. For this purpose, various dendrimer-Neu5Ac conjugates have been
developed. Different strategies to construct such bioconjugates is shown in Figure 1.11.

Figure 1.11. Conjugation strategies for Neu5Ac.
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Thus far, the formation of a thioether linkage is the most commonly reported approach
for the conjugation of Neu5Ac to the peripheries of dendrimers.113-120 To construct these
conjugates, a thiol must be installed on either sialic acid or on the dendrimer periphery.
Because unprotected thiols tend to dimerize readily, a process that is facilitated on the
dense peripheries of dendrimers, the introduction of the thiol to Neu5Ac has been a more
viable approach. For example, Roy and coworkers have prepared a protected 2-αthioacetyl-Neu5Ac and reacted it with three types of N-chloroacetylated dendrimers
including

polypeptide,113

PAMAM,114,115

and

gallic

acid-oligoethylene

glycol

dendrimers.116 The acetyl groups on the sugars were then removed under basic conditions
to yield the unprotected dendrimers. An enzyme-linked lectin inhibition assay using
human α1-acid glycoprotein as the coating antigen and horseradish peroxidase-labeled
Limax flavus agglutinin (LFA) for detection purposes was performed. Their results
showed that the globular dendrimer with a valency of 12 exhibited a 182-fold increase in
inhibitory potency compared to the reference monomeric Neu5Ac.115
To investigate different spacers between Neu5Ac and dendrimers, Matsuoka and
coworkers prepared a library of brominated carbosilane dendrimers with different types
of spacers on their peripheries.118,119 The thiol-functionalized Neu5Ac derivative was
similar to that employed by Roy and coworkers but with an additional 5-carbon aliphatic
spacer between the sugar and the thiol. Introduction of this molecule onto different
brominated carbosilane dendrimers with either normal, ether elongated, or amide
elongated peripheral groups was accomplished by initially treating the thioacetic acidfunctionalized sugar and bromide terminated dendrimer mixture with sodium methoxide
(NaOMe)/methanol (MeOH) in N,N-dimethylformamide (DMF) followed by addition of
acetic anhydride/pyridine. Fully deprotected dendrimers were obtained by treatment of
these dendrimers with NaOMe/MeOH and 0.1 M sodium hydroxide solution. Biological
evaluations of these glycodendrimers showed that all of the ether- and amide-elongated
compounds had inhibitory activities for the influenza sialidases in the millimolar range.
Surprisingly, the glycodendrimers having normal aliphatic linkages did not exhibit any
activities except for a dendrimer with a valency of 12.119
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Hawker and coworkers recently reported the glycosylation of a 4th generation
dendrimer via a free-radical thiol-ene coupling reaction between thiol-functionalized
carbohydrates including Neu5Ac, mannose, glucose, and lactose and a dendrimer having
peripheral alkene moieties.120 This reaction results in the formation of a thioether linkage
in high yield.
McReynolds and coworkers have investigated amide linkages between Neu5Ac and
PAMAM dendrimers.120 They have constructed their bioconjugates with or without
spacers between the dendrimer and Neu5Ac. In the case without any spacers,
commercially available Neu5Ac was directly conjugated to the amine peripheral groups
of

the

dendrimers

using

(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium

hexafluorophosphate (BOP). Alternatively, to minimize steric congestion between
Neu5Ac and the dendrimer, a bifunctional spacer molecule was first conjugated to the
carboxylic acid functionality of Neu5Ac. After deprotection of the other terminus of the
spacer, which resulted in the formation of a free amine, it was coupled to the periphery of
acid-functionalized PAMAM dendrimers. Subsequent sulfation of the conjugates was
accomplished by reacting the obtained dendrimers with an SO3-pyridine complex. When
evaluated for inhibition of Human immunodeficiency virus (HIV)-1 infection, the
sulfated Neu5Ac-PAMAM glycodendrimer bearing 16 Neu5Ac moieties with 11 sulfate
groups was found to inhibit all four HIV-1 strains tested in the low micromolar range.
Finally, thiourea conjugates of Neu5Ac and dendrimers have also been prepared. An
acetate protected p-isothiocyanatophenyl derivative of Neu5Ac was prepared and was
coupled to the peripheral amines of PAMAM dendrimers to give the protected Neu5Ac
dendrimers in high yields (71-100%).121,122 Complete deprotection was accomplished by
sequential ester hydrolysis in first NaOMe/MeOH followed by 50 mM NaOH solution to
hydrolyze the acetyl followed by methyl ester groups. By performing a competitive
enzyme-linked lectin assay, it was demonstrated that these dendrimers exhibited a
substantial 210-fold increase in the inhibitory activity compared to monomeric
Neu5Ac.121
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1.2.2.3

Dendrimer Conjugates with Imaging Agents

With rapid developments in imaging technology, along with an increased focus on the
early detection of diseases and the monitoring of treatment effects, there has been great
interest in the development of new contrast agents for various imaging modalities
including magnetic resonance imaging (MRI), x-ray computed tomography (CT), single
photon emission computed tomography (SPECT), positron emission tomography (PET)
and optical imaging. These contrast agents aid in distinguishing between normal and
diseased tissues through their localization at specific sites in vivo. Among the new
contrast agents under development, nanosized agents based on materials such as linear
polymers, organic and inorganic nanoparticles, proteins, and dendrimers have received
particular attention in recent years. When the size and chemical functionalities of these
agents are optimized, they can exhibit significantly longer in vivo circulation times than
small molecule analogues. This enables new applications such as vascular imaging and
the targeting of specific disease sites such as tumors to be explored. In addition,
nanosized agents enable the conjugation of multiple contrast agent molecules to a
nanomaterial, enhancing the contrast on a per molecule or per particle basis. Furthermore,
this same attribute can allow the conjugation of both contrast agents and targeting
moieties or multiple contrast agents for different imaging modalities to the same system
providing enhanced, multifunctional properties.
Among the various nanomaterials available, as previously discussed, the well-defined
chemical structures of dendrimers provide a significant advantage in terms of
reproducibility in the synthesis and resulting properties of the agents, allowing wellcharacterized materials to be prepared to the satisfaction of regulatory agents. Relevant to
this thesis are dendrimer conjugates as MRI contrast agents. As a result, various
examples involving the conjugation of MRI contrast agents will be described.

1.2.2.3.1

Dendrimer Conjugates for MRI

MRI is a prominent noninvasive imaging modality due to its excellent spatial resolution,
soft tissue contrast, and the absence of harmful ionizing radiation in its application.
Despite its high levels of soft tissue contrast, contrast agents based on small molecule
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chelates of Gd(III) are frequently employed in clinical MRI scans to aid in the
differentiation between healthy and diseased tissues.123-125 These agents, which act by
altering the relaxation times of the protons in nearby water molecules, have enabled
significant advancements in MRI over the last couple of decades. However, the low
contrast efficiency (ie. low relaxivity), fast renal excretion, and low specificity of these
agents results in a requirement for high doses. This can be problematic for patients with
chronic renal disease.126 It can also limit their applicability in molecular imaging
applications, where target receptors are present only at low concentrations.127 Dendrimerbased MRI contrast agents have been intensively investigated over the past couple of
decades for several reasons.128,129 First they allow for the attachment of multiple MRI
labels to a single scaffold, greatly increasing the molecular relaxivity and allowing a
single targeting moiety to carry multiple labels. In addition, their size can be wellcontrolled by tuning both their core and generation, allowing their biodistribution
properties to be tuned. Finally, because of the nanoscale dimensions of the dendrimer and
steric hindrance at the periphery, the molecular tumbling rate of the conjugated Gd(III)
chelates is significantly slowed, resulting in an increase in R, the rotational correlation
time. This can result in substantial enhancements in the longitudinal relaxivity (r1) of the
contrast agents, as predicted by Solomon-Bloombergen-Morgan theory, which is
described in detail elsewhere.123,130
An important class of clinically used small molecule Gd(III) chelates is based on the
ligand diethylenetriaminepentaacetic acid (DTPA) (Figure 1.12a). Seminal work by
Lauterbur and coworkers in the area of dendrimer MRI contrast agents involved the
conjugation of a DTPA derivative containing an aromatic isothiocyanate to various
generations of PAMAM dendrimers having peripheral amine groups (Figure 1.12b).131
Gd(III) was introduced in the final synthetic step. On a per ion basis, r1 of this agent was
found to be 34 mM-1s-1, about 6-fold greater than that of the clinical agent Gd(III)-DTPA
(Magnevist). This result was attributed to the slower tumbling rate of the chelates at the
dendrimer periphery. Subsequently, a series of PPI dendrimer-DTPA conjugates up to the
5th generation were synthesized by Kobayashi and coworkers using the same linker
chemistry and increasing relaxivity was observed with increasing generation, up to 29
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mM-1s-1.132 In other work, Meijer and coworkers used a different linker to conjugate the
DTPA derivative (Figure 1.12c).133 This resulted in a less significant increase in r1, up to
a maximum of 20 mM-1s-1 for the 5th generation dendrimer. In this case, the flexibility of
the linker likely allowed for relatively high local mobility of the chelates at the dendrimer
periphery, illustrating the importance of the conjugation chemistry.

Figure 1.12. Chemical structures of: a) the clinical agent Gd(III)-DTPA (Magnevist)
and dendrimer conjugates of DTPA derivatives containing b) an aromatic isothiocyanate
and c) a more flexible aliphatic isocyanate.
Another major class of clinical Gd(III) chelates is based on the ligand 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (Figure 1.13a). This chelate
forms Gd(III) complexes that are kinetically and thermodynamically more stable than
those formed with DTPA. Like DTPA, DOTA derivatives have also been conjugated to
PAMAM dendrimers from the 2nd to 10th generations. Isothiocyanate linkages have
commonly been used to conjugate these ligands to the peripheral amine groups of the
dendrimer (Figure 1.13b). It was found that the ionic (per Gd(III)) r1 values for these
dendrimers plateaued at 36 mM-1s-1 due to slow water exchange with the chelates, an
important consideration for systems with long R.134,135 A derivative containing a
phosphinic acid moiety in the linkage was also investigated with PAMAM dendrimers,
resulting in good relaxivity values due to steric crowding and the formation of a
secondary hydration sphere by the bulky phosphinate group (Figure 1.13c).136,137
Researchers at Schering AG (Berlin, Germany) have developed Gadomer-17, bearing 24
DOTA derivatives attached to a lysine based dendrimer backbone via amide linkages
(Figure 1.13d).138 In a different approach, DOTA has also been incorporated at the core
of polyglycerol dendrimers, where the motion of the Gd(III) should be coupled to the
motion of the whole dendrimer.139 The dendritic arms were conjugated to the chelates via
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amide linkages. This indeed resulted in a remarkably high relaxivity of 39 mM -1s-1,
though the rate of water exchange was slowest for the largest dendrimer limiting further
gains in r1.

Figure 1.13. Chemical structures of: a) the clinical agent Gd(III)-DOTA (Dotarem) and
dendrimer conjugates of DOTA derivatives containing b) an aromatic isothiocyanate
linker; c) a a phosphinic acid linker; d) an amino acid-based linker.
As described above, for the highest generation dendrimers, when R is increased by
substantially slowing the tumbling rates of the Gd(III) chelates, the rate of water
exchange can be a limiting factor in achieving higher relaxivity values. Chelates with
faster water exchange rates are desired. In addition, the coordination of multiple water
molecules can also increase r1. However, due to the toxicity of unchelated Gd(III), it is
also critical to maintain the stability of the complexes. These aspects have been addressed
by Raymond and coworkers through the development of a new class of ligands based on
hydroxypyridinone (HOPO).140 The Gd(III) chelates of these ligands bind two water
molecules yet exhibit high stability due to their oxygen donor atoms and the high
oxophilicity of the Gd(III) center. In addition, they possess rapid, near optimal water
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exchange rates. This results in enhanced relaxivities about 2-fold higher than the DTPA
or DOTA chelates.
HOPO derivatives have also been incorporated into dendrimer systems. Initially,
HOPO was conjugated to the focal point of a dendron based on aspartic acid and
tris(hydroxymethyl)aminomethane via the formation of a rigid amide linkage between an
aromatic carboxylate of the ligand and the amine of the focal point aspartic acid (Figure
1.14a).141 HOPO derivatives have also been conjugated to the peripheries of PLL and
esteramide dendrimers that also bear solubilizing poly(ethylene glycol) (PEG) chains.142
In this case, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC)-mediated amide
bond formation was performed using the peripheral carboxylic acids of the dendrimers
and the amines of the HOPO chelates containing precomplexed Gd(III). This
precomplexation was argued to prevent the nonspecific binding of Gd(III) to the
dendrimer backbone, which might occur if a subsequent Gd(III) chelation step were
performed. The effect of the linker was investigated and it was found that the shorter
ethylene diamine spacer (Figure 1.14b) provided an r1 of 38 mM-1s-1 with the esteramide
dendrimer, whereas a more flexible diethylene triamine spacer resulted in a lower r1 of 32
mM-1s-1 with the same dendrimer. In addition, the PLL dendrimer backbones resulted in
lower relaxivity, perhaps due to increased hydrogen bonding between the dendrimer
backbone and the water coordination sites or due to a shorter R of the conjugated
chelates. Overall, these results again demonstrate the importance of the bioconjugation
chemistry, with shorter, more rigid spacers leading to the highest relaxivity values for
Gd(III) contrast agents.
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Figure 1.14. Dendrimer conjugates of HOPO derivatives using a) a rigid amide linkage
between the carboxylic acid on the ligand and the dendron’s focal point amine; b) an
ethylene diamine spacer between the ligand and the dendrimer’s peripheral carboxylic
acids.
Several of the above dendrimer MRI contrast agents have been investigated in
vivo.128,129 In general, it has been found that low generation dendrimers such as the 3rd
and 4th generations exhibit rapid renal clearance, while higher generations remain in the
bloodstream for longer periods making them useful for the visualization of vasculature.
The highest generation dendrimers such as the 8th and 9th generations tend to accumulate
in the liver but they have also been useful for MR lymphangiography. Exploiting the
multivalent peripheries of dendrimers, moieties for targeting specific tissues in vivo have
been conjugated along side the Gd(III) chelates. However, a noteworthy example is a 4th
generation dendrimer with DTPA and folic acid conjugated to the periphery, which
enabled the selective labeling of ovarian cancer tumors overexpressing the folate
receptor.143,144

1.3 Surface Functionalization of Polymersomes
As discussed in the earlier sections, a wide range of materials with various compositions
and architectures have been developed for biomedical applications. While the bulk
composition of a material is important for its function and long-term biocompatibility, the
functionalities present at its surface are also critical. It is the surface of a material that
will first come into contact with the biological system and as such will play a major role
in its toxicity and biodistribution behavior.145 The surface can also provide sites for the
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introduction of drugs and moieties to target the material to specific sites in vivo.146,147
Furthermore, the high levels of multivalency available at the surface of a material can
provide therapeutic properties by inhibiting undesirable multivalent interactions between
host cells and pathogens including bacteria and viruses using ligands such as
carbohydrates.107,148 Of particular interest to this thesis are polymersomes. In this section,
approaches to the surface functionalization of polymersomes with a focus on dendritic
groups will be discussed.
Two main approaches for the surface functionalization of polymersomes with
functional ligands can be envisioned. In the first approach, polymersomes with functional
handles on their surfaces are first formed. In a second step, ligands of interest with
complementary functional groups are installed onto their surfaces. The attachment of the
ligands onto the surfaces of polymersomes via this approach can be accomplished
through either covalent or non-covalent attachment of the ligand. Covalent attachment of
the ligand takes advantage of high-yielding chemical reactions such as Cu(I)-catalyzed
alkyne-azide cycloaddition click reactions, thiol-N-hydroxysuccinimidyl ester and thiolvinyl sulfone reactions to form S-C bonds, amine- succinimidyl ester reactions to form
amide bonds, aldehyde-amine reactions to form imines, and conjugation reaction via bisarylhydrazone bond formation.149,150 On the other hand, in functionalization of
polymersomes via the non-covalent attachment approach, strong non-covalent attractions
such as biotin–streptavidin binding, nitrilotriacetic acid–metal complexation binding, and
cyclodextrin–adamantane interactions have been employed.149,150 One advantage of
covalent over non-covalent attachment of ligands is the increased ligand binding stability,
which is accompanied with its higher site specificity and reproducibility. Using these two
methods various surface ligands have been conjugated to the surface of polymersomes
including proteins, peptides, dendrons, carbohydrates, imaging agents, and antibodies
.93,94,149,150
In the second approach, the hydrophilic terminus of the BCPs is first prefunctionalized with the ligand of interest. In the second step, the functionalized BCP is
used for polymersome formation. As a result, this approach makes it possible to isolate,
purify, and characterize the newly functionlized polymer. In addition, by blending
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appropriate ratios of the functionalized and non-functionalized polymers it is possible to
have precise control over the surface density of desired ligand. However, a disadvantage
of this approach is that potentially 50% of the ligands will be inaccessible in the interior
of the polymersome for the given application. Applying this approach, different
carbohydrates and organic dyes have been incorporated onto the surfaces of
polymersomes.93,94,149,150

1.3.1 Dendritic Surface Functionalization of Polymersomes
Based on the unique properties of dendrons and dendrimers discussed in the earlier
sections, the introduction of dendritic groups to polymersome surfaces provides the
opportunity to alter the surface chemistry in a single step without changing the BCPs
comprising the polymersome membranes. This provides a unique opportunity to impart
new biological properties and functions.
In previous work by the Gillies group,151 as shown in Figure 1.15, polymersomes
composed of the amphiphilic linear diBCP poly(butadiene-b-ethylene oxide) (PBD-PEO)
were used. An azide was introduced to the polymer terminus and polymersomes were
prepared containing varying ratios of the azide and hydroxyl terminated polymers. A
polyester dendron, having an alkyne focal point and peripheral amine groups with ~1
rhodamine dye per dendron, was reacted with the polymersomes under standard click
conditions

involving

CuSO4,

sodium

ascorbate,

and

the

ligand

bathophenanthrolinedisulfonic acid. It was found that the use of this ligand prevented the
adsorption of copper ions to the dendritic amines. The conjugation yields for the various
polymersomes were quantified based on the ultraviolet (UV)-visible absorbance of the
rhodamine dye on the dendrons.
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Figure 1.15. Schematic showing the functionalization of polymersomes bearing
peripheral azide groups with dendrons having focal point alkynes.
It was found that the conjugation yields were typically greater than 60% at low surface
azide content ( 20%). This was greater than expected as ~50% of the azides would be on
the interior of the polymersome and it was not expected that the dendrons could pass
through the membrane into the polymersome’s aqueous core. However, it is likely that
through various processes, some interior azides can move to the surface during the 24 h
reaction time. At higher azide content, the conjugation yields dropped off dramatically.
This was attributed to steric hindrance at the polymersome surface due to the bulky
nature of the dendrons. In addition, well-dispersed polymersomes were observed at low
azide content. On the other hand, at higher azide content, significant aggregation was
observed which may be attributed to either a disruption of the hydrophilic/hydrophobic
balance within the polymersome membrane upon dendron conjugation, or to interactions
between the dendrons on different polymersomes. However, at azide content  20% this
method was highly promising for the surface functionalization of polymersomes. Overall,
this proof of concept study indicated that this approach could be used as an effective
method to impart new properties to polymersomes.
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In a subsequent study, the surface functionalization of PBD-PEO polymersomes with
dendritic versus non-dendritic ligands was studied.152 Mannose was selected as the ligand
as its multivalent binding to targets such as Concanavalin A (Con A) has been
extensively investigated and a number of assays have been developed to evaluate this
binding. In this study, a 3rd generation mannose-functionalized polyester dendron as well
as a mannose-terminated PBD-PEO BCP were prepared (Figure 1.16). As shown in
Figure 1.16a, dendritic mannose polymersomes were prepared by the “click” conjugation
of the mannose dendron to polymersomes containing 5% azide-functionalized PBD-PEO.
Non-dendritic mannose polymersomes were prepared by the assembly of polymersomes
from a 50:50 mixture of mannose and hydroxyl-terminated polymers (Figure 1.16b).
These quantities were selected in order to provide the same overall mannose content in
the dendritic and non-dendritic polymersomes, but displayed in a different manner.

Figure 1.16. Schematic for the preparation of a) dendritic mannose polymersomes; b)
non-dendritic mannose polymersomes.
The

dendritic

and

non-dendritic

polymersomes

were

compared

using

a

hemagglutination assay. The results showed that despite their multivalency, the non-
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dendritic polymersomes provided only a very modest 3.7-fold enhancement in affinity on
a per mannose basis. In contrast, the dendritic mannose functionalized polymersomes
provided a much greater 42-fold increase in relative binding affinity. This enhancement
relative to the non-dendritic system was attributed to several factors including the
relatively rigid display of ligands on the dendritic scaffold resulting in an entropic
advantage, the ability of the dendritic scaffold to overcome steric inhibition of binding by
the PEO layer, and an enhanced “proximity” effect resulting from the clustered display of
ligands on the dendron. Through the preparation of the analogous dendritic and nondendritic systems on dextran coated superparamagnetic iron oxide nanoparticles, it was
demonstrated that these enhancements were generalizable to other nanoparticles and
other polymer coatings in addition to PEO.153 Thus, this study revealed that it is
important to consider carefully not only the choice of biological ligand, but also the mode
in which it is conjugated to the surface in order to exploit the benefits of nanomaterials.
Furthermore, it showed that dendritic scaffolds are an effective means of displaying
biological ligands on surfaces.

1.4 Stimuli Responsive Dendrimers
As described above, dendrimers have been explored in a broad range of biomedical
applications.154,155 Despite these advancements, the area of responsive dendrimers
(dendrimers that can either disassemble or change their conformation in response to
external stimuli) is in its infancy. This field is of a great importance because triggering
such behavior in a controlled manner can impart new properties and expand their scope
of applications. External stimuli used thus far for the triggering of stimuli-responsive
dendrimers include pH,156,157 light,158 temperature,159,160 and redox state.161,162 In this
section, representative examples of each stimulus will be discussed with an emphasis on
light-responsive dendrimers. For exhaustive examples of stimuli-responsive dendrimers,
readers are referred to review articles published in this field.163-165
It is known that tumor cells along with lysosomes and endosomes of healthy cells have
a mildly acidic pH. As a result, delivery vehicles that are sensitive to variations in pH can
act as smart materials for the selective delivery of drugs in such micro-environments. In a
study by Pistolis and coworkers,156 the peripheral groups of a PPI dendrimer were first
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functionalized with quaternary ammonium salts. This positively charged dendrimer was
used to physically encapsulate pyrene as a model drug. In the next step, the release
behaviour of this system at low pH values was followed by fluorescence studies. It was
found that when the pH was decreased from 11 to 2-4 by addition of hydrochloric acid,
the fluorescence intensity of the system was enhanced dramatically as a result of pyrene
release. It was proposed that such an acidic pH results in protonation of internal
secondary and tertiary amine groups of the dendrimer, which in turn increases its
hydrophilicity. Such an increase in the hydrophilicity of the system results in the release
of the cargo. Although not pointed out by the authors, the increase in the internal volume
of the dendrimer as a result of the repulsion between the positive charges of the
protonated amines cannot be ignored. In another study by Fréchet and coworkers,157 the
peripheral groups of either polyester or polylysine dendrons were functionalized with
hydrophobic groups via highly acid-labile cyclic acetal groups. These dendrons were then
functionalized with PEO at the focal point to obtain linear-dendritic BCPs. It was shown
that these materials were able to undergo self-assembly to form stable micelles at neutral
pH. These micelles were used to encapsulate Nile Red as a model drug in their
hydrophobic dendritic core. Upon exposure to mildly acidic pH, Nile Red was released
from the micelles as a result of acetal hydrolysis, which results in disintegration of
micelles by disturbing the hydrophilic-hydrophobic balance of the system.
Dendrimers that can release their payload in response to temperature are also highly
attractive systems as advanced materials. These materials have the potential to be used in
thermotherapy. The response often observed as a result of a change in temperature is a
change in the solubility of the macromolecule. This can be accomplished by modifying
dendrimers with a molecule that exhibits a lower critical solution temperature (LCST).
This is a temperature above which a molecule becomes insoluble due to entropic factors.
For example, Kimura and coworkers159 reported the synthesis of a thermoresponsive
dendrimer in which the catalytic activity of the encapsulated molecule showed a
significant increase upon increasing the temperature of the system from 25-37 °C. The
thermoresponsive dendrimer was constructed by first reacting the peripheral amine
groups of a 3rd generation PPI dendrimer with 11-(thioacetyl)-undecanoic acid followed
by the hydrolysis of the thioacetyl groups to install thiols on the dendrimer. In the second
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step, these thiols were used as chain transfer reagents for free radical polymerization of
N-isopropylacrylamide (NIPAAm). The resulting dendrimer was used to encapsulate a
water-soluble cobalt(II) phthalocyanine complex which is a known catalyst for thiol
oxidation. It was observed that catalytic activity of this system for the oxidation of
mercaptoethanol was only 6% of that with the PPI dendrimer at 25 °C. This implies that
PNIPAAm arms effectively restrict the penetration of starting materials (thiols and
dioxygen) to the catalytic site inside the dendrimer. However, at a temperature above the
LCST of the PNIPAAm arms (34 °C), a dramatic increase in the turnover frequency of
the catalyst was observed. The authors concluded that below LCST of the PNIPAAm
arms, these chains are soluble and expand over the dendrimer core and sterically hinder
substrate penetration. Above the LCST, the PNIPAAm arms phase-separate and shrink
which results in accessibility of the catalytic center to substrates. In addition, Kono and
coworkers showed that functionalization of the periphery of PAMAM dendrimers with
phenylalanine imparts thermoresponsive behaviour to the resulting dendrimers.160 They
were able to show that the LCSTs of such dendrimers were tuneable by the introduction
of more hydrophilic amino acid residues, as well as through changes in dendrimer
generation and pH.
To prepare redox-responsive materials, McCarley and coworkers took advantage of
trimethyl-locked quinones (TLQ) as redox-active moieties. They prepared G1-5 PPI
dendrimers functionalized with this redox-active group on their peripheries.162 Using
Na2S2O4 as a chemical reducing agent, they demonstrated successful liberation of the
peripheral groups from the dendrimers as lactones. Intramolecular reaction of the
hydroxyl groups, formed from the quinone reduction, with the amide-containing
substituents on the quinone moiety resulted in the liberation of the above-mentioned
lactones. Interestingly, this process did not show any generation-dependent rates and
reached completion in about 20 minutes (min) for all generations. In a subsequent study
by the same group, electrochemical reduction of the same dendrimers was also
demonstrated to be an effective way of achieving dendrimer peripheral group cleavage.
The authors showed that bulk electrochemical reduction of dendrimers resulted in PPI
dendrimers with dianionic TLQ2- peripheral groups which produced the transient
hydroquinone intermediates upon protonation with water. These intermediates were

37
finally liberated from the dendrimers as lactones in the same fashion as the chemicallyinduced pathway.161
In addition to conventional dendrimer backbones mentioned above, non-conventional
dendritic backbones such as cascade release dendrimers have also been used as
responsive dendrimers. In this case, stimuli such as enzymes and light have been applied
to trigger the release of drug molecules. This class of materials has been recently
reviewed.166

1.4.1 Photodegradable Dendrimers
Among the above-mentioned stimuli, light is of particular interest for the development of
smart materials as it can be applied at a specific time and location, with control over its
intensity and wavelength. Among the many photocleavable groups that have been
investigated, o-nitrobenzyl ester derivatives have gained tremendous attention. This
photolabile group was initially used as a protecting group in organic synthesis.167 The
mechanism of action for this group is based on the photoisomerization of the onitrobenzyl ester group into the corresponding o-nitrosobenzaldehyde and the release of
the corresponding carboxylic acid upon irradiation with UV light (Scheme 1.1). This
mechanism has been the subject of in-depth studies recently by Wirz and coworkers.168
This isomerization and cleavage of the ester bond often occur within minutes upon
exposure to 300-360 nm light. The irradiation wavelength can be tuned by including
substituents on both the aromatic ring and the benzylic position of the linker.
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Scheme 1.1. Photoisomerization mechanism for o-nitrobenzyl ester derivatives.
Application of the photolabile o-nitrobenzyl ester group has not been restricted to
organic synthesis and protecting groups. In fact, numerous applications of this moiety in
polymer and materials science within different backbones such as BCPs, hydrogels, and
dendrimers have been the subject of several reviews.165,169,170 In the context of dendritic
materials, systems have been developed through the incorporation of photodegradable
units either at the core of the dendrimer171 or at the junction between the hydrophobic
and hydrophilic portions of amphiphilic dendrons.158,172
In an early example, photolabile dendrimers based on o-nitrobenzyl ester groups in
which the photolabile moieties were installed at the cores of the dendrimers were
reported by McGrath and coworker.171 In this study, first through third generation
dendrimers that contained three o-nitrobenzyl ester groups at their cores were
synthesized. Due to the hydrophobic backbones of the dendrimers, their photolysis was
carried out in chloroform. The degradation studies revealed that upon irradiation with 350
nm light, these dendrimers released discrete dendrons as shown in the cartoon in Figure
1.17.
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Figure 1.17. Schematic representation of sequential photodegradation of dendrimers
functionalized with three o-nitrobenzyl ester groups at their core.
In a second study by Kostiainen and coworkers,172 first and second generation
amphiphilic dendrons with hydrophilic spermine peripheral groups and o-nitrobenzyl
ester groups at the junctions between the hydrophilic and hydrophobic segments were
synthesized. The chemical structures of these dendrons are shown in Figure 1.18. The
photolytic behaviors of these dendrons were first studied in aqueous media by irradiating
dendron solutions at 350 nm. The results showed that the degradation needed only 200
seconds to reach completion. As an application of these optically triggerable dendrons,
they were used for complexation of DNA. It was found that both generations of the
dendrons were able to effectively bind to DNA with the second generation dendron
having slightly higher binding strength compared to the first generation dendron due to
the increased multivalent effect at higher generations of dendrons and dendrimers. To
release DNA, the complexed samples were irradiated at 350 nm. The authors showed that
at a lower NaCl concentration of 9.4 mM, dendrons were able to release the DNA within
only 90 seconds, while at higher salt concentration of 150 mM, the release time was
decreased. The DNA release behaviour of the dendrons were also confirmed by light
scattering, ς-potential, and gel electrophoresis measurements.
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Figure 1.18. Chemical structures of a) first generation and b) second generation
photodegradable amphiphilic dendrons used for DNA complexation and release.
More recently, Thayumanavan and coworkers developed nanocontainers comprised of
photodegradable amphiphilic dendritic structures that are capable of encapsulation and
release of hydrophobic guest molecules.158 First and second generation dendrons in this
study were based on hydrophilic oligo ethylene glycol groups and hydrophobic alkyl
chains which were conjugated together through o-nitrobenzyl ester linkers (Figure 1.19).
It was found that the micellar structures formed by G1 and G2 dendrons in aqueous
media were 80 and 85 nm in diameter respectively. In the next step, the micelles were
used to encapsulate Nile Red as a model hydrophobic drug within their hydrophobic
cores. To study the release of the cargo from the micelles, Nile Red-containing micelles
were irradiated with 365 nm light and the release of the organic dye was monitored by
fluorescence spectroscopy. The authors showed that after 200 seconds, the G1 dendron
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was able to release up to 88% of the loaded guest molecule while this value for the G2
dendron was about 72%, presumably due to the more tightly packed nature of the
micelles obtained from the G2 dendron. Moreover, it was observed by dynamic light
scattering (DLS) measurements, that the sizes of the assemblies were decreased from
about 80 nm down to about 37 nm by irradiating the micellar samples with UV light.

Figure 1.19. Chemical structures of a) first generation and b) second generation
amphiphilic photodegradable dendrons used for encapsulation and release of Nile Red.
These examples highlight the potential of such photo-responsive dendrimers for
biomedical applications. However, to better achieve this goal, dendrimers that could
respond to NIR or visible wavelengths of light are highly desirable. This demands
extensive research on developing chromophores that absorb light at higher wavelengths
or a combination of dendrimers with metal nanoparticles, such as up-converting
nanoparticles, that are capable of absorbing light in NIR or visible region and converting
it to UV light. In such an example, Almutairi and coworkers have developed selfimmolative dendritic scaffolds caged with a coumarin derivative that are capable of
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releasing their terminal groups (in this case L-glutamic acid) in response to two photons
of NIR light.173 The structures of the quinone-methide based dendrimers used in this
study are shown in Figure 1.20. NIR light-induced release of the L-glutamic acid terminal
groups occurs via a cascade of molecular rearrangements upon the removal of the caging
coumarin derivative.

Figure 1.20. Structures of photodegradable dendrimers containing coumarin as NIR
light-degrading groups.

1.5 Scope of This Thesis
The main goal of this thesis is to demonstrate the potential of biodegradable and
biocompatible polymersomes, conventional and photodegradable dendrimers and
dendrons, and polymersome-dendron hybrid materials toward biomedical applications.
When work began on this thesis, the concept of dendritic surface functionalization of
polymersomes was previously developed by our group. However, based on the fact that
in the previous work, non-biodegradable polymersomes with unknown biocompatibilty
were used, one of the first goals of this thesis was to develop biocompatible and
biodegradable drug delivery systems. Once this was accomplished, several biomedical
applications of the system, such as MRI contrast agents and potential antiviral agents,
were pursued using these constructs. In addition, a new photodegradable dendritic
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backbone was developed with the ultimate goal of constructing dendrimer-based vesicles,
known as dendrimersomes, as smart materials for the controlled release of drugs.
Chapter two focuses on development of biocompatible and biodegradable
polymersomes based on poly(ethylene oxide)-b-polycaprolactone (PEO-PCL) BCPs. The
synthesis of azide-functionalized PEO-PCL BCPs and their assembly into polymeric
micelles and vesicles with activated surface azide groups will be shown. The surface
functionalization of these assemblies with both dendritic groups and small molecules will
be discussed.
Chapter three will describe the application of PEO-PCL polymersomes as scaffolds for
the development of polymersome-dendritic hybrid materials as effective MRI contrast
agents. It will be shown how nanoscale components can be readily combined to provide
additive enhancements in relaxivity of MRI contrast agents.
Chapter four describes the development of a polymersome-based potential influenza
virus inhibitor agent. The synthesis of sialic acid-functionalized polyester dendrons, their
installation onto polymersome surfaces, and evaluation of their inhibitory potentials will
be shown in this chapter.
Chapter five describes the synthesis of backbone photodegradable dendrons and
dendrimers by the incorporation of photodegradable o-nitrobenzyl ester moieties into the
widely used 2,2-bis(hydroxymethyl) propionic acid (bis-MPA) dendrimer backbone. The
photodegradation behaviours of G1-3 dendrimers will also be discussed.
Chapter six will demonstrate the incorporation of photodegradable dendrons into
AJDs which will be shown to self-assemble to form dendrimersomes with a
photodegradable membrane with the goal of encapsulation and triggered release of
hydrophilic and hydrophobic model drugs.
Chapter seven will summarize the key results discussed in previous chapters in the
context of the field and will outline the future directions for the ongoing projects.
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Chapter 2
2 Dendritic Surface Functionalization of Biodegradable
Polymer Assemblies*

2.1 Introduction
In solution, amphiphilic BCPs can undergo self-assembly, forming a diverse range of
structures from spherical micelles1 to helical rods,2 toroids,3 vesicles,4,5 tubes,6 and
multicompartment cylinders.7 In recent years, micelles and vesicles have received
significant attention as they can be readily accessed using a wide range of BCPs by
controlling the relative volume fractions of the constituent blocks.8 Relative to their
counterparts formed from low MW surfactants,9 these assemblies typically exhibit much
lower critical aggregation concentrations and enhanced thermodynamic and kinetic
stabilities.7,10 Because of these properties, there has been particular interest in biomedical
applications of these materials and they have been demonstrated as promising carriers of
proteins,11-13 hydrophilic and hydrophobic drugs,14-17 and imaging contrast agents.18-20
Micelles and vesicles are complementary systems in that micelles possess a hydrophobic
core that is typically used to encapsulate hydrophobic species, while vesicles possess an
aqueous core capable of encapsulating water-soluble species. However, vesicles also
possess a hydrophobic membrane that can also encapsulate hydrophobes, making these
assemblies multifunctional.
While much research thus far has focused on controlling the assembly and
encapsulation properties of BCPs and their corresponding assemblies,21-23 the
functionalization of micelle and vesicle surfaces is emerging as an important area of
research. The surfaces of the materials will come into direct contact with biological

*

This chapter contains work that has been published: Nazemi, A.; Amos, R. C.; Bondulle, C. V.; Gillies, E.
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systems and will therefore play a critical role in determining their properties such as
toxicity and biodistribution behaviour.16 Furthermore, the conjugation of ligands to the
surface can potentially lead to targeting of specific tissues such as tumours in vivo.20,24
Our group has recently reported a method for the introduction of dendritic groups to the
surfaces of polymer vesicles using the widely applicable Cu(I)-catalyzed click reaction
between vesicle azide groups and dendrons bearing focal point alkynes.25 Owing to the
high multivalency of the dendrons, this approach provides a rapid means of controlling
the surface functionalities on the assembly. Furthermore, using mannose as a model
biological ligand, it was demonstrated that binding to the target receptors was
significantly enhanced using a dendritic approach in comparison to the conjugation of
small molecules directly to the vesicle surface.26 This result was also generalizable to
polymer functionalized nanoparticles and was attributed to the increased availability of
the ligands on the surface of the nanomaterial when presented on the dendritic
framework, as well as the clustered nature of ligand display.
Overall, the results of our previous studies suggested that this dendritic surface
functionalization approach is highly promising for controlling the surface functionalities
of nanomaterials in order to impart specific biological properties and functions such as
targeting. However, this initial work was performed on vesicles composed of PEO-PBD
BCP, a non-biodegradable polymer with unknown biocompatibility. Furthermore, the
micron-scale sizes of these vesicles were unsuitable for in vivo circulation.27 To address
these limitations, and thus provide a significant advancement towards biomedical
applications, we describe here the application of the dendritic surface functionalization
approach to nano-sized PEO-PCL vesicles and micelles.

PCL is a well-known

biodegradable polymer that is currently Food and Drug Administration (FDA)-approved
for uses in tissue engineering28,29 and drug delivery.30,31 Although PEO is not
biodegradable, it is generally considered non-toxic and is currently used in several FDAapproved products including PEG-INTRON, ONCASPAR, and NEULASTA. Both
micelles32-38 and vesicles15,38-46 based on PEO-PCL have been previously reported and
have been investigated as delivery vehicles for drugs such as DOX,40 TAX,15 docetaxel,36
hemoglobin,41 dihydrotestosterone,33 cyclosporine A,34 and rapamycin.35 In current work,
we describe the synthesis of azide terminated PEO-PCL BCPs, their assembly into
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micelles and vesicles, and the conjugation of dendrons bearing different surface
functionalities including hydroxyls, amines, and guanidines, as well as a small molecule
rhodamine derivative to both vesicles and micelles. The effects of these conjugations on
the properties of the assemblies are explored.

2.2 Results and Discussion
2.2.1 Synthesis of Block Copolymers
In order to functionalize polymer assemblies using the previously described azide +
alkyne click chemistry approach, new PEO-PCL BCPs bearing terminal azides on the
hydrophilic PEO blocks were required. As the polymerization of -caprolactone (CL) is
generally initiated from small molecule47,48 or macromolecular alcohols,49-51 these target
copolymers could be most readily derived from asymmetrically functionalized PEOs
bearing azide and hydroxyl termini (N3-PEO-OH). While there are numerous reports
describing the asymmetric functionalization of oligo(ethylene glycol)s,52-54 their higher
MW analogues, particularly those lacking charged moieties are more difficult to prepare
due to the purification challenges associated with statistical functionalization reactions.
For example, in recent work Hillmyer and coworkers did not succeed in purifying their
target asymmetrically functionalized PEO, and therefore used the statistical mixture of
end-functionalized molecules in the preparation of a BCP.55 They later separated the
resulting copolymers based on their differing solubilities and sizes. On the other hand,
Taton and coworkers have recently reported asymmetric PEOs that were obtained
directly from the ring-opening polymerization (ROP) of ethylene oxide using Nheterocyclic carbenes as catalysts.56
In the current work, to obtain the target N3-PEO-OH, hydroxy-terminated PEO (HOPEO-OH, 2.1) with a MW of 2000 g/mol was first reacted with 1.1 equivalent (equiv.) of
p-toluenesulfonyl chloride (TsCl) in the presence of 4-dimethylaminopyridine (DMAP)
as a catalyst and triethylamine (NEt3) (Scheme 2.1). The crude product was then reacted
with sodium azide to obtain the target N3-PEO-OH (2.2) along with the diazide N3-PEON3 and diol HO-PEO-OH resulting from the statistical functionalization. Although the
properties of the three products were quite similar to each other, using very careful
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column chromatography it was possible to isolate an 18% yield (out of a possible 50%
theoretical yield) of the target compound 2.2 in pure form as evidenced by MALDI-MS
(Figure A2.11.). Despite the relatively low yield, the low cost of all of the reagents and
starting materials for this chemistry resulted in this being a viable route for the
preparation of the required macroinitiator.

Scheme 2.1. Synthesis of HO-PEO-N3 (2.2).
As shown in Scheme 2.2, N3-PEO-OH (2.2) was then used as a macroinitiator in the
ROP of CL. The commercially available PEO monomethyl ether (MeO-PEO-OH) was
also used as a macroinitiator to provide BCPs without terminal azides. These nonfunctionalized copolymers were required in the preparation of the assemblies to control
the number of surface azide groups and thus the degree of functionalization with the
dendritic groups. Most reports involving the preparation of PEO-PCL have involved the
use of metal catalysts such as tin 2-ethylhexanoate (stannous(II) octanoate),37,42,44,57 zinc
bis[bis(trimethylsilyl)amide],39 or triethylaluminum.58,59 For in vivo applications, the use
of non-metallic catalysts is highly desired in order to minimize the potential toxicity
effects. Acids such as hydrochloric acid (HCl),36,60 trifluoromethanesulfonic acid,61 and
methanesulfonic acid61 (MSA) have been reported to polymerize CL with small molecule
alcohols as initiator. Among these catalysts, MSA was shown to produce PCLs with
lower PDIs and in shorter reaction times. For these reasons, MSA was selected as the
catalyst for this work and the polymerization was conducted at 30 C for 2.5-3.5 h. Based
on previous reports that PEO-PCL BCPs with monomer ratios of approximately 44:9 to
44:40 assemble into spherical micelles, while those with ratios of 44:82 to 44:105
assemble into vesicles, the four BCPs 2.3 - 2.6 shown in Table 2.1 were synthesized with
the aim of preparing both micelles and vesicles from these materials.
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Scheme 2.2. Synthesis of PEO-PCL BCPs.
Table 2.1. MW characteristics of PEO-PCL BCPs.

a

MW expected from the

polymerization based on the initiator and monomer ratio. bMW determined by 1H NMR
spectroscopy in CDCl3. cMw obtained from SEC-MALS. dPDI determined from SECMALS.

Copolymer

PDId

Experimental
Yield

5500

1.14

97%

5000

4600

1.18

97%

11300

11300

12400

1.40

95%

11300

11600

12000

1.19

93%

MWexpected

MWNMR

Mw

(g/mol)a

(g/mol)b

(g/mol)c

MeO-PEO44-PCL24 (2.3)

4700

4800

N3-PEO44-PCL24 (2.4)

4700

MeO-PEO44-PCL82 (2.5)
N3-PEO44-PCL82 (2.6)

The MWs of the resulting polymers were determined by 1H NMR spectroscopy and
size exclusion chromatography with detection by multi-angle light scattering (SECMALS). The MW characteristics of the synthesized BCPs are summarized in Table 2.1
and SEC traces of the polymers are shown in Figure 2.1. It is worth noting that high
reaction yields and relatively low PDIs were generally obtained, with the measured MWs
in agreement with target monomer ratios.
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Figure 2.1. SEC traces for copolymers: (a) 2.3 and 2.4 and (b) 2.5 and 2.6. Detection was
based on light scattering (90  trace shown).

2.2.2 Synthesis of Alkyne-Functionalized Dendrons
To explore the functionalization of the PEO-PCL vesicles and micelles, two different
dendrons with focal point alkynes were initially explored. The third generation dendron
1.33 bearing peripheral amine functional groups and statistically one rhodamine dye per
molecule was selected, as this dendron was used in previous work with the PEO-PBD
vesicles25 and would allow comparison between the different vesicle systems.
Additionally, to demonstrate that the dendritic surface functionalization approach can
impart new functions, the guanidine functionalized dendron 2.8 was prepared by first
reacting 1.3325 with the tert-butoxycarbonyl (Boc)-protected guanidine derivative 2.762 in
the presence of o-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
(HBTU), 1-hydroxybenzotriazole (HOBt), and N,N-diisopropylethylamine

(DIPEA),

then removing the Boc groups by treatment with 1/1 trifluoroacetic acid (TFA)/CH2Cl2
(Scheme 2.3). Similar guanidine functionalized dendrons62 have been demonstrated by
our group to have cell penetrating properties comparable to those of the well known HIV
Tat peptide,63,64 and were capable of enhancing the transport of iron oxide nanoparticles
into cells.62 Therefore, they might enhance the capacity of these micelles and vesicles to
carry cargo into cells. The molar extinction coefficients (ε) for dendrons 1.33 and 2.8
were determined by UV-visible spectroscopy in order to enable the quantification of their

59
conjugation yields to the surfaces of the nanoassemblies. Finally, as the conjugation
yields for the dendrons can be limited by steric hindrance at the surface of the assembly,
it was also of interest to compare these reactions with those of a small molecule alkyne.
Thus, the rhodamine derivative 2.965 was reacted with propargyl bromide to provide 2.10
(Scheme 2.4). As the local environment of the dye may alter its extinction coefficient,
rhodamine-functionalized derivatives of copolymers 2.4 and 2.6 were also prepared as
shown in Scheme 2.5, and the extinction coefficients of the resulting polymers 2.11 and
2.12 were measured in order to enable the accurate quantification of the conjugation
yields for 2.10.

Scheme 2.3. Synthesis of rhodamine-labeled guanidine dendron 2.8.

Scheme 2.4. Synthesis of alkyne-functionalized rhodamine 2.10.
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Scheme 2.5. Synthesis of rhodamine-labeled PEO-PCL block copolymers 11 and 12.

2.2.3 Formation of Nanoassemblies and Surface Functionalization
Reactions
PEO-PCL vesicles and micelles can be formed through a number of different methods
including rehydration of copolymer thin films on roughened teflon plates36,43,44 and
nanoprecipitation.38,42,45,46 In our hands, thin film rehydration of copolymers 2.3 and 2.4
provided micelles with diameters on the order of 25 nm. With copolymers 2.5 and 2.6,
rehydration of copolymer thin films on roughened teflon plates resulted in the formation
of micron-sized vesicles, accompanied by many aggregates. The large sizes and
aggregation were undesirable, so this method was not explored further. On the other
hand, using a nanoprecipitation method involving the dissolution of the copolymer in
tetrahydrofuan (THF), followed by a gradual addition of water and then dialysis against
water to remove the THF, led reproducibly to micelles with diameters of approximately
20 nm (copolymers 2.3 and 2.4) and vesicles with diameters of approximately 140 nm
(copolymers 2.5 and 2.6) as measured by both DLS (Figure 2.2) and transmission
electron microscopy (TEM) (Figure 2.3). As materials smaller than 100 nm are desired
for in vivo applications, it was demonstrated that the vesicles could be extruded through a
100 nm polycarbonate membrane at 65 ˚C. This resulted in a decrease in the vesicle
diameter to about 65 nm.
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Figure 2.2. Size distribution profiles measured by DLS for: a) micelles prepared from
copolymer 2.3; b) vesicles prepared from copolymer 2.5; c) extruded vesicles prepared
from copolymer 2.5.

Figure 2.3. TEM images of: a) micelles prepared from copolymer 2.3; b) vesicles
prepared from copolymer 2.5.
Micelles and vesicles with varying densities of surface azides were prepared from
mixtures of copolymers 2.3 and 2.4 or 2.5 and 2.6 respectively using the
nanoprecipitation method described above. Click reactions were subsequently performed
using CuCl2, sodium ascorbate, and four equivalents of the alkyne 1.33, 2.8, or 2.10
relative to the azide (Scheme 2.6). After 18 h, the excess alkyne and other reagents were
removed by dialysis. Following the removal of water, the materials resulting from each
reaction were dissolved in CHCl3/MeOH (3/2), and their UV-visible absorbances were
measured. Using the extinction coefficients measured for 1.33, 2.8, 2.11, and 2.12, the
yields of the alkynes conjugated to the micelle and vesicle surfaces were then calculated.
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Scheme 2.6. Preparation of functionalized a) vesicles and b) micelles.
The conjugation yields for the vesicles are shown in Figure 2.4a. It was found that the
yields for the conjugation of dendron 1.33, bearing peripheral amines were very similar
to those previously obtained with PEO-PBD vesicles.25 It should be noted that
approximately 50% of the azides should be located in the interior of the vesicles, and thus
inaccessible to the dendron, which is unlikely to diffuse through the vesicle membrane.
Nevertheless, as previously reported,25 conjugation yields higher than 50% were obtained
at low azide loadings. This may be attributed to the dynamic nature of the vesicles,
allowing azides from the vesicle interior to migrate to the vesicle surface during the 18 h
reaction time and then subsequently react. The slow migration of dendron 1.33 from the
reaction solution into the vesicle core also cannot be excluded. As the azide loading
increased beyond 20%, the reaction yields decreased. This was likely due to the steric
hindrance at the vesicle surface which restricted the conjugation of dendrons. The yields
for the conjugation of the guanidine-functionalized dendron 2.8 were consistently lower
than those for dendron 1.33. This result was not surprising considering the larger size of
this dendron.
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Figure 2.4. Click reaction yields as a function of azide loading on: a) vesicles (remaining
copolymer is 2.5); b) micelles (remaining copolymer is 2.3).
Yields for the conjugation of the small molecule rhodamine derivative 2.10, calculated
using the extinction coefficient of 2.12, were consistently greater than 90% for azide
loadings of 1% to 40%. In order to ensure that the measured reaction yields accurately
reflected covalently conjugated dye, and not simply dye entrapped within the vesicle core
or membrane, these yields were determined following not only the usual aqueous dialysis
but also a dialysis against DMF, which would disrupt the vesicles and enable the release
of any non-covalently bound dye. Indeed these yields are lower than those observed after
just the aqueous dialysis, which were consistently greater than 100% (at all azide
loadings). Overall, these results suggested that the dye can diffuse across the vesicle
membrane during the reaction time and react with azides on the interior membrane
surface. Consistent with this hypothesis, we have observed the release of non-covalently
encapsulated rhodamine out of vesicle cores over a 24 h period suggesting that the
reverse process could also occur given the appropriate concentration gradient. Somewhat
surprisingly, the reaction yields even for this small molecule dropped off at higher azide
loadings above 20%. This might be attributed to the presence of dye molecules on the
membrane disrupting the availability of nearby azides, or perhaps due to diffusion of the
rhodamine across the vesicle membrane providing insufficient concentrations of
rhodamine to react with all of the azides at the vesicle core. Moreover, the covalent or
non-covalent attachment of the substrates to the nanoassemblies was evaluated by
performing control experiments. Two PEO-PCL vesicle samples with 0% azide polymer
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content were prepared. Both samples were subjected to click reaction condition with
either alkyne-functionalized rhodamine dye 2.10 or dye-labled amine dendron 1.33 equal
to vesicles containing 10% azide-functionalized PEO-PCL copolymer 2.6. The vesicle
sample with 1.33 was dialyzed only against water and the sample with 2.10 was dialyzed
against water followed by dialysis against DMF. Quantification of the samples, with
respect to 10% azide-functionalized PEO-PCL copolymer, revealed that 1.3% of the dyelabeled amine dendron 1.33 and 2.3% of the alkyne-functionalized rhodamine dye 2.10
were non-covalently attached to the vesicles samples. Comparing these values with the
overall conjugation yields shows that non-covalent attachment of the substrates to
nanoassemblies is negligible compared to covalently bonded substrates.
In the conjugation reactions of dendron 1.33 with the micelles, it was expected that the
yields would approach 100% at low azide loadings as all of the azides should be available
for reaction at the micelles surface. However, as shown in Figure 2.4b, this was not the
case, and surprisingly the conjugation yields were consistently lower than those obtained
for the vesicles. The reasons for these lower yields are still unclear at this time, but could
perhaps be related to the large size of the dendrons relative to the micelles. The yields for
the conjugation of the guanidine-functionalized dendron 2.8 were similar to those
obtained with dendron 1.33 and were similar to the yields obtained on the vesicles. Like
for the vesicles, the conjugation yields for the small molecule rhodamine 2.10 were high,
but unlike for the vesicles, these yields did not drop off as significantly at higher azide
loadings. This suggests that the decrease in yields observed for the vesicles at high azide
loading was more likely due to insufficient quantities of rhodamine 2.10 for reaction with
the interior azides due to its limited diffusion across the vesicle membrane, rather than
due to the presence of dye molecules hindering the reaction of nearby azides.
Furthermore, in the context of the micelles, it suggests that the lower conjugation yields
obtained for the dendrons were likely related to their size. It should also be noted that in
order to investigate the reproducibility of the conjugation reactions, each reaction
combination was repeated three times at the azide loading of 10%. The standard
deviations, represented as error bars in Figure 2.4 ranged from  2% to  9%, indicating
that the results were quite reproducible.
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2.2.4 Effects of Surface Functionalization on the Nanoassemblies
During the conjugation reactions, all of the micelles and vesicles remained well-dispersed
and the solutions were clear. As shown in Figures 2.5a and 2.5d, TEM confirmed that the
micelles and vesicles remained intact following the click reaction. However, upon
removal of the excess alkyne and other reagents by aqueous dialysis, aggregation was
observed in some cases. In the case of dendron 1.33 with the vesicles, DLS
measurements revealed aggregation, even at low azide loadings (Figure 2.6a), and
beyond 10% azide loading, macroscopic aggregates were observed that could not even be
measured by DLS. In our previous work with PEO-PBD, vesicle aggregates were
observed at azide loadings beyond approximately 20%, but at low loadings the vesicles
remained well-dispersed based on fluorescence confocal microscopy images.25 Thus, the
PEO-PCL vesicles appear to be more sensitive to aggregation. In the case of the
guanidine dendron 2.8, the aggregation was even more extensive. The aggregates formed
at 2% azide loading were detected by DLS (Figure 2.6a) and were imaged by TEM
(Figures 2.5b and c). Based on the TEM images, these aggregates seem to be composed
primarily of vesicles. Beyond 2% azide, macroscopic precipitates were formed and
unfortunately it was not possible to image these by TEM.

Figure 2.5. TEM images of: a) vesicles with 2% azide loading, following conjugation of
dendron 2.8 (prior to dialysis); b) and c) vesicles with 2% azide loading, following
conjugation of dendron 2.8 and dialysis, showing aggregation; d) micelles with 20%
azide loading, following conjugation of dendron 2.8 and dialysis.
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Figure 2.6. Size distribution profiles following click reactions and dialysis, measured by
DLS for: a) vesicles and b) micelles.
The high sensitivity of the vesicles to aggregation upon dendron conjugation may be
in part due to the resulting linear-dendritic copolymers being architecturally unfavorable
for membrane formation. In addition, incorporation of the dendron may disrupt the
hydrophilic-hydrophobic balance of the copolymer that is required for vesicle formation.
These factors may destabilize the vesicle membrane. Nevertheless, the formation of the
aggregates only upon dialysis suggests that these are not the only factors. It is noteworthy
that dendrons 1.33 and 2.8 both possess cationic charges and it is possible that the
presence of the excess dendrons somehow helps to stabilize the dispersed vesicles
through hydrogen bonding or ionic interactions. To further investigate this aggregation
phenomenon additional experiments were performed. First, a fourth generation polyester
dendron 2.14 with a focal point alkyne was prepared as shown in Scheme 2.7.66 This
dendron was selected as it was estimated to have a size similar to dendron 1.33 but
without the cationic charges. Dendron conjugation at azide loadings from 5% to 40%
were investigated and no aggregation was detected in any of these cases, even after
dialysis (Figure 2.6a). This suggests that the dendritic architecture alone is not sufficient
to trigger aggregation in this system, and that the charge of the dendrons was involved.
The use of NaCl solutions (0.2 or 0.5 M) rather than pure water for the dialyses was also
investigated as a means of controlling the counterion and ionic strength of the medium,
but aggregation was still observed. In addition to this, dialysis against buffer solutions at
different pH values were also examined. Dialysis of the samples against phosphate buffer

67
at pH = 6 and acetate buffer at pH = 5 also resulted in the aggregation of the vesicle
samples functionalized with amine and guanidine dendrons. The role of the rhodamine
dye molecule was also investigated. Vesicles functionalized with alkyne 2.10, did exhibit
some aggregation, likely due to the dye's cationic charge and the tendency of polycyclic
aromatic systems to undergo - stacking (Figure A2.12).67 However, the rhodamine was
certainly not the only contributor, as the conjugation of previously reported dendrons
analogous to dendrons 1.33 and 2.8 but lacking the rhodamine,25,62 led to the same degree
of vesicle aggregation as observed with the dye-labeled dendrons. Therefore, it appears
that the PEO-PCL vesicles are sensitive to aggregation, particularly upon conjugation of
cationic molecules. On the other hand, uncharged dendritic molecules, despite their
architecture, seem to be well-tolerated and will be the focus of future work.

Scheme 2.7. Synthesis of dendron 2.14.
In the case of dendron conjugation to the micelles, much less aggregation was
observed. For example, upon conjugation of amine-functionalized dendron 1.33, no
significant aggregation was observed, even at azide loadings up to 100% (Figure 2.6b).
The guanidine dendron 2.8 and the rhodamine 2.10 could also be conjugated at azide
loadings up to 100% without significant aggregation (Figure 2.6b). Thus, overall the
micelles were much less sensitive to aggregation than the vesicles. Unlike the vesicles,
the incorporation of linear-dendritic polymers into micelles is known to be well-tolerated,
and there are several examples of micelles comprising linear dendritic copolymers where
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the dendritic block is hydrophilic or even hydrophobic.68-70 Furthermore, micelle
formation is generally favored for BCPs possessing hydrophilic volume fractions of
>50%.8 Thus, the formation of micelles may be less affected by the increase in
hydrophilic volume fraction imparted by the dendritic groups. The micelles also seem to
be able to tolerate the introduction of charged groups much better than the vesicles. This
may be attributed to the inherent structural differences between the micelles and vesicles.
If the introduction of cationic groups to the vesicle surfaces results in repulsive
interactions that destabilize the membrane, the hydrophobic portions of the membranes
can perhaps become exposed, triggering the aggregation. In contrast, the micelles posses
much shorter hydrophobic blocks that are well-buried at the cores of the micelles. This
may make them inherently more resistant to the aggregation phenomena observed in this
work.

2.2.5 Cellular Uptake of the Guanidine Dendron-Functionalized
Micelles
It has been shown by our group that dextran-coated superparamagnetic iron oxide
nanoparticles bearing guanidine-functionalized polyester dendrons exhibit enhanced cell
uptake relative to the unfunctionalized nanoparticles or those bearing hydroxyl- or aminefunctionalized dendrons.62 To demonstrate that the dendritic surface functionalization
approach can impart new functions to our nanoassemblies, the cellular uptake of micelles
bearing guanidine-functionalized dendrons was investigated in HeLa cancer cells.
Micelles were prepared from a 70/20/10 ratio of polymers 2.3/2.4/2.11 as described
above (Figure 2.7). This provided an azide loading of 20% and the incorporation of
polymer 2.11 provided the rhodamine for visualization of cell uptake. A dendron
analogous to 2.8 but with an eighth guanidine in place of the rhodamine62 was then
conjugated to the micelle surface by the click chemistry protocol described above. This
approach was used as the presence of the rhodamine dye in 2.8 might alter the transport
properties of the dendron. Micelles comprising a 90/10 ratio of copolymers 2.3/2.11 were
used as a control. Due their high levels of aggregation, even at low azide loadings,
guanidine-functionalized vesicles were not included in this experiment.
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Figure 2.7. Preparation of PEO-PCL micelles functionalized with dendrons having
peripheral guanidines, and their uptake into HeLa cells as visualized by fluorescence
microscopy (detection of the rhodamine label). In contrast, micelles bearing the
rhodamine label, but no dendron exhibited no detectable uptake.
Micelles were incubated with the cells at a concentration of 0.1 mg/mL (estimated 0.2
μM concentration of dendron) for 4 h, and then the cells were fixed and imaged by
fluorescence confocal microscopy. As shown in Figure 2.7, cells incubated with the
guanidine-functionalized micelles were strongly fluorescent, while no fluorescence was
detected in cells incubated with the unfunctionalized micelles using the same microscope
settings (Figure A2.13). This suggests that the dendritic surface functionalization
approach can be used to impart cell penetrating properties to PEO-PCL micelles, which
may allow them to more effectively deliver materials such as drugs, DNA, or labels into
cells. Further experimentation will be required to quantify the cell uptake, study the
intracellular tracking of these materials, and explore applications of these materials.

2.3 Conclusion
In conclusion, azide- and methoxy-terminated PEO-PCL BCPs with the appropriate
relative block lengths for formation of micelles and vesicles were prepared with the aim
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of developing surface-functionalized biodegradable assemblies. The azide- and methoxyterminated copolymers were combined in varying ratios to provide assemblies with
varying loadings of surface azide groups. Subsequently, dendrons having focal point
alkyne moieties and peripheral amines, guanidines, or hydroxyl groups, as well as a small
molecule alkyne derivative of rhodamine were conjugated to the surfaces of the micelles
and vesicles using a Cu(I)-catalyzed azide + alkyne cycloaddition reaction. It was found
that the conjugation yields for the dendrons on the vesicles were similar to those reported
previously for PEO-PBD vesicles, while those for the small molecule were higher, likely
due its ability to cross the vesicle membrane. Conjugation yields on the micelle surface
were somewhat lower than expected for the dendrons, but were high for the small
molecule. While the micelles remained well-dispersed following all conjugation
reactions, the vesicles exhibited a propensity to aggregate, particularly upon the
conjugation of cationic alkynes. To demonstrate the applicability of the dendritic surface
functionalization approach, micelles with conjugated dendritic guanidines were shown to
have enhanced cell uptake relative to unfunctionalized micelles.

2.4 Experimental
General Procedures and Materials
Chemicals were purchased from Sigma-Aldrich and were used without further
purification unless otherwise noted. Anhydrous DMF, toluene, and CH2Cl2 were obtained
from a solvent purification system. NEt3 was distilled from CaH2. CL was stirred over
CaH2 for 24 h at room temperature and overnight at 60 ˚C and then it was distilled from
CaH2 at reduced pressure under nitrogen immediately prior to polymerization. PEO
derivatives were purified by precipitation from CH2Cl2 into cold diethyl ether (1:10). The
precipitated PEO was then dried by azeotropic distillation (×3) with dry toluene using a
Schlenk line system under nitrogen. Unless otherwise stated, all reactions were
performed under a N2 atmosphere using flame or oven dried glassware. Column
chromatography was performed using silica gel (0.063-0.200 mm particle size, 70-230
mesh). Dialyses were performed using Spectra/Por regenerated cellulose membranes with
either a 12000-14000 g/mol or 3500 g/mol molecular weight cutoff (MWCO). 1H NMR
spectra were obtained at 400 MHz and

13

C NMR spectra were obtained at 100 MHz.
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NMR chemical shifts are reported in ppm and are calibrated against residual solvent
signal of CDCl3 ( 7.26 and 77 ppm), CD3OD ( 3.34 ppm), or (CD3)2SO ( 2.50 and 40
ppm). Coupling constants (J) are expressed in Hertz (Hz). Infrared spectra (IR) were
obtained as films from CH2Cl2 or THF/MeOH on NaCl plates. UV-visible absorption
spectroscopy was performed on a Varian Cary 300 Bio UV-Visible Spectrophotometer.
SEC was performed in THF using a Waters 515 HPLC pump, Wyatt OptilabRex RI and
miniDAWN-TREOS detectors and two ResiPore (300 x 7.5 mm) columns from Polymer
Laboratories. Polymer MWs were calculated based on the multi-angle light scattering
data using the Wyatt Astra software, with dn/dc values of the polymers determined from
the refractive index (RI) detector using Astra. DLS data were obtained using a Zetasizer
Nano ZS instrument from Malvern Instruments. MALDI-TOF mass spectrometry data
were obtained using a 4700 Proteomics Analyzer, MALDI TOF TOF (Applied
Biosystems, Foster City, CA, USA). Reflectron and linear positive ion modes were used.
High-resolution mass spectrometry (HRMS) was performed using a Finnigan MAT 8400
electron impact (EI) mass spectrometer. Extinction coefficients () of compounds 1.33,
2.8, 2.10, 2.11 and 2.12 were obtained from calibration curves based on the measurement
of UV-visible absorbance versus concentration in CHCl3/MeOH (3/2).
Synthesis of N3-PEO-OH (2.2): HO-PEO-OH (2.1) with a MW of 2000 g/mol (2.0 g,
1.0 mmol, 1.0 equiv.), TsCl (0.22 g, 1.1 mmol, 1.1 equiv.), and DMAP (0.061 g, 0.50
mmol, 0.50 equiv.) were dissolved in dry CH2Cl2 (30 mL). Dry NEt3 (0.12 g, 1.2 mmol,
1.2 equiv.) was then added via syringe. The resulting mixture was stirred at room
temperature for 24 h. Following this, the mixture was washed with cold 1M HCl solution
(1×20 mL) and cold brine (1×20 mL). The organic phase was dried over MgSO4. After
removal of MgSO4 via filtration, CH2Cl2 was removed under reduced pressure. The
residue was taken up in minimal CH2Cl2 and the product was precipitated into cold
diethyl ether. This material was then dissolved in dry DMF (15 mL). Sodium azide (0.16
g, 2.5 mmol, 2.5 equiv. relative to 2.1) was then added and the resulting mixture was
stirred at 100 oC overnight. After cooling to room temperature, distilled water (15 mL)
and CH2Cl2 (15 mL) were added. The organic phase was separated. The aqueous phase
was extracted with CH2Cl2 (3×10 mL) and the combined CH2Cl2 layers were dried over
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MgSO4. After removal of MgSO4 via filtration, the CH2Cl2 was removed under reduced
pressure. The residue was taken up in minimal CH2Cl2 and precipitated into cold diethyl
ether. Subsequent purification by column chromatography using CH2Cl2/MeOH as eluent
(gradient: 19/1 to 14/1) gave compound 2.2 (0.36 g, 0.18 mmol) as a white solid. Overall
yield: 18%. 1H NMR (400 MHz, CDCl3): δ 3.42-3.80 (m, 180H), 3.36 (t, 2H, J = 4.0).
IR (cm-1): 3445, 2884, 2102. MS calcd. for [M+Na]+ based on functionalization of the
starting polymer 2.1 with a peak MW of 1802 g/mol (n = 40): 1827. Found (MALDITOF+): 1827.
Synthesis of Copolymer 2.3 and General Procedure for the Preparation of
Copolymers 2.3-2.6: Dry MeO-PEO-OH (0.25 g, 0.12 mmol, 1.0 equiv.) was added to a
Schlenk flask as a solution in dry toluene (1.5 mL). CL (0.34 g, 3.0 mmol, 24 equiv.) was
then added to the macroinitiator and the resulting solution was equilibrated at 30 oC for
10 min. MSA (0.12 mmol, 7.8 μL, 1.0 equiv.) was then added and the reaction mixture
was stirred at 30 oC for 2.5 h. After cooling to room temperature, the mixture was treated
with Amberlyst® A21 in order to remove the catalyst. The resin was removed by
filtration and the product was precipitated in excess cold hexane. The resulting white
solid was filtered and dried in vacuo to give 0.57 g of the product. Yield = 97%. 1H NMR
(400 MHz, CDCl3): δ 4.21 (t, J = 6.0), 4.05 (t, J = 8.0, 50H), 3.46-3.82 (m, 180H), 3.37
(s, 3H), 2.29 (t, J = 8.0, 50H), 1.63 (m, 100H), 1.37 (m, 50H). IR (cm-1): 3436, 2889,
1724. SEC: Mw = 5500 g/mol, PDI = 1.14, dn/dc = 0.086.
Synthesis of Copolymer 2.4: The copolymer was prepared by the same method
described above for copolymer 2.3 except that compound 2.2 was used as the
macroinitiator. Yield = 97%. 1H NMR (400 MHz, CDCl3): δ 4.21 (t, J = 6.0, 2H), 4.05 (t,
J = 8.0, 56H), 3.46-3.82 (m, 180H), 3.37 (t, J = 6.0, 2H), 2.29 (t, J = 8.0, 56H), 1.63 (m,
112H), 1.37 (m, 56H). IR (cm-1): 3438, 2869, 2105, 1724. SEC: Mw = 4600 g/mol, PDI =
1.18, dn/dc = 0.078.
Synthesis of Copolymer 2.5: The copolymer was prepared by the same method
described above for copolymer 2.3 except that 82 equiv. of CL were used and the
reaction time was 3.5 h. Yield = 95%. 1H NMR (400 MHz, CDCl3): δ 4.19 (t, J = 6.0,

73
2H), 4.03 (t, J = 8.0, 164H), 3.43-3.79 (m, 180H), 3.35 (s, 3H), 2.28 (t, J = 8.0, 164H),
1.64 (m, 328H), 1.37 (m, 164H). IR (cm-1): 3437, 2867, 1724. SEC: Mw = 12400 g/mol,
PDI = 1.40, dn/dc = 0.060.
Synthesis of Copolymer 2.6: The copolymer was prepared by the same method
described above for copolymer 2.3 except that compound 2.2 was used as the
macroinitiator, 82 equiv. of CL were used, and the reaction time was 3.5 h. Yield = 93%.
1

H NMR (400 MHz, CDCl3): δ 4.21 (t, J = 6.0, 2H), 4.05 (t, J = 8.0, 168H), 3.45-3.80

(m, 180H), 3.38 (t, J = 4.0, 2H), 2.30 (t, J = 8.0, 168H), 1.64 (m, 336H), 1.37 (m, 168H).
IR (cm-1): 3433, 2866, 2100, 1725. SEC: Mw = 12000 g/mol, PDI = 1.19, dn/dc = 0.080.
Synthesis of Dendron 2.8: Dendron 1.3325 (81 mg, 39 µmol, 1.0 equiv.) and the
protected guanidine derivative 2.762 (0.20 g, 0.55 mmol, 14 equiv.) were dissolved in
anhydrous DMF (7 mL) under a nitrogen atmosphere. HBTU (0.20 g, 0.55 mmol, 14
equiv.) was added, followed by HOBt (73 mg, 0.55 mmol, 14 equiv.) and DIPEA (0.14
mL, 0.78 mmol, 20 equiv.). The reaction mixture was stirred under nitrogen in the dark
for 48 h. The product was then purified by dialysis against DMF using a 3500 MWCO
membrane for 24 h. After removal of DMF under reduced pressure, the residue was
dissolved in 2 mL of 1/1 TFA/CH2Cl2, and the reaction mixture was stirred at room
temperature and in dark for 2 h. The solvent was removed under reduced pressure to
provide dendron 2.8 (0.11 g) with approximately one chromophore per dendron
statistically. Yield: 87%. 1H NMR (400 MHz, CD3OD): δ 7.92 (d, J = 8.0, 1H), 7.84-7.75
(m, 3H), 7.65-7.47 (m, 3H), 7.28 (d, J = 12, 1H), 7.10 (dd, J1 = 12.0 , J2 = 4.0, 1H), 7.00
(d, J = 4.0, 1H), 4.84-4.81 (m, 2H), 4.39-4.10 (m, 30H), 3.78-3.65 (m, 8H), 3.55-3.37 (m,
20H), 3.20 (t, J = 8.0, 16H), 3.04 (br s, 1H), 2.76-2.68 (m, 2H), 2.66-2.47 (m, 16H), 2.482.21 (m, 20H), 1.81-1.55 (m, 32H), 1.52-1.07 (m, 49H). IR (cm-1): 3282, 3180, 2943,
2125, 1730, 1670, 1590, 1467. ε: 28008 L mol-1 cm-1 at 563 nm (CHCl3/MeOH, 3/2).
Synthesis of Rhodamine Derivative 2.10: To a solution of 2.965 (0.40 g, 0.73 mmol, 1.0
equiv.) in anhydrous DMF (2 mL) were added propargyl bromide (0.11 g, 0.92 mmol, 1.2
equiv.) and DIPEA (0.16 g, 1.3 mmol, 1.8 equiv.). The reaction mixture was stirred at
room temperature in the dark for 24 h. An additional 1.2 equiv. of propargyl bromide and
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DIPEA was then added, and the resulting solution was stirred for 2 additional h. The
reaction mixture was then partitioned between ethyl acetate and saturated aqueous
NaHCO3. The aqueous layer was extracted with isopropanol/CH2Cl2 (1/3). The organic
layer was collected, dried over MgSO4, filtered, and concentrated to provide 0.33 g of the
desired product. Yield: 82%. 1H NMR (400 MHz, CDCl3): δ 7.69-7.67 (m, 2H), 7.567.54 (m, 1H), 7.37-7.35 (m, 1H), 7.28 (s, 1H), 7.25 (s, 1H), 7.05-7.02 (dd, J1 = 12.0, J2 =
12.0, 2H), 6.81 (d, J = 4.0, 2H), 3.71-3.61 (m, 8H), 3.46-3.41 (m, 2H), 3.38-3.32 (m, 2H),
3.26 (d, J = 4.0, 2H), 2.41-2.33 (m, 4H), 2.24 (t, J = 4.0, 1H), 1.33 (t, J = 8.0, 12H). 13C
NMR (400 MHz, CDCl3): δ 167.2, 157.5, 155.4, 135.2, 131.8, 130.2, 130.0, 129.7, 127.4,
114.0, 113.4, 110.7, 96.1, 73.8, 51.4, 50.7, 47.2, 46.4, 46.0, 41.3, 12.5. HRMS (m/z)
calc’d for C35H42N4O2, 550.3308; found (EI), 550.3221 [M]+. ε: 86201 L mol-1 cm-1 at
563 nm (CHCl3/MeOH, 3/2).
Preparation of Rhodamine-Labeled Copolymers 2.11 and 2.12: Copolymer 2.4 or 2.6
(1.0 equiv.) and rhodamine derivative 2.10 (5.0 equiv.) were dissolved in THF/H2O (2/1).
To the solution were added CuCl22H2O (5.0 equiv.) and sodium ascorbate (50 equiv.),
and the reaction mixture was stirred in the dark at room temperature for 20 h. The
product was purified by first dialysis against distilled water for 24 h followed by dialysis
against DMF for an additional 24 h using a 3500 MWCO dialysis membrane. DMF was
removed in vacuo to give dye-labeled polymers 2.11 (yield: 81%) or 2.12 (yield: 89%),
respectively. Due to low intensity of aromatic peaks of the dye compared to the polymer
peaks, the integration of the 1H NMR spectrum was not possible. However, completion of
the reaction was confirmed by disappearance of the peaks corresponding to the methylene
protons adjacent to the azide group in the polymer (Figure A2.8 and Figure A2.9). ε for
2.11: 22851 L mol-1 cm-1 at 563 nm (CHCl3/MeOH, 3/2). ε for 2.12: 19847 L mol-1 cm-1
at 563 nm (CHCl3/MeOH, 3/2).
Synthesis of Dendron 2.14: Dendron 2.1366 (0.42 g, 0.20 mmol) was dissolved in
methanol (150 mL) and concentrated sulfuric acid (1.5 mL) was added. The resulting
solution was stirred at room temperature for 2 h and then was then neutralized with 7 M
NH3 in MeOH to pH 7. The solution was filtered to remove the (NH4)2SO4 precipitate
and then the solvent was removed under reduced pressure to provide 2.14 (0.35 g) as a
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white solid. Yield: 99%. 1H NMR (400 MHz, DMSO-d6): δ 7.35-6.80 (br s, 16H), 4.72
(d, J = 7.8, 2H), 4.70-4.50 (m, 12H), 4.21-4.07 (m, 16H), 3.49-3.30 (m, 32H), 2.42 (t, J =
7.0, 1H), 1.22 (s, 3H), 1.18 (s, 6 H), 1.15 (s, 12H), 1.00 (s, 24H).

13

C NMR (400 MHz,

DMSO-d6): δ 174.5, 172.2, 171.8, 171.7, 78.3, 78.2, 64.8, 64.1, 53.3, 50.6, 46.7, 46.6,
33.7, 25.7, 24.9, 17.8, 17.6, 17.3, 17.1. MS (m/z) calc'd for C78H124NaO46, 1820; found
(MALDI-TOF), 1820 [M+Na]+.
General Procedure for the Preparation of PEO-PCL Micelles and Vesicles: The BCP
(5 mg) was dissolved in THF (0.5 mL). Distilled water (2 mL) was added dropwise over
10 min with vigorous stirring. After the addition was complete, the resulting
nanoassembly suspension was stirred for 10 min and then dialyzed against 2 liters of
distilled water, using a 12000-14000 MWCO dialysis membrane, with multiple changes
for at least 36 h to remove THF. The vesicles were extruded ten times through a 0.1 μm
polycarbonate membrane at 65 ˚C using a pressure driven Lipex Thermobarrel Extruder
(1.5 mL capacity, Northern Lipids).
General Procedure for Surface Functionalization of Micelles and Vesicles: Micelles
or vesicles were prepared as described above using mixtures of copolymers 2.3 and 2.4
(micelles) or 2.5 and 2.6 (vesicles) in varying ratios (Scheme 2.6). To the assemblies
were added CuCl22H2O (0.40 equiv. relative to total polymer), sodium ascorbate (4.0
equiv. relative to total polymer), and dye labeled dendron 1.33, 2.8, or dye 2.10 (4.0
equiv. relative azides) in sequence and the reaction mixture was stirred at room
temperature for 18 h and then dialyzed against distilled water for 24 h using a 1200014000 MWCO or 3500 MWCO dialysis membrane.
Quantification of Surface Dendritic Groups: Following dialysis, the samples were
lyophilized in order to remove water and were then taken up in about 2 mL of
CHCl3/methanol 3/2. The solutions were centrifuged at 4500 rpm for 4 h to remove any
insoluble material. Finally, the absorbance was measured at 563 nm. The degree of
functionalization was calculated using the measured ε for the dye-labeled dendron 1.33,
dye-labeled guanidine dendron 2.8, or rhodamine-functionalized polymers 2.11 or 2.12 in
the same solvent.
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Transmission Electron Microscopy: The suspension of micelles or vesicles (20 μL, 0.1
mg/mL) was placed on a carbon formvar grid and was left to stand for 5 min. The excess
solution was then blotted off using a piece of filter paper. The resulting sample was dried
in air overnight before imaging. Imaging was performed using a Phillips CM10
microscope operating at 80 kV with a 40 µm aperture.
Uptake of Micelles into HeLa Cells: HeLa cells were maintained at 37 oC and 5% CO2
in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10%
fetal bovine serum (FBS, Invitrogen). Sterilized microscope glass cover slips (22mm 
22mm) were placed in the wells of a 6-well plate and 1.5  105 cells per well were seeded
onto each cover slip. The cells were allowed to adhere for 24 h. The culture medium was
then aspirated and replaced with fresh serum free medium containing control or
functionalized micelles at a concentration of 0.1 mg/mL of polymer. The experiments
were completed in triplicate. The cells were incubated at 37 oC for 4 h. They were then
washed 3 times with phosphate buffered saline (PBS) then fixed with 10%
paraformaldehyde solution for 10 min. The cells were washed again with PBS, and then
the cover slips were placed face down onto microscope slides for confocal microscopy.
Confocal images were obtained using a confocal laser scanning microscope (LSM 510,
Carl Zeiss Inc.) using a 63 (N.A. = 1.4) oil immersion objective and an excitation
wavelength of 543 nm (He-Ne laser).
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Chapter 3
3 Biodegradable Dendritic Polymersomes as Modular, High
Relaxivity MRI Contrast Agents*

3.1 Introduction
The early detection and diagnosis of disease is currently one of the major challenges in
medicine. Clinical imaging plays a significant role in this process. Among the various
imaging modalities, MRI has become a well-established and powerful tool, due to its
excellent spatial resolution and soft tissue contrast. To aid in the differentiation between
healthy and diseased tissues, small molecule Gd(III) chelates such as Magnevist® are used
in approximately 50% of MRI scans. While the availability of these agents has enabled
significant developments in MRI, they do suffer from some significant limitations. For
example, they typically possess longitudinal relaxivities (r1) in the range of 3 - 5 mM-1s-1,
only a small fraction of the theoretically possible values.1 This results in the requirement
for very large doses of these agents and also limits their applicability in molecular
imaging.2 In addition, most of these agents are non-targeted and have very short
circulation half-lives in the blood.
To address these limitations, Gd(III) complexes have been conjugated to a wide
variety of macromolecular scaffolds including dendrimers,3,4 linear polymers,5 proteins,6
viral particles,7 micelles,8,9 liposomes,10,11 and polymersomes.12-14 This can result in
improvements in r1 values due to the slower tumbling rates of macromolecules and the
resulting increases in the rotational correlation times of the Gd(III).15,16 In addition,
macromolecular systems can exhibit prolonged blood circulation times, enabling the
targeting of tissues either passively or actively through the conjugation of targeting
ligands. Among the available macromolecular assemblies, BCP vesicles, commonly
referred to as polymersomes, have attracted significant attention due to their potential
*
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multifunctionality. They possess an aqueous core capable of encapsulating water-soluble
species, a hydrophobic membrane that can encapsulate hydrophobes, and a surface to
which specific targeting ligands or other species can be conjugated. Thus far, there are
very few reports of polymersome-based MRI contrast agents.12-14 Cheng et al. have
investigated porous polymersomes containing Gd(III)-labeled dendrimers within their
aqueous cores, and have obtained an r1 of 7.5 mM-1s-1 (60 MHz, 40 ˚C) on per Gd
basis.12,13 More recently, Grüll et al. incorporated Gd(III)-labeled lipids into a
polymersome membrane, resulting in an r1 of 22 mM-1s-1 (20 MHz, 25 ˚C).14
Our group has developed approaches for the functionalization of polymersome
surfaces with dendritic groups.17,18 It was shown that this is an effective method for
tuning the surface chemistries of polymersomes in a single step, resulting in properties
such as enhanced target binding and cell uptake.19,20 For the current work, it was
proposed that polymersome-immobilized dendrons functionalized with Gd(III)
complexes may serve as highly efficient MRI contrast agents. While conjugation of
Gd(III) complexes to high generation dendrimers is known to enhance their relaxivities,3,4
immobilization on the polymersome surface should provide further enhancements, at the
same time opening the possibility to exploit the multifunctional properties of
polymersomes. We describe here the preparation of the dendron and polymersome
components, and studies of their relaxivities. It is demonstrated how nanoscale
components can be readily combined to provide additive enhancements in relaxivity.

3.2 Results and Discussion
3.2.1 Design and Synthesis
Figure 3.1 depicts the general approach for the preparation of the polymersome MRI
contrast agents. PCL-PEO BCPs were selected due to the biodegradability of the PCL
block and the well demonstrated biocompatibility of PEO in various applications.21
Methoxy- (2.5) and azide-terminated (2.6) PCL-PEO were prepared as previously
reported and were assembled into azide-functionalized vesicles.22 The z-average diameter
of the polymersomes was 140 nm, as measured by DLS.
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Figure 3.1. Schematic for the preparation of dendritic and non-dendritic Gd(III)functionalized polymersomes.
Gd(III)-functionalized dendron 3.1, having a focal point alkyne, was prepared starting
from the third generation polyester dendron 3.5.17 As shown in Scheme 3.1, the
peripheral amine groups of 3.5 were reacted with the commercially available DTPA
isothiocyanate derivative 3.6. The resulting dendron 3.7 was then treated with GdCl3 to
provide the target dendron 3.1.
As shown in Figure 3.1, in order to determine the contribution of the dendron versus
polymersome to the relaxivity, it was also desirable to prepare a non-dendritic alkyne
derivative of the Gd(III) chelate (3.2). As shown in Scheme 3.2, this was accomplished
by the reaction of propargyl amine with 3.6 to provide 3.8, followed by chelation of
Gd(III) to obtain the target compound 3.2.
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Scheme 3.1. Synthesis of Gd(III)-functionalized dendron 3.1.

Scheme 3.2. Synthesis of Gd(III) complex 3.2.
Prior to Gd(III) insertion, compounds 3.7 and 3.8 were characterized by 1H and

13

C

NMR spectroscopy. In addition, IR spectroscopy was informative for this class of
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compounds. For example, upon conversion of dendron 3.5 to 3.7, the absence of the
characteristic C=S stretch of the isothiocyanate functional group that was present in
compound 3.6 confirmed the successful removal of excess 3.6 (Figure A3.1). After
insertion of Gd(III), NMR spectroscopic analysis was no longer possible due to the
paramagnetic nature of the Gd(III) ion. However, inductively coupled plasma mass
spectrometry (ICP-MS) was performed, confirming the successful insertion of Gd(III)
into dendron 3.1 and compound 3.2. In addition, IR spectroscopy demonstrated that the
peaks corresponding to the C=O stretches of the ligand shifted to significantly lower
frequencies in compounds 3.1 and 3.2 relative to 3.7 and 3.8 respectively (Figure A3.1
and Figure A3.2). This is also an indication of successful coordination of the carboxylate
groups to Gd(III).23

3.2.2 Functionalization of Polymersome Surfaces with Dendritic and
Non-Dendritic Contrast Agents
The next step was to conjugate 3.1 and 3.2 to the polymersome surfaces. This was
accomplished by a Cu(I)-mediated 3+2 “click” cycloaddition to provide the dendritic
Gd(III)-functionalized polymersomes 3.3, and non-dendritic Gd(III)-functionalized
polymersomes, 3.4, respectively. Unreacted 3.1 and 3.2 were removed by dialysis. ICPMS measurements were performed on the products and the results indicated that 38% of
the azide groups were functionalized in polymersomes 3.3 and 26% in polymersomes 3.4.
The sizes and morphologies of the resulting polymersomes were evaluated by DLS and
TEM. As shown in Figure 3.2, small increases in the z-average diameters to 158 and 156
nm were found for vesicles 3.3 and 3.4 respectively. It should be mentioned that the
shoulder observed at higher molecular weight region in polymersomes 3.3 (Figure 3.2c)
suggests the existence of a small degree of aggregation upon conjugation of the bulky
dendron 3.1 to the polymersome surfaces. Moreover, TEM showed that the vesicular
morphology was preserved and the contrast was enhanced upon incorporation of the
Gd(III) in both dendritic and non-dendritic polymersomes (Figure 3.3).
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Figure 3.2. Size distribution profiles for: a) naked polymersome; non-dendritic
polymersome 3.4; c) dendritic polymersome 3.3.

Figure 3.3. TEM images of (a) naked polymersome; (b) dendritic Gd(III)-functionalized
polymersomes 3.3; (c) non-dendritic Gd(III)-functionalized polymersomes 3.4.

3.2.3 Evaluation of the Relaxivity Properties of the Contrast Agents
The properties of the three newly developed contrast agents (3.1, 3.3, and 3.4) were
assessed in phosphate buffer (0.1 M, pH 7.4) at 298K (Figure 3.4) and 310 K (Figure
A3.3) between 0.01 and 42 MHz using a field cycling relaxometer. On a per Gd(III)
basis, dendron 3.1 and polymersomes 3.3 and 3.4 exhibited r1 values of 12.1 ± 0.3, 26.1 ±
1.2, and 10.6 ± 0.4 mM-1s-1, respectively (20 MHz, 298 K). In comparison with the
clinical agent Magnevist® (Gd(III)-DTPA) which has a reported relaxivity of 4.6 mM-1s-1
under the same conditions24, this corresponds to 2.6-, 5.7-, and 2.3-fold increases in r1 for
dendron 3.1, and polymersome 3.3 and 3.4 respectively. All of the systems exhibit an r1
versus frequency curve shape that is characteristic of restricted tumbling motion of the
Gd(III) complex.1
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Figure 3.4. Longitudinal relaxivity (r1) of dendron 3.1, polymersome 3.3, and
polymersome 3.4 in phosphate buffer (0.1 M, pH 7.4) as a function of field strength at
298 K.
While polyester dendrons such as 3.1 have not previously been investigated as MRI
contrast agents, the r1 value of 12.1 mM-1s-1 is within the range expected for a third
generation dendrimer.3,4 As with other dendrimers, this enhancement can likely be
attributed to the crowded nature of the dendron periphery, which inhibits the free rotation
of the Gd(III) complexes. The enhanced r1 value of 10.6 mM-1s-1 obtained for the nondendritic polymersomes 3.4 is also likely a result of the hindered motion of the Gd(III)
complexes at the vesicle surface, as well as the slow tumbling rate of the entire vesicle
system. This r1 value is lower than the value of 22 mM-1s-1 at (20 MHz, 25 ˚C) obtained
by Grüll et al. with lipid functionalized Gd(III) chelates incorporated into polymersomes.
This is probably because their chelates were attached directly to the lipids, rather than
through a long linker. The PEO chains in the current work introduce flexibility, which
can decrease the rotational correlation time. PEO surrounding the chelate may also slow
water exchange. However, r1 is higher than for the system reported by Cheng et al.
which contained Gd(III) complexes within the polymersomes.12,13 This can be attributed
to our selective attachment of the chelates to the periphery, where they are easily
accessible to bulk water.
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When both the dendritic component and the polymersome component are combined in
polymersome 3.3, the resulting r1 of 26.1 mM-1s-1 is the highest reported relaxivity for a
polymersome system. This additive effect can result from the availability of chelates at
the vesicle surface for water exchange, hindered motion of the Gd(III) complexes
imparted by the dendron at a local level, as well as the large size and slow tumbling rate
of the polymersome at the nanoscale level. Thus, this work elegantly demonstrates that
different components can be combined through rational design to obtain additive effects
on the relaxivity. An additional feature of the current system relative to those previously
reported is the biodegradability imparted by the PCL block of the copolymer and the
polyester dendron which is known to break down over a period of several days in
physiological conditions.25 This should enable the release of low MW Gd(III) complexes
and polymer products from the body, an important consideration for MRI contrast agents.

3.3 Conclusion
In conclusion, through the synthesis of dendritic and non-dendritic Gd(III) chelates and
their conjugation to polymersome surfaces, three new MRI contrast agents were
developed. Using these systems, the effects of the dendritic and polymersome
components on the relaxivities of the agents were elucidated. They were found to have an
additive effect, resulting in the highest currently reported r1 for a polymersome system. In
addition, this system possesses the advantage of being composed of PEO and
biodegradable polyester components. Future work will be aimed at exploring the
biodegradability and in vivo properties of the system as well as exploiting the
multifunctional capabilities of polymersomes.

3.4 Experimental
General Procedures and Materials
Compound 3.6 was purchased from Macrocyclics (Dallas, USA). All the other chemicals
were purchased from Sigma-Aldrich and were used without further purification unless
otherwise noted. Anhydrous DMF was obtained from a solvent purification system using
aluminum oxide columns. NEt3 was distilled from CaH2. Ultrapure water was obtained
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from a Barnstead EASYpure II system. Unless otherwise stated, all reactions were
performed under a nitrogen atmosphere using flame or oven dried glassware. Dialyses
were performed using Spectra/Por regenerated cellulose membranes with either a 1000,
3500, or 50000 g/mol MWCO. 1H NMR spectra were obtained at 400 MHz, and

13

C

NMR spectra were obtained at 100 MHz. NMR chemical shifts are reported in ppm and
are calibrated against the residual solvent signal of CD3OD (δ 3.31 and 50.41 ppm), or
(CD3)2SO (δ 2.50 and 40.45 ppm). J values are expressed in Hz. IR spectra were obtained
as NaCl pellets using a Bruker Tensor 27 instrument. HRMS was performed using a
Finnigan MAT 8400 electron impact mass spectrometer. DLS data were obtained using a
Zetasizer NanoZS instrument from Malvern Instruments. ICP-MS analysis was
performed at the Environmental Analytical Laboratories of the Saskatchewan Research
Council. Relaxation rate measurements were performed on a Stelar Spinmaster FFC2000
1T C/DC relaxometer at 298 and 310 K using 100 mM pH 7.4 phosphate buffer as
solvent. Error measurements on the relaxivity are based on the combined uncertainties of
the relaxometer measurements and the Gd(III) concentrations in the solutions.
Synthesis of Dendron 3.7: Dendron 3.517 (49 mg, 22 µmol, 1.0 equiv.) and DTPA
derivative 3.6 (0.11 g, 0.18 mmol, 8.0 equiv.) were dissolved in anhydrous DMF (2 mL)
with sonication. Anhydrous NEt3 (0.4 mL) was then added and the reaction mixture was
stirred at room temperature overnight. An additional portion of 3.6 (0.11 g, 0.18 mmol,
8.0 equiv.) was added the next morning and the mixture was stirred for another 12 h at
room temperature. Distilled water (1 mL) was then added to dissolve the resulting solid
and the solution was dialyzed against distilled water (2 L) using a 3500 g/mol MWCO
membrane for 24 h. The sample was lyophilized to provide dendron 3.7 as a light yellow
fluffy solid (0.12 g, 73%). 1H NMR (CD3OD): δ 7.54-7.35 (m, 16H), 7.32-7.19 (m, 16H),
4.79 (br s, 2H), 4.40-4.16 (m, 28H), 3.89-3.40 (m, 112H), 3.24-2.94 (m, 296H), 2.80-2.68
(m, 16H), 1.27 (t, 384H, J = 8). 13C NMR (CD3OD): δ 180.7, 174.6, 171.7, 169.9, 169.4,
158.4, 138.2, 129.3, 124.1, 123.6, 62.3, 57.2, 55.6, 54.3, 53.9, 53.8, 52.5, 45.8, 39.6, 38.6,
38.4, 37.8, 33.4, 32.0, 25.4, 24.7, 17.1, 17.0, 7.9. IR (cm-1): 3444, 2976, 2939, 2678,
2495, 1740, 1628.
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Synthesis of Dendron 3.1: Dendron 3.7 (30 mg, 3.9 µmol, 1.0 equiv.) was dissolved in
ultrapure water (4 mL). Using 0.1 M NaOH (in ultrapure water), the pH of the dendron
solution was carefully adjusted to 7.4. GdCl3·6H2O (46 mg, 0.12mmol, 32 equiv.) was
then added as a solution in ultrapure water. The pH of the solution was again adjusted to
7.4 using the 0.1M NaOH. The resulting solution was stirred at room temperature for 20
h. After this period of time, the mixture was transferred to a 1000 g/mol MWCO
membrane and dialyzed against ultrapure water for 24 h. The sample was centrifuged at
5000 rpm for 30 min to remove any insoluble species. Finally, the sample was
lyophilized to give the target Dendron 3.1 as a fluffy white solid (19 mg, 65%). IR (cm-1):
3421, 2924, 1735, 1602.1H and

13

C NMR of this compound could not be obtained

because of paramagnetic Gd(III) ions. ICP-MS: mass of dendron analyzed: 2.4 mg; mass
of Gd(III) expected: 0.43 mg; mass of Gd(III) found: 0.42 ± 0.01 mg. This suggests that
all eight positions at the periphery of dendron 3.1 were functionalized with the DTPA
derivative and these successfully chelated Gd(III).
Synthesis of compound 3.8: Compound 3.6 (21 mg, 33 µmol, 1.0 equiv.) and
propargylamine hydrochloride (2.7 mg, 30 µmol, 0.90 equiv.) were dissolved in
anhydrous DMF (0.5 mL) and anhydrous NEt3 (0.4 mL). The mixture was stirred at room
temperature overnight. The solvents were removed under reduced pressure and the
obtained target molecule 3.8 was used without further purification (quantitative yield). 1H
NMR (DMSO-d6): δ 7.45 (d, 2H, J = 8), 7.10 (d, 2H, J = 8), 5.21 (d, 2H, J = 16), 4.74 (s,
1H), 3.63 (br s, 2H), 3.52-3.18 (m, 12H), 3.12-2.91 (m, 5H), 2.88-2.75 (m, 5H), 2.47-2.40
(m, 1H), 1.18 (br s, 9H).

13

C NMR (DMSO-d6): δ 189.6, 162.7, 153.2, 132.2, 129.7,

118.6, 78.0, 77.6, 74.4, 45.6, 37.0, 31.2, 31.2, 28.5, 8.8. IR (cm-1): 3422, 2978, 2676,
2495, 2125, 1637. HRMS: calcd [M]+ (C25H33N5O10SNa): 618.1846 Found: (EI)
618.1830.
Synthesis of compound 3.2: Compound 3.8 (23 mg, 21 µmol, 1.0 equiv.) was dissolved
in ultrapure water (3 mL). Using 0.1 M NaOH (in ultrapure water) the pH of the solution
was carefully adjusted to 7.4. GdCl3·6H2O (12 mg, 31 µmol, 1.5 equiv.) was then added
as a solution in ultrapure water. The pH of the solution was again adjusted to 7.4 using
0.1 M NaOH. The resulting solution was stirred at room temperature for 20 h. The
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sample was centrifuged at 5000 rpm for 30 min to remove any insoluble species. Finally,
the sample was lyophilized to give the target molecule 5 as a white solid (12 mg, 70%).
IR (cm-1): 3412, 2924, 1603. 1H and

13

C NMR of this compound could not be obtained

because of paramagnetic Gd (III) ions. ICP-MS: mass of sample analyzed: 0.51 mg; mass
of Gd(III) expected: 0.10 mg; mass of Gd(III) found: 0.16 ± 0.01 mg. The higher amount
of Gd(III) found for this sample was expected as no purification was performed on
compound 3.2. However, this is not problematic as the relaxivity of this molecule will not
be evaluated and the excess Gd(III) will subsequently be removed during dialysis of
polymersomes 3.4.
Preparation of dendritic Gd(III)-functionalized polymersomes 3.3: PCL-PEO
polymersomes (2 mg/mL, 5 mL) containing an 80:20 ratio of methoxy-terminated PCLPEO (2.5): azide-terminated PCL-PEO-N3 (2.6) were prepared in ultrapure water as
previously reported.18 To the vesicle suspension was then added 3.1 (5.1 mg, 0.70 µmol,
4.0 equiv. relative to azide polymer) dissolved in minimal ultrapure water. Separately,
CuCl2·2H2O (0.34 mg, 2.0 µmol, 2.3 equiv. relative to total polymer) and
bathophenanthrolinedisulfonic acid (2.4 mg, 4.0 µmol, 4.6 equiv. relative to total
polymer) were combined in ultrapure water (0.2 mL) for 15 min and then the resulting
complex was added to the vesicle suspension followed by addition of sodium ascorbate
(4.0 mg, 20 µmol, 23 equiv. relative to total polymer). The resulting mixture was stirred
at room temperature for 18 h and then dialyzed against phosphate buffer (0.10 M, pH 7.4)
for 24 h using a 50000 g/mol MWCO dialysis membrane. ICP-MS of the sample
prepared

for

relaxivity measurement:

mass

of

Gd(III)

expected

for

100%

functionalization of 2.6: 220 µg; mass of Gd(III) found: 83 ± 4 µg, which corresponds to
38% functionalization of polymer 2.6 in the polymersomes with dendron 3.1. To exclude
the possibility of presence of any free Gd, Xylenol orange test26 was performed and it
was found that less than 0.01% of the Gd(III) present was unchelated. Moreover, ICP-MS
results showed that > 94% of the copper used for reaction was successfully removed by
dialysis.
Preparation of non-dendritic Gd(III)-functionalized polymersomes 3.4: PCL-PEO
polymersomes (2 mg/mL, 5 mL) containing a 50:50 ratio of methoxy-terminated PCL-
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PEO (2.5): azide-terminated PCL-PEO-N3 (2.6) were prepared in ultrapure water as
previously reported.18 To the vesicle suspension was then added 3.2 (1.4 mg, 1.7 µmol,
4.0 equiv. relative to azide polymer) dissolved in minimal ultrapure water. Separately,
CuCl2·2H2O (0.34 mg, 2.0 µmol, 2.3 equiv. relative to total polymer) and
bathophenanthrolinedisulfonic acid (2.4 mg, 4.0 µmol, 4.6 equiv. relative to total
polymer) were combined in ultrapure water (0.2 mL) for 15 min and then the resulting
complex was added to the vesicle suspension followed by the addition of sodium
ascorbate (4.0 mg, 20 µmol, 23 equiv. relative to total polymer). The resulting mixture
was stirred at room temperature for 18 h and then dialyzed against phosphate buffer (0.10
M, pH 7.4) for 24 h using a 50000 g/mol MWCO dialysis membrane. ICP-MS of the
sample prepared for relaxivity measurement: mass of Gd(III) expected for 100%
functionalization of 2.6: 68 µg; mass of Gd(III) found: 18 ± 1 µg, which corresponds to
26% functionalization of polymer 2.6 in the polymersomes with compound 3.2. Xylenol
orange test showed that only 0.06% of the of the Gd(III) present was unchelated. In
addition, ICP-MS results confirmed successful removal of more than 97% of the copper
used for the reaction by dialysis.
*Note: The reason why a different composition of 2.5:2.6 was used for polymersome
formation here than for polymersomes 3.3 is to account for the higher loading of Gd that
was introduced by each dendron 3.1, because each dendron can potentially introduce
eight Gd ions while each of molecule 3.2 can only introduce one Gd ion.
Transmission electron microscopy: A small portion of the vesicle suspension was
dialyzed against distilled water to remove any salts from the phosphate buffer. The
suspension (20 µL, 0.1 mg/mL) was then placed on a Carbon/Formvar® grid and was left
to stand for 5 min. The excess solution was then blotted off using a piece of filter paper.
The resulting sample was dried in air overnight before imaging. Imaging was performed
using a Phillips CM10 microscope operating at 80 kV with a 40 µm aperture.
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Chapter 4
4 Multifunctional Dendritic Sialopolymersomes as Potential
Antiviral Agents: Their Lectin Binding and Drug Release
Properties*

4.1 Introduction
Amphiphilic BCPs have been demonstrated to undergo self-assembly in solution to form
a wide range of structures including spherical micelles,1 helical rods,2 toroids,3 vesicles,1,4
tubes,5 and multicompartment cylinders.6 In recent years, polymer vesicles, commonly
referred to as polymersomes, have garnered significant attention.7-9 They are attractive
materials because they can be readily accessed using a wide range of BCPs, and relative
to their counterparts formed from low MW surfactants, polymersomes typically exhibit
much lower critical aggregation concentrations and enhanced thermodynamic and kinetic
stabilities.6,10 In addition, they are potentially multifunctional, possessing an aqueous core
capable of encapsulating water-soluble molecules, a hydrophobic membrane that can
encapsulate hydrophobic species, and a surface to which specific targeting ligands or
other moieties can be conjugated. Based on these properties, there has been particular
interest in biomedical applications of polymersomes and they have been employed as
carriers for proteins,11,12 hydrophilic drugs,13,14 and imaging contrast agents.15
Influenza viruses are highly contagious viruses known to cause widespread seasonal
epidemics as well as potentially catastrophic pandemics. The two glycoproteins
hemagglutinin (HA) and neuraminidase (NA) on the virus are responsible for the
initiation and sustenance of the infection process. N-Acetylneuraminic acid (Neu5Ac) is
the most abundant sialic acid found in mammalian cells. It is known that all types of
influenza viruses interact with Neu5Ac residues on the host cell surface through their
HA, and this is followed by endocytosis of the virus into the cell.16-18 Release of the
*
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progeny virus from the infected cell is then triggered by NA-catalyzed cleavage of the
terminal Neu5Ac.16 Most of the effort in developing anti-influenza drugs has been
devoted to the design of drugs that can cease the release of progeny virus after cell
infection. Drugs in this category include the proton channel M2 targeting drugs such as
amantadine and rimantadine,19 and NA inhibitors such as zanamivir and oseltamivir.20
However, it has been proposed that various influenza strains are prone to the
development of resistance to these drugs.19 An alternative approach involves the
inhibition of the initial adhesion of the virus HA glycoprotein to Neu5Ac moieties on
target cells and thus prevention of the initial cell infection. Monomeric Neu5Ac can
inhibit this interaction, but only at millimolar concentrations.19 In order to achieve
inhibition at lower concentrations, Neu5Ac has been conjugated to various scaffolds to
obtain multivalent displays. In this context, polymers,17,18,21-24 dendrimers,25-30
liposomes,31-33

gold

nanoparticles,34,35

nanogels,36

and

polymer

nanoparticles37

functionalized with Neu5Ac have been proposed as potential inhibitors of influenza virus
infection.
Because of their high multivalency, multifunctional capabilities, tunable size, and
morphological resemblance to mammalian cells, polymersomes are attractive scaffolds
for the study of carbohydrate-protein interactions38-44 and for the potential development
of therapeutics and vaccines.38-45 However, to the best of our knowledge there are
currently no examples of carbohydrate-functionalized polymersomes capable of
interacting with viral proteins. Our group has recently developed approaches for the
introduction of dendritic groups to the surfaces of polymersomes.46,47 Owing to the high
multivalency of dendrons, this approach provides a means of tuning the polymersome’s
surface chemistry using a single synthetic step.48 Furthermore, using mannose as a model
biological ligand, it was demonstrated that binding to the target protein Con A was
significantly enhanced using the dendritic approach in comparison with the conjugation
of small molecule mannose derivatives directly to the polymersome surface.42 This was
attributed to the increased availability of the dendritic mannose in comparison to the
small molecule mannose derivatives on the polymersome surface, as well as a cluster
effect resulting from the dendritic ligand display. This suggested the promise of dendritic
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polymersomes for the development of new therapeutic inhibitors based on multivalent
carbohydrate displays.
Here we exploit the multivalent and multifunctional capabilities of polymersomes in a
dendritic sialopolymersome system designed to interact with the influenza virus at two
different stages in the infection process. First, the preparation of biodegradable PEO-PCL
polymersomes functionalized with dendritic Neu5Ac is described, and their binding
affinities to the sialic acid-binding lectin Limax flavus agglutinin (LFA) were compared
with those of a small-molecule Neu5Ac derivative as well as dendritic Neu5Ac in an
enzyme-linked lectin inhibition assay (ELLA). Second, it is demonstrated that in addition
to the Neu5Ac at the polymersome surface, which is designed to interact with HA,
preventing uptake of the virus into the host cells, it is also possible to encapsulate the
drug zanamivir, an NA inhibitor, into the aqueous core of the polymersomes. Release of
this drug in the vicinity of infected cells, should further hinder the spread of viral
infection through a synergistic effect. The release rates of the drug from both naked and
dendritic sialopolymersomes are studied and compared.

4.2 Results and Discussion
4.2.1 Sialodendron Synthesis
To obtain the desired Neu5Ac-functionalized dendron for conjugation to the
polymersome surface, a polyester dendron (3.5) based on bis-MPA (Scheme 4.1) was
selected due to its demonstrated biocompatibility and ease of synthesis.46,49 It was
envisioned that as previously reported, the focal point alkyne moiety would enable
conjugation to azide functionalized vesicles via Cu(I)-catalyzed azide + alkyne “click”
cycloaddition chemistry,

46,47

while peripheral amine groups would provide sites for the

conjugation to an Neu5Ac derivative. This dendron was prepared as previously
reported.46 An isothiocyanate derivative of Neu5Ac was selected because an unprotected
Neu5Ac isothiocyanate can be prepared and selectively reacted with the dendritic amines
to provide a stable thiourea linkage, without the need for deprotection of the carbohydrate
once on the polyester dendron backbone. To prepare the target Neu5Ac derivative, the
amine-functionalized Neu5Ac 4.1 was first synthesized in five steps starting form
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commercially available Neu5Ac according to previously published procedures.29,50 Next,
upon reacting 4.1 with thiophosgene, the isothiocyanate group was successfully installed
to obtain the target molecule 4.2 in quantitative yield (Scheme 4.1). Dendron 3.5 was
then reacted with Neu5Ac derivative 4.2 in the presence of NEt3 to obtain the target
Neu5Ac-functionalized dendron 4.3 in good yield.

Scheme 4.1. Synthesis of sialodendron 4.3.
To quantify the functionalization of the polymersomes with the Neu5Acfunctionalized dendron, it was necessary to tag the sialodendron with a chromophore for
quantification using UV-visible absorption spectroscopy. This approach has proven to be
reliable for the quantification of polymersome surface functionalization with dendritic
groups.46-48,51 For this purpose, the third generation dendron 1.3346 bearing peripheral
amine functional groups and statistically one rhodamine dye per molecule was reacted
with Neu5Ac derivative 4.2 under the same reaction conditions used for the synthesis of
4.3, to obtain the rhodamine-labeled sialodendron 4.4 (Scheme 4.2). ε for 4.4 was then
measured in MeOH/DMF (10/1) to be 43980 Lmol-1cm-1 at 563 nm.

99

Scheme 4.2. Synthesis of rhodamine-labeled sialodendron 4.4.

4.2.2 Functionalization of Polymersomes with Sialodendrons
To functionalize PEO-PCL polymersomes with sialodendrons, polymersomes with
varying densities of surface azides were first prepared from mixtures of methoxy- (2.5)
and azide-terminated (2.6) PEO-PCL BCPs as previously reported.47 With the aim of
quantifying the conjugation yields at different azide densities, azide + alkyne “click”
reactions were then performed using CuCl2, sodium ascorbate, and four equivalents of
dendron 6 relative to the azide (Scheme 4.3). The reaction mixtures were stirred at room
temperature in the dark overnight and then the unreacted dendrons and other reagents
were removed by dialysis. After water was removed by lyophilization, the product of
each reaction was dissolved in DMF/MeOH (10/1), and the UV–visible absorbance was
measured. Using the ε measured for dendron 4.4, the yield of the conjugation reaction on
polymersome surface was calculated.
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Scheme 4.3. Preparation of dendritic sialopolymersomes.
The conjugation yields for the reaction of polymersomes with the rhodamine-labeled
sialodendron 4.4 are shown in Figure 4.1. Consistent with our previous studies, the yields
were higher than 50% at lower loadings of azide-terminated copolymer.42,46,47 It should
be noted that approximately 50% of the azides should be located in the interior of the
vesicles, and thus inaccessible to the dendron, which is unlikely to diffuse through the
vesicle membrane. As a result, this observation may be attributed to the dynamic nature
of the vesicles, allowing azides from the vesicle interior to migrate to the vesicle surface
during the reaction time and then subsequently react. To ensure that the high reaction
yields were not the result of noncovalently immobilized dendron remaining after dialysis,
a control experiment was also performed on polymersomes composed entirely of
methoxy-terminated copolymer 2.5 but with the same excess of dendron and other
reaction and purification conditions used for vesicles containing 20 wt% copolymer 2.6.
In this case, the apparent ‘‘yield’’ was less than ~5%, indicating that no significant
amount of noncovalently immobilized dendron remained after dialysis. The reproducibity
of the conjugation was assessed by performing the conjugation experiment in triplicate on
polymersomes composed of 20 wt% copolymer 2.6 and it was found that the standard
deviation was less than 6%.
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Figure 4.1. Yields for the azide + alkyne “click” conjugation reaction between dendron
4.4 and PEO-PCL polymersomes having varying percentages of azide-terminated
copolymer 2.6 (remaining percentage is methoxy-terminated PEO-PCL 2.5). Note that
the error bar on the 20 wt% copolymer 2.6 measurement represents the standard deviation
of triplicate experiments designed to assess the reproducibility of the conjugation.
These polymersomes were also characterized by DLS. The initial PEO-PCL
polymersomes had a z-average diameter of 140 nm and a low PDI of 0.11. After
conjugation with dendron 4.4, no significant changes were observed at lower percentages
of azide-functionalized copolymer 2.6. Beyond 40 wt% copolymer 2.6, some aggregation
was observed (Figure A4.2). This can be explained by taking into account that the lineardendritic architecture of the resulting triBCPs as well as the newly imparted hydrophilichydrophobic balance might be unfavourable for polymersome formation at high degrees
of dendritic functionalization.

4.2.3 Evaluation of Inhibitory Potencies Using an Enzyme-Linked
Lectin Inhibition Assay
On the basis of the quantification of sialodendron conjugation to the polymersomes, as
well as the aggregation observed at the highest degrees of dendritic functionalization, two
dendritic sialopolymersome samples based on 20 wt% and 40 wt% azide-functionalized
copolymer 2.6 were prepared in order to evaluate their lectin binding potencies using an
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ELLA. These polymersomes were prepared as described above but using fully sialylated
dendron 4.3 rather than dendron 4.4. As shown in Figure 4.2a, for the volume
distribution, DLS showed no change in the size of polymersomes after reaction with
dendron 4.3. The intensity distribution was very similar, with no aggregation detected
(Figure A4.3). Although a modest increase in polymersome hydrodynamic diameter
might be expected upon dendron conjugation, this has generally not been observed in our
previous work.47,60 It is possible that the hydrophobic backbone may be able to integrate
itself to some extent into the polymersome membrane, mainly leaving the hydrophilic
surface groups exposed to the aqueous solution, and also that the modest size change may
be difficult to reliably detect by DLS.

TEM was also used to confirm that the

polymersomes retained their integrity after their reaction with dendron 4.3 and their
diameters were in agreement with those measured by DLS. This result, as well as the
TEM image of the naked polymersomes, are shown in parts b and c, respectively, of
Figure 4.2.

Figure 4.2. a) Size distribution profiles for naked polymersomes and polymersomes
composed of different percentages of azide-functionalized copolymer 2.6 following
“click” conjugation of dendron 4.3; b) TEM image of polymersomes prepared from 40
wt% copolymer 2.6 following conjugation of dendron 4.3; c) TEM image of naked
polymersomes prepared from 100 wt% copolymer 2.5. Scale bars are 500 nm.
With the dendritic sialopolymersomes in hand, their protein binding properties were
then evaluated using an ELLA. In this assay, the polymersomes were compared to
dendron 4.3 and to a monovalent Neu5Ac derivative phenyl 2-thio-α-sialoside (4.5)50.
LFA has been shown to be a specific lectin for Neu5Ac and N-glycolylneuraminic acid
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with a much greater binding affinity towards Neu5Ac. This has made it a good candidate
to study Neu5Ac-protein binding.52 The ELLA was performed as reported by Roy and
coworkers,28,29 where the inhibition of the binding of horseradish peroxidase-labeled LFA
(HRP-LFA) to human α1-acid glycoprotein (coating antigen) was studied.
The results of the ELLA are shown in Figure 4.3. In general, the inhibition did not
reach 100%, which has commonly been observed in such assays with Neu5Ac28 and other
sugars.53,54 For the monovalent Neu5Ac derivative 4.5, the concentration required for
50% inhibition of LFA binding to the coating antigen (IC50) was 4.0 ± 1.0 mM. In
contrast, dendron 4.3 having 8 Neu5Ac moieties exhibited an IC50 value of 30 ± 5 µM
(240 µM per sialoside moiety), which means that it was approximately 17 times more
potent than the monovalent sialoside 4.5 on a per sialoside basis. This result is
comparable with the results obtained previously by Roy and coworkers for dendritic
sialosides.28 When this dendron was conjugated to the polymersome surface, the resulting
materials exhibited a much stronger potency towards the inhibition of LFA binding to
human α1-acid glycoprotein. For instance, when dendritic sialopolymersomes prepared
from 20 wt% and 40 wt% azide-terminated copolymer 2.6 were tested, IC50 values of
0.24 ± 0.10 µM and 0.28 ± 0.12 µM were obtained respectively on a per dendron basis
(1.92 µM and 2.24 µM per sialoside respectively). This means that the
sialopolymersomes exhibit a greater than 100-fold increase in LFA binding inhibition
potency compared to dendron 4.3 and almost 2000-fold enhanced potency relative to
monovalent compound 4.5 on per sialoside basis. This can perhaps be attributed to the
increased ability of the larger polymersome systems to span the two Neu5Ac binding
sites on LFA in comparison with the relatively small and compact dendrons on their own.
The two different polymersome systems exhibit very similar IC50 values on a per dendron
(or per sialoside) basis relative to one another, indicating that in this range of dendron
densities there is no further increase in multivalent effect to be gained from increased
Neu5Ac density at the polymersome surface, though the sialopolymersomes prepared
from 40 wt% copolymer 2.6 would exhibit higher potency on a per polymersome basis.
Such plateauing of multivalent effects is commonly observed with dendrimeric and
polymeric sialosides and has been attributed to factors such as lack of involvement of
some of the glycoside residues in binding due to conformation constraints.28,55-60
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Figure 4.3. Inhibition of binding of LFA to human α1-acid glycoprotein by a)
monovalent Neu5Ac derivative 4.5; b) sialodendron 4.3; c) dendritic sialopolymersomes
prepared from the conjugation of sialodendron 4.3 to polymersomes prepared from 20
wt% and 40 wt% azide-functionalized copolymer 2.6. Note that in b) and c) the inhibitor
concentration corresponds to the dendron concentration.

4.2.4 Encapsulation and Release of Zanamivir by Naked
Polymersomes and Dendritic Sialopolymersomes
While the binding properties of the sialopolymersomes to LFA were promising on their
own, a key advantage of polymersomes over other macromolecular systems that have
previously been used to display multivalent Neu5Ac, is their potential to simultaneously
perform multiple functions by also exploiting their hydrophobic membrane domains
and/or their aqueous core to encapsulate other bioactive molecules. To demonstrate this,
the water-soluble antiviral drug zanamivir was selected for encapsulation into the
polymersome’s aqueous core. Zanamivir is a dehydrated neuraminic acid derivative in
which a guanidinyl group has been substituted for the hydroxyl group on carbon 4. The
presence of the alkene group in the molecular framework mimics the geometry of the
transition state in the enzymatic reaction and the guanidinyl functional group enhances its
interaction with enzyme’s active site.20 Zanamivir is a highly specific inhibitor for
influenza NA and causes viral replication to cease. Currently there is one prior report
involving the preparation of polymers with both Neu5Ac and zanamivir covalently
conjugated and these were found to be potent inhibitors of wild-type influenza virus,
suggesting the promise of the approach.61 The encapsulation of zanamivir into the
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polymersome core should lead to sustained release of drug, which may prolong and
enhance its therapeutic efficacy, while the binding of the sialopolymersomes to the virus
may target the release to occur in the vicinity of the virus.
To prepare the multifunctional system, dendritic sialopolymersomes prepared from the
conjugation of dendron 4.3 to polymersomes composed of 20 wt% azide-terminated
copolymer 2.6 were selected. To encapsulate the drug, a solution of zanamivir in distilled
water was added to a THF solution of copolymers 2.5 and 2.6. After removal of THF
through evaporation, sialodendron 4.3 was conjugated to the vesicle surface by the Cu(I)catalyzed cycloaddition reaction. Finally, nonencapsulated drug, unreacted 4.3, and click
reaction reagents were removed by rapid dialysis against pH 7.4 phosphate buffer using
Slide-A-Lyser dialysis cassette at room temperature for 3.5 h. That 3.5 h was sufficient
for removal of unencapsulated drug was determined in a separate control experiment
where the free drug was dialyzed in the absence of polymersomes under the same
conditions. After 3.5 h, the sample was transferred to fresh phosphate buffer at 37 °C.
The release of the drug was then evaluated by measuring the UV-visible absorption of the
dialysate at 234 nm, until no further changes in absorbance were observed. To verify that
complete release had been achieved, the polymersomes were disrupted by the addition of
THF. After the THF was removed under reduced pressure, the aqueous solutions were
returned to the dialysis cassette and dialyzed for an additional 24 h. No absorption peak
was detected in the dialysate, confirming that all drug had been previously released. The
release of zanamivir from naked polymersomes was also evaluated to investigate the
effect of the dendritic groups on the encapsulation and release properties of the polymers.
These polymersomes were prepared in the same manner described above for the dendritic
sialopolymersomes except that no dendron conjugation was performed. The release
experiment was performed following the same protocol.
As shown in Figure 4.4a, approximately 50% of the zanamivir was released from the
naked polymersomes over the first day, and complete release was observed after about 6
days. The dendritic sialopolymersomes also released about 50% of the drug over the first
day, and complete release required approximately 4 days (Figure 4.4b). This suggests that
the release rates were quite similar for the naked and dendritic polymersomes, though the
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data suggests that there was a small increase in the release rate of drug imparted by the
dendritic functionalization, perhaps due to the effect of the large dendritic groups on
polymersome stability. Examination of the DLS and TEM data for polymersomes after
the release was complete suggested that the polymersomes were still intact and that drug
release likely occurred through diffusion across the polymersome membrane (Figure
A4.5). Overall, the polymersome systems exhibit a sustained release of zanamivir, which
could be beneficial for its therapeutic effect.

Figure 4.4. Release profiles of zanamivir from a) naked PEO-PCL polymersomes and b)
dendritic sialopolymersomes. All experiments were performed in triplicate.
Using the drug release data as well as the measured extinction coefficient for
zanamivir in phosphate buffer (ε = 6540 Lmol-1cm-1) the amount of encapsulated drug in
each polymersome system was determined, allowing the loading efficiency (mass of drug
in loaded polymersomes relative to mass of initial drug used for sample preparation) and
drug content (mass of drug in loaded polymersomes relative to mass of polymer) to be
calculated. The naked polymersomes were found to have a loading efficiency of 8% ±
1% and a drug content of 31% ± 5% and the dendritic sialopolymersomes had a loading
efficiency of 8.8% ± 0.2% and a drug content of 35% ± 1%. The relatively low loading
efficiencies are intrinsic to the loading method as the drug is expected to partition equally
between the polymersome cores and external solution, and the external solution
constitutes a much greater volume than the polymersome cores. However, the drug
content in these systems is high, which is a desirable property for their application.

107

4.3 Conclusion
In summary, we have developed for the first time, a multifunctional polymersome system
with the potential to interfere with the viral infection process at two levels. First dendritic
Neu5Ac incorporated onto the polymersome surface was designed to inhibit the binding
of the influenza virus HA to Neu5Ac moieties on mammalian host cells. Secondly, the
antiviral drug zanamivir was incorporated into the polymersome core with the aim of also
inhibiting influenza virus NA, thus preventing the release of progeny virus from host
cells. In this study, we showed that sialodendrons based on a polyester backbone could be
synthesized, and their conjugation to biodegradable PEO-PCL polymersomes was
demonstrated and quantified using a rhodamine-labeled dendron. Using an ELLA with a
model sialic acid binding lectin, LFA, it was found that incorporation of Neu5Ac onto the
dendritic scaffold led to a 17-fold enhancement in binding on a per-Neu5Ac basis in
comparison to a small molecule analogue. Incorporation of the dendritic Neu5Ac onto the
polymersome surface led to an almost 2000-fold enhancement, showing the advantage of
the polymersome system for enhancing binding. The antiviral drug zanamivir was
encapsulated in the aqueous core of the dendritic sialopolymersomes during their
preparation and the drug release behavior was studied and compared to that of naked
polymersomes encapsulating the same drug. Sustained release of drug was observed for
both systems with release occurring over a period of several days. Furthermore the drug
content was high (30-35 wt%) for these systems. Combined, this work demonstrates how
polymer self-assembly can serve as a promising approach for enhancing interactions with
biological targets, with an additive effect on target binding imparted by the different
nanoscale components of the system including the dendron and the polymersome, and
with different components of the polymersome performing different functions including
target binding and drug release. Future work will involve an evaluation of this
multifunctional system in in vitro and in vivo models to demonstrate how the combined
functions of the drug loaded dendritic sialopolymersomes can lead to potent inhibition of
viral infection.

4.4 Experimental
General Procedures and Materials
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Compounds 3.551, 4.129,50 and 1.3346 were synthesized according to previously published
procedures. Neu5Ac was purchased from RIA International LLC. HRP-LFA was
purchased from E-Y Laboratories. α1-acid glycoprotein from human plasma was
purchased from Sigma-Aldrich. All the other chemicals were purchased from SigmaAldrich or Alfa Aesar and were used without further purification unless otherwise noted.
Anhydrous DMF was obtained from a solvent purification system using aluminum oxide
columns. NEt3 was distilled from CaH2. Unless otherwise stated, all reactions were
performed under a nitrogen atmosphere using flame or oven dried glassware. Dialyses
were performed using Spectra/Por regenerated cellulose membranes with a 1,000 g/mol,
3500 g/mol, or 25,000 g/mol MWCO. 1H NMR spectra were obtained at 400 MHz, and
13

C NMR spectra were obtained at 100 MHz. NMR chemical shifts are reported in ppm

and are calibrated against the residual solvent signal of (CD3)2SO (δ 2.50 and 39.52
ppm), or CD3OD (δ 3.31 and 49.00 ppm). J values are expressed in Hz. IR spectra were
obtained as NaCl pellets using a Bruker Tensor 27 instrument. HRMS was performed
using a Finnigan MAT 8400 electron impact mass spectrometer. UV–visible absorption
spectroscopy was performed on a Varian Cary 300 Bio UV–visible spectrophotometer.
DLS was performed using a Zetasizer Nano ZS instrument from Malvern Instruments, at
a polymer concentration of 0.05 mgmL-1. Nunclon (Delta) microtiter 96-well plates were
purchased from Thermo Scientific and were used for the incubation of inhibitors and
Horseradish peroxidase-conjugated LFA. Nunc Immuno 96-well plates with flat bottom,
Maxi Sorp, Pinchbar 400 µL/well were purchased from Fisher Scientific and were used
for intigen coating. Absorbances of each well were measured at 410 nm and 570 nm
using a plate reader (Tecan Safire).
Synthesis of Neu5Ac derivative 4.2: Compound 4.129,50 (0.43 g, 1.0 mmol, 1.0 equiv.)
was dissolved in ethanol (80%, 50 mL). Thiophosgene (0.17 mL, 2.3 mmol, 2.2 equiv.)
was then added and the resulting solution was stirred at room temperature for 3 h. The
solvent was then removed under reduced pressure. The remaining residue was then
azeotroped with toluene to remove all traces of water and HCl byproducts (3×20 mL).
The target compound 4.2 was obtained as a light orange solid in quantitative yield (0.47
g). 1H NMR (CD3OD) δ: 7.63 (d, J = 8.0, 2H), 7.27 (d, J = 8.0, 2H), 3.82-3.66 (m, 4H),
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3.58 (dd, J1 = 16.0, J2 = 8.0, 1H), 3.47 (dd, J1 = 8.0, J2 = 4.0, 1H), 3.38 (dd, J1 = 8.0, J2 =
4.0, 1H), 2.87 (dd, J1 = 16.0, J2 = 8.0, 1H), 2.00 (s, 3H), 1.85 (dd, J1 = 12.0, J2 = 4.0, 1H).
13

C NMR ((CD3)2SO) δ: 172.0, 170.1, 137.0, 134.9, 131.2, 129.2, 126.2, 86.2, 76.2, 72.0,

68.6, 66.7, 63.0, 52.2, 48.6, 22.7. IR (film from THF/MeOH, cm-1): 3348, 3085, 2930,
2859,

2090,

1716,

1635,

1558,

1271,

1128.

HRMS:

calcd

for

[M+Na]+

(C18H22N2O8S2Na): 481.0715. Found: (EI) 481.0710.
Synthesis of dendron 4.3: Dendron 3.551 (40 mg, 17 µmol, 1.0 equiv.) was dissolved in
DMF (5 mL). Neu5Ac derivative 4.2 (0.12 g, 0.27 mmol, 16 equiv.) and NEt3 (0.5 mL)
were then added and the resulting solution was stirred at room temperature for 48 h. The
mixture was then dialyzed against distilled water using a 1000 g/mol MWCO membrane
for 24 h with multiple dialysate changes. Target dendron 4.3 was obtained in 86% yield
by lyophilization as a light yellow fluffy solid (75 mg, 15 µmol). 1H NMR ((CD3)2SO) δ:
10.16 (br s, 8H), 8.10 (br s, 8H), 7.70-7.25 (br m, 32H), 5.14 (br s, 8H), 4.72 (br s, 10 H),
4.43-4.04 (br m, 28H), 3.86-3.06 (br m, 104H), 2.80-2.51 (br m, 25H), 1.86 (s, 24H),
1.61-1.44 (br m, 8H), 1.32-1.04 (br m, 21H).

13

C NMR ((CD3)2SO) δ: 180.1, 172.0,

171.8, 171.4, 171.3, 171.1, 171.0, 140.5, 135.6, 124.3, 121.6, 87.6, 87.4, 86.0, 77.9, 75.7,
71.7, 68.6, 67.2, 64.9, 63.0, 52.3, 46.2, 46.0, 45.5, 41.4, 36.6, 34.3, 32.9 (2), 22.6, 17.3,
17.0, 8.6. IR (film from THF/MeOH, cm-1): 3340, 3066, 2923, 2855, 2102, 1733, 1652,
1541, 1251, 1126.
Synthesis of rhodamine-labeled dendron 4.4: Dendron 1.3346 (17 mg, 8.4 µmol, 1.0
equiv.) and Neu5Ac derivative 4.2 (54 mg, 0.12 mmol, 14 equiv.) were dissolved in DMF
(2 mL). NEt3 (0.2 mL) was then added and the resulting solution was stirred at room
temperature in dark for 48 h. The resulting material was dialyzed first against DMF, then
against distilled water using a 3500 g/mol MWCO membrane. Dendron 4.4 was obtained
in 81% yield (36 mg, 6.8 mmol) by lyophilization. 1H NMR ((CD3)2SO) δ: 10.07 (br s,
7H), 9.10 (s, 1H), 8.18-8.05 (m, 5H), 7.72 (m, 1H), 7.66-7.22 (m, 28H), 7.16-7.03 (m,
2H), 6.93 (s, 1H), 6.70 (s, 1H), 5.13 (br s, 7H), 4.80-4.60 (m, 9H), 4.40-4.00 (m, 28H),
3.89 (br s, 2H), 3.78-3.08 (m, 93H), 2.71-2.59 (m, 23H), 2.48-2.32 (m, 10H), 2.26 (s,
7H), 1.86 (s, 21H), 1.59-1.45 (m, 7H), 1.29-0.98 (m, 33H). IR (film from THF/MeOH,

110
cm-1): 3309, 3076, 2923, 2852, 2127, 1735, 1649, 1591, 1541, 1247, 1131. ε: 43979
Lmol-1cm-1 at 563 nm (DMF/MeOH, 10/1).
General procedure for dendritic surface functionalization of polymersomes: Azidefunctionalized PEO-PCL polymersomes were prepared as described previously using
BCPs 2.5 and 2.6 to obtain a final polymer concentration of 2 mg/mL in distilled water.47
Dendron 4.3 or 4.4 (4.0 equiv. relative to azide polymer), CuCl2·2H2O (0.40 equiv.
relative to total polymer), and sodium ascorbate (4.0 equiv. relative to total polymer)
were added in sequence to the aqueous suspension of polymersomes and the resulting
reaction mixture was stirred at room temperature and in dark overnight. After this time,
the mixture was dialyzed against distilled water (dendron 4.3 for TEM analysis and
dendron 4.4) or against 10 mM pH 7.3 phosphate buffer (dendron 4.3 for ELLA) for 24 h
using a 25,000 g/mol MWCO membrane to remove excess dendrons and reagents
required for click reaction. We have previously shown by ICP-MS measurements that
this dialysis method effectively removes copper ions up to 97% from the reaction
mixture.62 Therefore, no extra purification methods were applied to remove copper as
trace levels should not interfere with the ELLA assay.
Quantification of click reaction yields on polymersome surfaces: The functionalized
polymersomes were prepared as described above. After dialysis, the samples were
lyophilized to remove water. The resulting residues were then taken up in about 2 mL of
DMF/MeOH (10/1) and were centrifuged at 4500 rpm for 4 h to remove any insoluble
material. Next, the absorbance was measured at 563 nm. The reaction yields were then
calculated using the measured ε for the rhodamine-labeled dendron 4.4 in the same
solvent.
Transmission Electron Microscopy: The suspension of polymersomes (10 µL, 0.05
mgmL-1) was placed on a carbon formvar grid and was left to dry overnight. Imaging
was performed using a Phillips CM10 microscope operating at 80 kV with a 40 µm
aperture.
Enzyme-linked lectin assay: The procedure developed by Roy and coworkers was
adopted for this assay.28,29 The detailed description of this assay is as follows: A stock
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solution of human α1-acid glycoprotein in phosphate buffer (10 mM, pH 7.3) was first
prepared at a concentration of 10 µg/mL. Nunc Immuno 96-well plates were then coated
with this solution overnight. A phosphate buffer (10 mM, pH 7.3) solution containing
0.05% (v/v) Tween 20 (PBST) was then used to wash the wells (3 × 300 µL/well). This
PBST solution was used to wash the wells after each incubation periods throughout the
assay. In the next step, the wells were blocked with phosphate buffer (10 mM, pH 7.3)
containing 1% bovine serum alumin (150 µL/well) for 1 h at 37°C. After washing with
PBST, the inhibitor/HRP-LFA solutions were added to wells (100 µL/well) following by
another 1 h incubation at 37°C. These inhibitor solutions were premade in Nunclon
(Delta) microtiter 96-well plates as follows: The inhibitor (dendritic sialopolymersomes,
sialodendron 4.3, or sialoside 4.5) solutions in PBS were added in serial 2-fold dilutions
to each well (60 µ/well). To these was then added HRP-LFA solution in PBS (60 µL/well
of 100-fold dilution of a 1 mg/mL stock solution of HRP-LFA in PBS) and incubated at
37 °C for 1 h. The inhibitor/HRP-LFA solutions (100 µL/well) were then transferred to
the blocked antigen-coated plate and incubated for 1 h at 37 °C. After washing with
PBST, 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt solution (1
mg/mL) in citrate-phosphate buffer (0.2 M, pH 4.0 with 0.015% H2O2) was added to each
well (50 µL/well) which causes the reaction with the enzyme. After 20 min, the reaction
was stopped by adding 1 M sulfuric acid solution (50 µL/well). Finally, the optical
density was measured at 410 nm relative to 570 nm using plate reader. The percent
inhibition was calculated using the following equation:
% inhibition = [(Ano inhibitor - Awith inhibitor)/Ano inhibitor]×100
In this assay, the concentration of sialopolymersomes was calculated based on initial
loading of azide copolymer 2.6 in the polymersome formation (described above), the
conjugation yield of sialodendron on the polymersome surface at each azide loading,
calculated by UV-visible measurement, as described above, and the total volume of
polymersome solution added in the assay.
Preparation of zanamivir-loaded dendritic sialopolymersomes: To a solution of
polymers 2.5 (4 mg) and 2.6 (1 mg) in THF (0.5 mL) was added zanamivir solution (2
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mL, 10 mg/mL) in distilled water with vigorous stirring. The resulting mixture was
stirred at room temperature overnight with an open cap to remove THF by evaporation.
The click reaction was then performed with dendron 4.3 as described above. The sample
was then transferred to a Slide-A-Lyzer dialysis cassette with a MWCO of 20,000 g/mol
and dialyzed against phosphate buffer (10 mM, pH 7.4) at room temperature for 3.5 h to
remove the unencapsulated drug and other reagents required for click reaction. The time
required for the removal of free drug was determined by performing the same dialysis
using a cassette containing the same concentration of only free zanamivir and waiting
until the absorbance of the drug in the dialysate reached equilibrium as measured by UVvisible spectroscopy at 234 nm. This time was measured to be 3.5 h.
Preparation of zanamivir-loaded naked polymersomes: To a solution of polymer 2.5
(5 mg) in THF (0.5 mL) was added zanamivir solution (2 mL, 10 mg/mL) in phosphate
buffer (10 mM, pH 7.4) with vigorous stirring. The resulting mixture was stirred at room
temperature with an open cap to remove THF by evaporation. The sample was then
transferred to a Slide-A-Lyzer dialysis cassette with a MWCO of 20,000 g/mol and
dialyzed against phosphate buffer (10 mM, pH 7.4) at room temperature to remove the
unencapsulated drug.
Measurement of zanamivir release from the polymersomes: After the removal of free
drug, the Slide-A-Lyzer dialysis cassette containing the loaded polymersomes was
transferred to phosphate buffer (400 mL, 10 mM, pH 7.4) preheated to 37 °C. This point
was taken as t = 0. At certain time points, 3 mL aliquots of the dialysate were taken for
UV-visible measurement. The aliquots were placed back in the dialysate immediately
after measurements. An average of the absorption intensities at 234 nm of aliquots where
the release had clearly plateaued was defined as 100% release and the percent release at
other time points was calculated relative to this value. Moreover, to ensure that complete
release had been achieved, the individual polymersome solutions were mixed with THF
(4 mL) to disrupt the assemblies and release any potential remaining drug. The THF was
removed under reduced pressure and the aqueous solution was returned to the dialysis
cassette and allowed to stir for another 24 h in fresh buffer. At this point, the UV-visible
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spectrum of the dialysate was measured and did not show any absorption peak at 234 nm.
The release experiments were performed in triplicate.
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Chapter 5
5 Synthesis and Degradation of Backbone
Photodegradable Polyester Dendrimers*

5.1 Introduction
Dendrimers are highly branched macromolecules with exact MWs or very low PDIs
resulting from their step-wise synthesis. Higher generation dendrimers possess large
numbers of functional groups on their peripheries and often adopt globular conformations
with internal cavities. These properties have led to much research in the application of
dendrimers for light-harvesting,1,2 organic light-emitting diodes,3,4 catalysis,5,6 and
numerous biomedical areas.7-9 The development of dendrimers that are responsive to
specific stimuli is also of significant interest as this can impart new properties and further
expand their scope of applications. For example, the breakdown of a dendrimer in
response to a stimulus can provide a means of releasing encapsulated cargo or
fragmenting assemblies of dendritic materials.
The first reports on cleavable dendrimers emerged less than two decades ago.10,11
Since then, a number of examples of dendrimers that cleave in response to stimuli such as
pH change,12-14 light,15-24 transition metals,25,26 catalytic antibodies,27,28 and reducing
agents29,30 have been developed. Among these stimuli, light is of particular interest for
the development of smart materials as it can be applied at a specific time and location
with control over its intensity and wavelength. Thus far, several photodegradable
dendrimer systems have been developed through the incorporation of photodegradable
units either at the core of the dendrimer15,19 or at the junction between the hydrophobic
and hydrophilic portions of amphiphilic dendrons.16,20,22,23 The limitation of these
approaches is that following photodegradation, in most cases large residual fragments of
*
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the dendrimer remain, limiting the application of these materials. For example, residual
hydrophobic fragments may undergo aggregation in aqueous solutions. Self-immolative
dendrons that fragment in response to the cleavage of a photoresponsive focal point
moiety have also been developed.17,18,24 However, due to the inherent design of these
materials they have been limited to dendrons rather than dendrimers and are thus far
limited to a very select set of backbone monomers that are derivatives of
dihydroxybenzylalcohols.
Photodegradable linkages have not previously been incorporated throughout the
backbones of dendrimers or dendrons at each monomer unit. This approach would allow
for a rapid, simultaneous cleavage of multiple linkages through the dendrimer backbone,
and is potentially applicable to various dendrimer backbones. However, the incorporation
of photodegradable moieties throughout the dendrimer backbone is a significant synthetic
challenge due to the requirement for extremely clean and efficient chemistry in dendrimer
synthesis. Despite the multitude of reports on dendrimer synthesis over the last few
decades, only a limited number of dendrimer backbones have emerged as widely
accessible synthetically, and minor modifications to the monomer units can dramatically
alter the synthetic process and results. We report here the incorporation of
photodegradable o-nitrobenzyl ester moities31,32 into the widely used bis-MPA dendrimer
backbone and photodegradation studies of the resulting materials.

5.2 Results and Discussion
5.2.1 Design and Synthesis
Our synthetic strategy, an adaptation of the polyester dendrimer synthesis developed by
Ihre et al.,33 involved the divergent synthesis of first, second, and third generation (G1G3) dendrons with alkyne focal points followed by an azide + alkyne “click” conjugation
of the dendrons onto a trifunctional azide core to obtain the target G1-G3 dendrimers.
Due to the photosensitivity of the target molecules and intermediates, all reaction flasks
were protected from light using aluminum foil, but no special measures were required
during the isolation and purification steps. 4-Bromomethyl-3-nitrobenzoic acid (5.1) was
used as the starting material in the synthesis (Scheme 5.1). First, it was necessary to mask
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the carboxylic acid group on 5.1 using a protecting group that would not require acidic or
basic conditions for deprotection as these conditions would cause complications in
subsequent steps of the synthesis. Thus, an allyl ester was installed by reaction with allyl
alcohol using N,N'-dicyclohexylcarbodiimide (DCC) to provide 5.2. Bis-MPA (5.3) was
then introduced in the presence of Cs2CO3 in DMF to provide 5.4 in quantitative yield.
Finally, the principle monomer for dendrimer growth (5.5) was synthesized by
deprotection of the allyl group in 5.4 using Pd(PPh3)4 and piperidine.
With the key monomer in hand, the next step was the synthesis of the G1-G3
dendrons. As an alkyne focal point was desired for the eventual dendron coupling to the
core, the synthesis of the G1 dendron was carried out in a manner similar to that
described above for monomer 5.5, but using propargyl alcohol instead of allyl alcohol.
This provided first the propargyl ester derivative 5.6, followed by the bis-MPA derivative
5.7 (Scheme 5.1). Another key difference was that instead of cleaving the focal point
propargyl alcohol on 5.7, this was left intact and instead the acetonide protecting group
was removed using H2SO4 in MeOH to provide the G1 dendron 5.8 in high yield overall.

Scheme 5.1. Synthesis of monomer 5.5 and G1 dendron 5.8.
Synthesis of the G2 dendron was accomplished by coupling monomer 5.5 to the
deprotected G1 dendron 5.8 using EDC·HCl to provide 5.9 (Scheme 5.2). Removal of the
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acetonide groups under acidic conditions provided 5.10. Repetition of this coupling and
deprotection sequence provided G3 dendron 5.12 in high yield.

Scheme 5.2. Synthesis of G2 dendron 5.10 and G3 dendron 5.12.
In order to construct the target photodegradable G1-G3 dendrimers, dendrons 5.8,
5.10, and 5.12 were attached to a trifunctional azide core molecule 5.1334 via

a

copper(I)-catalyzed alkyne-azide cycloaddition reaction (Scheme 5.3). It should be noted
that 5.13 was handled with care as organic polyazides can be potentially explosive. While
heating the reaction vessel in an oil bath at 70 °C overnight resulted in low dendrimer
yields, likely due to breakdown of ester linkages under these conditions, the reaction
proceeded smoothly under microwave conditions at 120 °C in 20 min.35 Follow-up
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studies showed that the catalyst was still essential under these conditions and that
microwave irradiation played a significant role in accelerating the reaction, even at this
temperature.

Scheme 5.3. Synthesis of G1-G3 dendrimers 5.14 - 5.16.
The resulting dendrimers were characterized by 1H and

13

C NMR spectroscopy,

MALDI mass spectrometry, IR spectroscopy, and SEC. As shown in SEC traces (Figure
5.1), the resulting dendrimers exhibited monomodal molecular weight distribution
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profiles with the expected increases in hydrodynamic volume with each generation, as
well as very narrow PDIs.

Figure 5.1. SEC traces of G1 (5.14), G2 (5.15), and G3 (5.16) dendrimers with their
corresponding PDIs.

5.2.2 Photodegradation Study of the Dendrimers
Having the three dendrimers in hand, their photodegradation behaviors were then studied.
First, ~20 µg/mL solutions of each dendrimer in THF were irradiated with UV light for 1
h and the UV-visible absorption spectra of the solutions were recorded in 2 min intervals
for the first 10 min, followed by 5 min intervals for the remaining 50 min. The results for
the G3 dendrimer (5.16) are shown in Figure 5.2a. A decrease in absorbance was
observed for the peak at 225 nm while increases in absorbance were observed at 305 and
350 nm, along with corresponding red shifts in their absorption maxima. The results for
photolysis of G1 (5.14) and G2 (5.15) dendrimers are shown in Figure A5.1. These
observations are in accordance with the results obtained by other groups for this
photolabile group.15,16,20 The absorption band at 350 nm is attributed to onitrosobenzaldehyde, which is a product of o-nitrobenzyl ester photolysis, and exhibits a
weak absorption band at 350-360 nm that is solvent dependent.16 1H NMR spectroscopy
was also used to study the photodegradation of the dendrimers. A 10 mg/mL solution of
the dendrimer in (CD3)2SO was irradiated with UV light in a quartz NMR tube for 1 h
and

1

H NMR spectra were collected in 10 min intervals. The results for the

photodegradation of G3 dendrimer (5.16) are shown in Figure 5.2b. The results for
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photolysis of G1 (5.14) and G2 (5.15) dendrimers as well as extensive peak assignments
for the degradation of all three dendrimers are shown in Figure A5.2, Figure A5.3 and
Figure A5.4.

Figure 5.2. a) UV-visible spectra for G3 dendrimer (5.16) upon irradiation with UV light
for 60 min. Inset shows the expanded region between 285-450 nm. b) Evolution of 1H
NMR spectra during the photolysis of a 10 mg/mL sample of G3 dendrimer (5.16) in
(CD3)2SO.
As shown for the G3 dendrimer (5.16) in Figure 5.2b, the multiplets at 3.57 and 3.46
ppm, corresponding to the methylene groups of bis-MPA in the dendrimer backbone
decrease as irradiation time increases. At the same time, a new sharp multiplet at 3.45
ppm appears, corresponding to the same methylene groups in the released product bisMPA, a starting material for the dendrimer synthesis. The peak intensities of the methyl
groups in the dendrimer backbone at 1.46, 1.42, and 1.10 ppm also decrease and a single
methyl peak at 1.00 ppm corresponding to the released bis-MPA compound increases in
intensity. The appearance of other smaller multiplets in the region of 3.45 ppm and
singlets in the region of 1.00 ppm can result from the expected release of other bis-MPA
derivatives containing the photocleavable aromatic groups. In addition, a general trend of
peak broadening in the aromatic region was observable, which can be attributed to
formation of different aromatic species after photodegradation, as nitroso compounds are
known to be unstable and undergo side reactions to form other aromatic species such as
diazo compounds.31 However, if the aromatic region is expanded and increased in
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intensity, it is possible to see that the peaks at 7.27 and 8.31 ppm, corresponding to the
core molecule and triazole ring respectively, are still present after 1 h as they do not
participate in degradation process. Moreover, SEC traces of the degraded 1H NMR
samples showed that only small molecules were present, demonstrating the successful
full degradation of the dendrimers (Figure A5.5).

5.3 Conclusion
In summary, we have successfully designed and synthesized a new series of dendrons and
dendrimers that are able for the first time to undergo complete backbone
photodegradation to small molecules. We expect that the incorporation of these dendrons
and dendrimers into new materials will impart new photoresponsive properties and
functions. In addition, tuning of their optical properties by changing the photochemically
responsive group or through the incorporation of other photophysical processes in such a
way that they can undergo photodegradation in the visible or nearinfrared region can
potentially open up new opportunities to access materials with fully photodegradable
hydrophobic blocks suitable for biological or other applications.

5.4 Experimental
General Procedures and Materials
Compounds 5.336 and 5.1335 were synthesized according to the previously published
procedures. All the other chemicals were purchased from Sigma-Aldrich or Alfa Aesar
and were used without further purification unless otherwise noted. Anhydrous DMF was
obtained from a solvent purification system using aluminum oxide columns.
Dichloromethane was distilled from CaH2. Unless otherwise stated, all reactions were
performed under a nitrogen atmosphere using flame or oven dried glassware. For the
reactions that were mentioned to be stirred in dark, aluminum foil was used to isolate the
reaction flasks from light. No special precautions regarding light, were taken during
purification or isolation of these compounds. For long term storage the isolated materials
were stored in freezer. However no degradation issues were encountered when materials
were stored in the dark at ambient temperature. 1H NMR spectra were obtained at 400
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MHz, and

13

C NMR spectra were obtained at 100 MHz. NMR chemical shifts are

reported in ppm and are calibrated against the residual solvent signal of CDCl 3 (δ 7.26
and 77.16 ppm), (CD3)2SO (δ 2.50 and 39.52 ppm), or (CD3)2CO (δ 2.05 and 29.84 ppm).
J values are expressed in Hz. IR spectra were obtained as films from CH2Cl2 or THF on
NaCl plates using a Bruker Tensor 27 instrument. HRMS was performed using a
Finnigan MAT 8400 electron impact mass spectrometer. Electrospray mass spectrometry
(ESI) was performed using a PE-Sciex API 365 mass spectrometer. Melting points
(m.p.) were determined using a Gallenkamp variable heater. UV–visible absorption
spectroscopy was performed on a Varian Cary 300 Bio UV–visible spectrophotometer.
MALDI-TOF mass spectrometry data were obtained using a 4700 Proteomics Analyzer,
MALDI TOF (Applied Biosystems, Foster City, CA). Reflectron and linear positive ion
modes were used. 2-(4'-Hydroxybenzeneazo)benzoic acid (HABA) was used as the
matrix for the measurements. Dialyses were performed using Spectra/Por regenerated
cellulose membranes with either a 12,000–14,000 g/mol or 6000-8000 g/mol MWCO.
SEC instrument was equipped with a Viscotek GPC Max VE2001 solvent module.
Samples were analyzed using the Viscotek VE3580 RI detector operating at 30 C. The
separation technique employed a Polypore guard column (50x7.5mm) and two Agilent
Polypore (300x7.5mm) columns connected in series. Samples were dissolved in THF
(glass distilled grade) at approximately 5 mg/mL concentrations and filtered through 0.22
µm syringe filters. Samples were injected using a 100 µL loop. The THF eluent was
filtered and eluted at 1 ml/min for a total of 30 min. A calibration curve was obtained
from polystyrene standards with MWs ranging from 1,540-1,126,000 g/mol. Microwave
reactions were performed in a Biotage® Initiator Microwave Synthesizer. The light
source used for the photochemical reactions was either a Hanovia medium pressure
mercury lamp (PC 451050/616750, 450 Wage) or a model LZC-4X Luzchem
Photoreactor equipped with Luzchem LZC-UVB lamps.
Note: Triazide 5.13 has been reported to be relatively insensitive to heat and
shock.35,37 However, due to the explosive nature of organic polyazides, this compound
was handled with care. A blast shield was used during concentrating its solution on rotary
evaporator and during further drying under high vacuum.
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Synthesis of compound 5.2: Compound 5.1 (0.50 g, 1.9 mmol, 1.0 equiv.) and allyl
alcohol (2.2 g, 38 mmol, 20 equiv.) were dissolved in CH2Cl2 (14 mL). DCC (0.68 g, 3.3
mmol, 1.7 equiv.) and DMAP (0.12 g, 0.96 mmol, 0.50 equiv.) were then added. The
resulting solution was stirred at room temperature in dark while the course of the reaction
was monitored by thin layer chromatography (TLC) (ethyl acetate (EtOAc):cyclohexane,
1:2). TLC showed that the reaction was complete after 3.5 h. At this point, the solution
was filtered and the filtrate was washed with 1 M KHSO4 (1×50 mL), distilled water
(3×50 mL), and brine (1×50 mL). The organic solution was dried over magnesium
sulfate, filtered, and concentrated under reduced pressure. The product was purified by
column chromatography (EtOAc:cyclohexane, 1:6). Compound 5.2 (0.43 g, 1.4 mmol)
was obtained in 75% yield as a yellow oil. 1H NMR (CDCl3) δ: 8.68 (s, 1H), 8.26 (d, J =
8.0, 1H), 7.68 (d, J = 8.0, 1H), 6.09-5.99 (m, 1H), 5.46-5.41 (m, 1H), 5.36-5.32 (m, 1H),
4.87 (dd, J1 = 8.0, J2 = 4.0, 2H), 4.85 (s, 2H). 13C NMR (CDCl3) δ: 163.8, 148.2, 137.3,
134.3, 133.0, 131.9, 131.6, 126.7, 119.5, 66.7, 28.0. IR (cm-1, film from CH2Cl2): 3093,
2931, 2858, 2106, 1730, 1539, 1351, 1263, 1131. HRMS: calcd for [M]+ (C11H10BrNO4):
298.9793. Found: (EI) 298.9798.
Synthesis of compound 5.4: Compound 5.2 (0.90 g, 3.0 mmol, 1.0 equiv.) was dissolved
in DMF (25 mL). Compound 5.3 (1.0 g, 6.0 mmol, 2.0 equiv.) and cesium carbonate (2.9
g, 9.0 mmol, 3.0 equiv.) were then added. The resulting mixture was stirred at room
temperature in dark while the course of the reaction was monitored by TLC
(EtOAc:cyclohexane, 1:4). TLC showed that the reaction was complete after 1.5 h. At
this point, the mixture was diluted with EtOAc (100 mL), washed with distilled water
(1×100 mL), 1M KHSO4 (1×100 mL), 1M Na2CO3 (2×100 mL), and brine (1×100 mL).
The organic layer was dried over MgSO4, filtered, and concentrated under reduced
pressure. The product 5.4 (1.2 g, 3.0 mmol) was obtained in quantitative yield as a light
orange solid that did not require further purification. 1H NMR (CDCl3) δ: 8.76 (d, J = 4.0,
1H), 8.30 (dd, J1 = 8.0, J2 = 4.0, 1H), 7.86 (d, J = 8.0, 1H), 6.09-5.99 (m, 1H), 5.67 (s,
1H), 5.45-5.40 (m, 1H), 5.35-5.32 (m, 1H), 4.88-4.86 (m, 2H), 4.28 (d, J = 12.0, 2H),
3.72 (d, J = 12.0, 2H), 1.47 (s, 3H), 1.40 (s, 3H), 1.17 (s, 1H).
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C NMR (CDCl3) δ:

173.8, 164.0, 147.3, 137.3, 134.4, 131.6, 131.1, 129.1, 126.3, 119.3, 98.4, 66.6, 66.4,
63.3, 42.6, 26.8, 20.8, 18.4. IR (cm-1, film from CH2Cl2): 3096, 2994, 2932, 2877, 1728,
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1625, 1539, 1373, 1350, 1257, 1158. HRMS: calcd for [M+H]+ (C19H24NO8): 394.1502.
Found: (CI) 394.1499. m. p.: 79.3-81.1 °C.
Synthesis of

monomer 5.5: Compound 5.4 (1.1 g, 2.7 mmol, 1.0 equiv.) and

tetrakis(triphenylphosphine)palladium(0) (0.16 g, 0.14 mmol, 0.050 equiv.) were
dissolved in CH2Cl2 (20 mL). Piperidine (0.40 mL, 4.0 mmol, 1.5 equiv.) was added and
the resulting solution was stirred at room temperature in dark while the course of the
reaction was monitored by TLC (EtOAc:cyclohexane, 1:1). TLC showed that the reaction
was complete after 1 h. At this point, CH2Cl2 was removed under reduced pressure. The
residue was dissolved in EtOAc (100 mL). The organic solution was washed with 1 M
KHSO4 (3×100 mL), brine (1×100 mL), dried over MgSO4, filtered, and concentrated
under reduced pressure. The product was purified by column chromatography using a
gradient of EtOAc:cyclohexane (1:1) to pure EtOAc. Compound 5.5 (0.87 g, 2.5 mmol)
was obtained in 92% yield as a light yellow solid. 1H NMR (CDCl3) δ: 8.80 (d, J = 4.0,
1H), 8.32 (dd, J1 = 8.0, J2 = 4.0, 1H), 7.90 (d, J = 8.0, 1H), 5.69 (s, 2H), 4.31 (d, J = 12.0,
2H), 3.75 (d, J = 12.0, 2H), 1.49 (s, 3H), 1.42 (s, 3H), 1.18 (s, 3H). 13C NMR (CDCl3) δ:
173.9, 168.9, 147.4, 138.0, 134.9, 134.8, 129.2, 126.8, 98.6, 66.4, 63.3, 42.6, 27.0, 20.6,
18.4. IR (cm-1, film from CH2Cl2): 3460, 3249, 2995, 2933, 2887, 2104, 1737, 1625,
1541, 1352, 1222, 1157. HRMS: calcd for [M+H]+ (C16H20NO8): 354.1189. Found: (CI)
354.1198. m. p.: 146.1-148.8 °C.
Synthesis of compound 5.6: Compound 5.1 (0.50 g, 1.9 mmol, 1.0 equiv.) and propargyl
alcohol (2.2 g, 38 mmol, 20 equiv.) were dissolved in CH2Cl2 (14 mL). DCC (0.68 g, 3.3
mmol, 1.7 equiv.) and DMAP (0.12 g, 0.96 mmol, 0.50 equiv.) were then added. The
resulting solution was stirred at room temperature in dark while the course of the reaction
was monitored by TLC (EtOAc:cyclohexane, 1:2). TLC showed that the reaction was
complete after 3.5 h. At this point, the solution filtered and the filtrate was washed with 1
M KHSO4 (1×50 mL), distilled water (3×50 mL), and brine (1×50 mL). The organic
solution was dried over magnesium sulfate, filtered, and concentrated under reduced
pressure. The product was purified by column chromatography (EtOAc:cyclohexane,
1:4). Compound 5.6 (0.47 g, 1.6 mmol) was obtained in 82% yield as light yellow solid.
1

H NMR (CDCl3) δ: 8.70 (d, J = 4.0, 1H), 8.28 (dd, J1 = 8.0, J2 = 4.0, 1H), 7.70 (d, J =
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8.0, 1H), 4.98 (d, J = 4.0, 2H), 4.85 (s, 2H), 2.56 (t, J = 4.0, 1H).
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C NMR (CDCl3) δ:

163.4, 148.2, 137.7, 134.4, 133.1, 131.2, 126.9, 77.0, 76.0, 53.5, 28.0. IR (cm-1, film from
CH2Cl2): 3296, 3096, 2959, 2917, 2131, 1733, 1621, 1537, 1350, 1262, 1132. HRMS:
calcd for [M]+ (C11H8BrNO4): 296.9637. Found: (EI) 296.9641. m. p.: 54.8-56.5 °C.
Synthesis of protected G1 dendron 5.7: Compounds 5.6 (0.64 g, 2.1 mmol, 1.0 equiv.),
5.3 (0.74 g, 4.3 mmol, 2.0 equiv.), and cesium carbonate (2.1 g, 6.4 mmol, 3.0 equiv.)
were dissolved in DMF (20 mL). The resulting mixture was stirred at room temperature
in dark while the course of the reaction was monitored by TLC (EtOAc:cyclohexane,
1:4). TLC showed that the reaction was complete after 1.5 h. At this point, the mixture
was diluted with EtOAc (100 mL), washed with distilled water (1×100 mL), 1M KHSO4
(1×100 mL), 1M sodium carbonate (Na2CO3) (2×100 mL), and brine (1×100 mL). The
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure.
The product 5.7 was obtained in quantitative yield (0.82 g, 2.1 mmol) as an orange solid
that did not require any further purification. 1H NMR (CDCl3) δ: 8.78 (d, J = 4.0, 1H),
8.31 (dd, J1 = 8.0, J2 = 4.0, 1H), 7.88 (d, J = 8.0, 1H), 5.67 (s, 2H), 4.97 (d, J = 4.0, 2H),
4.28 (d, J = 12.0, 2H), 4.72 (d, J = 12.0, 2H), 2.56 (t, J = 4.0, 1H), 1.47 (s, 3H), 1.41 (s,
3H), 1.17 (s, 3H).
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C NMR (CDCl3) δ: 173.8, 163.6, 147.4, 137.7, 134.6, 130.4, 129.2,

126.4, 98.4, 77.1, 75.9, 66.4, 63.2, 53.4, 42.6, 26.9, 20.8, 18.4. IR (cm-1, film from
CH2Cl2): 3291, 3097, 2994, 2967, 2878, 2133, 1738, 1625, 1539, 1373, 1370, 1254,
1154. HRMS: calcd for [M+H]+ (C19H22NO8): 392.1345. Found: (CI) 392.1346. m. p.:
88.4-89.8 °C.
Synthesis of deprotected G1 dendron 5.8: Compound 5.7 (0.79 g, 2.0 mmol) was
dissolved in methanol (50 mL) and CH2Cl2 (5 mL). Concentrated sulfuric acid (0.40 mL)
was added and the resulting solution was stirred at room temperature in dark while the
course of the reaction was monitored by TLC (EtOAc:cyclohexane, 1:2). TLC showed
that the reaction was complete after 2 h. At this point, the solution was concentrated to
one-third of its initial volume. EtOAc (50 mL) was added and the organic solution was
washed with 1M Na2CO3 (2×50 mL) and brine (1×50 mL). The organic layer was dried
over MgSO4, filtered, and concentrated under reduced pressure. The product 5.8 was
obtained in quantitative yield as an orange solid that did not require any further
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purification. 1H NMR (CDCl3) δ: 8.76 (d, J = 4.0, 1H), 8.33 (dd, J1 = 8.0, J2 = 4.0, 1H),
7.84 (d, J = 8.0, 1H), 5.66 (s, 2H), 4.97 (d, J = 4.0, 2H), 4.00 (d, J = 12.0, 2H), 8.79 (d, J
= 12.0, 2H), 2.56 (t, J = 4.0, 1H), 1.12 (s, 3H). 13C NMR (CDCl3) δ: 175.3, 163.6, 147.5,
137.1, 134.7, 130.5, 129.4, 126.4, 77.1, 75.9, 68.8, 63.4, 53.4, 49.7, 17.3. IR (cm-1, film
from CH2Cl2): 3421, 3299, 3097, 2953, 2888, 2126, 1742, 1625, 1541, 1433, 1352, 1249,
1131. HRMS: calcd for [M+H]+ (C16H18NO8): 352.1032. Found: (CI) 352.1039. m. p.:
76.4-77.0 °C.
Synthesis of protected G2 dendron 5.9: Compounds 5.8 (0.30 g, 0.85 mmol, 1.0 equiv.)
and 5.5 (0.91 g, 2.6 mmol, 3.0 equiv.) were dissolved in CH2Cl2 (20 mL). EDC·HCl
(0.74 g, 3.8 mmol, 4.5 equiv) and DMAP (0.10 g, 0.85 mmol, 1.0 equiv.) were added in
one portion and the resulting solution was stirred at room temperature in dark while the
course of the reaction was monitored by TLC (EtOAc:cyclohexane, 1:1). TLC showed
that the reaction was complete after 7 h. At this point, CH2Cl2 was removed under
reduced pressure. The remaining residue was dissolved in EtOAc (50 mL) and washed
with 1M KHSO4 (3×100 mL), 1M Na2CO3 (3×100 mL), and brine (1×100 mL). The
organic layer was dried was dried over MgSO4, filtered, and concentrated under reduced
pressure. The product was purified by column chromatography (EtOAc:cyclohexane,
1:1). Compound 5.9 (0.80 g, 0.78 mmol) was obtained in 91% yield as a fluffy off white
solid. 1H NMR (CDCl3) δ: 8.63 (d, J = 4.0, 1H), 8.62 (d, J = 4.0, 2H), 8.20-8.15 (m, 3H),
7.84 (d, J = 8.0, 2H), 7.64 (d, J = 8.0, 1H), 5.66 (s, 4H), 5.62 (s, 2H), 4.96 (d, J = 4.0,
2H), 4.63 (s, 4H), 4.28 (d, J = 12.0, 4H), 3.73 (d, J = 12.0, 4H), 2.56 (t, J = 4.0, 1H), 1.50
(s, 3H), 1.47 (s, 6H), 1.39 (s, 6H), 1.18 (s, 6H). 13C NMR (CDCl3) δ: 173.7, 171.6, 163.5,
163.2, 147.8, 147.2, 137.7, 135.6, 134.3, 134.2, 130.9, 130.1, 130.0, 129.1, 126.3, 126.0,
98.3, 77.0, 76.0, 66.6, 66.2, 63.8, 63.0, 53.4, 47.1, 42.5, 26.7, 20.7, 18.3, 18.0. IR (cm-1,
film from CH2Cl2): 3269, 2999, 2885, 2137, 1730, 1652, 1539, 1257, 1122. HRMS: calcd
[M+Na]+ (C48H51N3O22Na): 1044.2862. Found: (ESI) 1044.2867.
Synthesis of deprotected G2 dendron 5.10: Compound 5.9 (0.22 g, 0.21 mmol) was
dissolved in a mixture of methanol (40 mL) and CH2Cl2 (4 mL). Concentrated sulfuric
acid (0.40 mL) was added and the resulting solution was stirred at room temperature in
dark while the course of the reaction was monitored by TLC (EtOAc:cyclohexane, 1:1).
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TLC showed that the reaction was complete after 2 h. At this point, the solution was
concentrated to one-third of its initial volume. EtOAc (50 mL) was added and the organic
solution was washed with 1M Na2CO3 (2×50 mL) and brine (1×50 mL). The organic
layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The
product 5.10 (0.20 g, 0.21 mmol) was obtained in quantitative yield as a fluffy light
orange solid that did not require any further purification. 1H NMR (CDCl3) δ: 8.61 (d, J =
4.0, 1H), 8.56 (d, J = 4.0, 2H), 8.17-8.14 (m, 3H), 7.80 (d, J = 8.0,, 2H), 7.65 (d, J = 8.0,
1H), 5.64 (s, 4H), 5.63 (s, 2H), 4.96 (d, J = 4.0, 2H), 4.64 (s, 4H), 4.00 (d, J = 12.0, 4H),
3.80 (d, J = 12.0, 4H), 2.93 (br s, 4H), 2.58 (t, J = 4.0, 1H), 1.49 (s, 3H), 1.13 (s, 6H). 13C
NMR (CDCl3) δ: 175.0, 171.8, 163.6, 163.3, 147.8, 147.1, 137.3, 135.7, 134.3 (2), 130.8,
130.1 (2), 129.2, 126.2, 126.0, 77.0, 76.1, 67.4, 66.8, 63.8, 63.1, 53.4, 49.8, 47.0, 18.1,
17.2. IR (cm-1, film from CH2Cl2): 3440, 3300, 3087, 2932, 2859, 2133, 1737, 1623,
1539, 1352, 1257, 1125. HRMS: calcd [M+Na]+ (C42H43N3O22Na): 964.2236. Found:
(ESI) 964.2266.
Synthesis of protected G3 dendron 5.11: Compounds 5.10 (55 mg, 58 µmol, 1.0 equiv.)
and 5.5 (0.12 g, 0.35 mmol, 6.0 equiv.) were dissolved in CH2Cl2 (10 mL). EDC·HCl
(0.11 g, 0.52 mmol, 9.0 equiv) and DMAP (15 mg, 0.12 mmol, 2.0 equiv.) were added
and the resulting solution was stirred at room temperature in dark overnight. CH2Cl2 was
removed under reduced pressure. The remaining residue was dissolved in EtOAc (50 mL)
and washed with 1M KHSO4 (3×100 mL), 1M Na2CO3 (3×100 mL), and brine (1×100
mL). The organic layer was dried was dried over MgSO4, filtered, and concentrated under
reduced pressure. The product was purified by dialysis against DMF (300 mL) using a
3500 MWCO membrane. The solvent was then removed under reduced pressure.
Dendron 5.11 (0.12 g, 50 µmol) was obtained in 86% yield as a fluffy off-white solid. 1H
NMR (CDCl3) δ: 8.60-8.59 (m, 5H), 8.49-8.48 (m, 2H), 8.20 (dd, J1 = 8.0, J2 = 4.0, 4H),
8.16 (dd, J1 = 8.0, J2 = 4.0, 1H), 8.10 (dd, J1 = 8.0, J2 = 4.0, 2H), 7.85 (d, J = 8.0, 4H),
7.67-7.63 (m, 3H), 5.64 (s, 8H), 5.61 (br s, 6H), 4.94 (d, J = 4.0, 2H), 4.64 (s, 8H), 4.62
(s, 4H), 4.27 (d, J = 12.0, 8H), 3.72 (d, J = 12.0, 8H), 2.57 (t, J = 4.0, 1H), 1.50 (s, 6H),
1.49 (s, 3H), 1.46 (s, 12H), 1.38 (s, 12H), 1.17 (s, 12H).
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C NMR (CDCl3) δ: 173.7,

171.6, 163.6, 163.3, 163.2, 147.9, 147.8, 147.2, 137.8, 135.7, 135.6, 134.3 (2), 134.1,
130.9, 130.8, 130.2, 130.1 (2), 129.1, 126.3, 126.1, 126.0, 98.3, 77.0, 76.0, 66.7, 66.6,
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66.2, 63.9, 63.1, 53.4, 47.1, 47.0, 42.5, 41.8, 26.7, 20.7, 18.3, 18.1, 18.0. IR (cm-1, film
from CH2Cl2): 3300, 3097, 2989, 2879, 2131, 1739, 1625, 1539, 1352, 1249, 1122.
HRMS: calcd [M+Na]+ (C106H111N7O50Na): 2304.6256. Found: (ESI) 2304.6218.
Synthesis of deprotected G3 dendron 5.12: Compound 5.11 (0.10 g, 44 µmol) was
dissolved in methanol (30 mL) and CH2Cl2 (15 mL). Concentrated sulfuric acid (0.50
mL) was added and the resulting solution was stirred at room temperature in dark while
the course of the reaction was monitored by TLC (EtOAc:cyclohexane, 4:1). TLC
showed that the reaction was complete after 2 h. At this point, the solution was
concentrated to one-third of its initial volume. EtOAc (50 mL) was added and the organic
solution was washed with 1M Na2CO3 (2×50 mL) and brine (1×50 mL). The organic
layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The
product 5.12 was further purified by dialysis against DMF (300 mL) using a 3500
MWCO membrane. The solvent was then removed under reduced pressure. Dendron 5.12
was obtained in quantitative yield (93 mg, 44 µmol) as a fluffy off-white solid. 1H NMR
(CDCl3) δ: 8.59 (d, J = 4.0, 1H), 8.51 (d, J = 4.0, 4H), 8.34 (d, J = 4.0, 2H), 8.16-8.14 (m,
5H), 8.06-8.01 (m, 2H), 7.78 (d, J = 8.0, 4H), 7.66-7.62 (m, 3H), 5.63-5.60 (m, 14H),
4.94 (d, J = 4.0, 2H), 4.64 (s, 8H), 4.61 (s, 4H), 3.96 (d, J = 12.0, 8H), 3.78 (d, J = 12.0,
8H), 3.03 (br s, 8H), 2.58 (t, J = 4.0, 1H), 1.50 (s, 6H), 1.48 (s, 3H), 1.12 (s, 12H).
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C

NMR ((CD3)2SO) δ: 174.3, 171.7, 171.6, 163.3, 163.1, 162.9, 147.5, 147.4, 146.9, 137.5,
135.8, 135.6, 134.0, 133.8 (2), 130.6, 130.5, 130.0, 129.8, 129.6, 129.2, 125.3, 125.2,
125.1, 78.4, 77.8, 66.6, 66.5, 64.0, 63.3 (2), 63.2, 62.0, 53.3, 50.7, 46.6, 17.3 (2), 16.9. IR
(cm-1, film from CH2Cl2): 3440, 3290, 3109, 2931, 2854, 2129, 1731, 1623, 1537, 1346,
1255, 1122.

HRMS: calcd [M+Na]+ (C94H95N7O50Na): 2144.5004. Found: (ESI)

2144.5006.
Synthesis of G1 dendrimer 5.14: Compound 5.13 (7.0 mg, 29 µmol, 1 equiv.), dendron
5.8 (36 mg, 0.10 mmol, 3.6 equiv.), copper sulfate (CuSO4) (2.8 mg, 17 µmol, 0.60
equiv.), and sodium ascorbate (14 mg, 69 µmol, 2.4 equiv.) were dissolved in DMF/water
(4:1) mixture (2 mL). The reaction vessel was sealed and irradiated in a Biotage
microwave at 120 °C for 20 min. The reaction content was then partitioned between brine
(50 mL) and EtOAc (50 mL). The organic layer was separated and the aqueous layer was
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extracted with EtOAc (3×50 mL). The organic layers were combined, dried over MgSO 4,
filtered, and concentrated under reduced pressure. The product was purified by column
chromatography (acetone:CH2Cl2, 2:1). Dendrimer 5.14 (33 mg, 25 µmol) was obtained
in 88% yield as a fluffy off-white solid. 1H NMR ((CD3)2SO) δ: 8.52 (d, J = 4.0, 3H),
8.32 (s, 3H), 8.26 (dd, J1 = 8.0, J2 = 4.0, 3H), 7.91 (d, J = 8.0, 3H), 7.26 (s, 3H), 5.61 (s,
6H), 5.50 (s, 6H), 5.43 (s, 6H), 4.79 (t, J = 6.0, 6H), 3.60-3.56 (m, 6H), 3.48-3.44 (m,
6H), 1.11 (s, 9H).
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C NMR ((CD3)2CO) δ: 175.3, 164.6, 148.2, 143.2, 138.6, 138.2,

134.9, 131.2, 130.2, 128.7, 126.3, 125.6, 65.8, 63.1, 59.6, 53.7, 51.5, 17.4. IR (cm-1, film
from THF): 3406, 3155, 2960, 2883, 1730, 1623, 1537, 1350, 1259, 1124. HRMS: calcd
[M+Na]+ (C57H60N12O24Na): 1319.3741. Found: (ESI) 1319.3728 and (MALDI-TOF)
1319.4. SEC data: Mn = 1700 gmol-1, PDI: 1.01.
Synthesis of G2 dendrimer 5.15: Compound 5.13 (4.0 mg, 16 µmol, 1 equiv.), dendron
5.10 (56 mg, 59 µmol, 3.6 equiv.), CuSO4 (1.6 mg, 9.8 µmol, 0.60 equiv.), and sodium
ascorbate (7.8 mg, 39 µmol, 2.4 equiv.) were dissolved in DMF/water (4:1) (2 mL). The
reaction vessel was sealed and irradiated in a Biotage microwave reactor at 120 °C for 20
min. The product was purified by dialysis against DMF (300 mL) using a 6000-8000
MWCO membrane. The target dendrimer 5.15 (45 mg, 15 µmol) was obtained in 92%
yield as a fluffy off-white solid. 1H NMR ((CD3)2SO) δ: 8.42 (d, J = 4.0, 6H), 8.33 (d, J =
4.0, 3H) 8.29 (s, 3H), 8.19 (dd, J1 = 8.0, J2 = 4.0, 6H), 8.06 (dd, J1 = 8.0, J2 = 4.0, 3H),
7.86 (d, J = 8.0, 6H), 7.79 (d, J = 8.0, 3H), 7.26 (s, 3H), 5.60 (s, 6H), 5.54 (s, 6H), 5.49
(s, 12H), 5.39 (s, 6H), 4.80 (t, J = 6, 12H), 4.64-4.57 (m, 12H), 3.61-3.57 (m, 12H), 3.493.45 (m, 12H), 1.45 (s, 9H), 1.12 (18H).
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C NMR ((CD3)2SO) δ: 174.4, 174.3, 171.6,

163.3, 147.5, 146.9, 141.6, 137.5, 137.1, 135.5, 133.9, 133.8, 130.7, 130.2, 129.5, 129.2,
127.6, 125.3, 125.2, 125.1, 66.5, 64.0, 63.2, 62.0, 58.6, 52.4, 50.7, 46.6, 17.3, 16.9. IR
(cm-1, film from THF): 3396, 3101, 2958, 2879, 1731, 1623, 1537, 1346, 1251, 1120.
HRMS: calcd [M+Na]+ (C135H138N18O66Na): 3089.7893. Found: (ESI) 3089.7893 and
(MALDI-TOF) 3089.9. SEC data: Mn = 3700 gmol-1, PDI: 1.03.
Synthesis of G3 dendrimer 5.16: Compound 5.13 (1.9 mg, 8.0 µmol, 1 equiv.), dendron
5.12 (61 mg, 29 µmol, 3.6 equiv.), CuSO4 (1.6 mg, 9.8 µmol, 1.2 equiv.), and sodium
ascorbate (7.8 mg, 39 µmol, 4.9 equiv.) were dissolved in DMF/water (4:1) mixture (2
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mL). The reaction vessel was sealed and irradiated in a Biotage microwave reactor at 120
°C for 20 min. The product was purified by dialysis against DMF (300 mL) using a
12000-14000 MWCO membrane. The target dendrimer 5.16 (48 mg, 7.3 µmol) was
obtained in 91% yield as a fluffy off-white solid. 1H NMR ((CD3)2SO) δ: 8.44-8.39 (m,
12H), 8.33-8.25 (m, 12H), 8.19 (d, J = 8.0, 12H), 8.02(d, J = 8.0, 9H), 7.90 (s, 3H), 7.887.83 (m, 9H), 7.81-7.73 (m, 9H), 7.27 (s, 3H), 5.61-5.32 (m, 54H), 4.84-4.72 (m, 24H),
4.70-4.49 (m, 36H), 3.61-3.53 (m, 24H), 3.50-3.42 (m, 24H), 1.46 (s, 18H), 1.42 (s, 9H),
1.10 (s, 36H).
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C NMR ((CD3)2SO) δ: 174.3, 171.6 (3), 163.3, 163.0, 147.4, 146.8,

137.5, 137.1, 137.0, 135.6, 135.5 (2), 133.9, 133.8 (2), 133.7, 130.5, 130.4, 130.2, 130.1,
130.0, 129.5, 129.2, 125.2, 125.1 (2), 66.5, 66.4, 64.0, 63.2 (2), 62.0, 54.8, 53.1, 50.7,
46.6, 46.5, 17.3, 17.2, 16.8. IR (cm-1, film from THF): 3429, 3097, 2927, 2854, 1731,
1623, 1537, 1350, 1253, 1122. MS: calcd [M+Na]+ (C291H294N30O150Na): 6633.6. Found
(MALDI-TOF) 6634.3. SEC data: Mn = 6000 gmol-1, PDI: 1.04.
General Procedure for Monitoring Dendrimer Degradation by UV-visible
Spectroscopy: Dendrimer solutions were prepared at the concentration of 23 µM in
spectroscopic grade THF. 3 mL of solution was transferred to a quartz cuvette and
irradiated with 313 nm UV light in a Luzchem Photoreactor for 1 h. UV-visible
absorption spectra were collected every 2 min for the first 10 min and then every 5 min
for the remaining 50 min.
General Procedure for Monitoring Dendrimer Degradation by

1

H NMR

Spectroscopy: Dendrimer solutions were prepared at the concentration of 10 mg/mL in
(CD3)2SO. The solutions were transferred to a quartz NMR tube and irradiated with UV
light using a Hanovia medium pressure mercury lamp (PC 451050/616750, 450 Wage)
light box for 1 h. 1H NMR spectra were collected every 10 min.
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Chapter 6
6 Photodegradable Amphiphilic Janus Dendrimers and
Dendrimersomes as Potential Smart Drug Delivery
Vehicles

6.1 Introduction
As discussed in Chapters 2 and 5, dendrimers are a major class of macromolecules that
are well-known for their three-dimensional globular architecture. Dendrimers are
structurally perfect dendritic structures with a single or very narrow molar weight
distribution. They comprise three structural regions: a core, layers of branching repeat
units comprising the backbone, where each layer typically results from one stage of
growth and is termed a “generation”, and a peripheral layer. Based on their unique
properties such as their very defined chemical structures, branched architectures, and
existence of multiple peripheral groups for conjugation of functional moieties,
dendrimers and dendrimer assemblies have received significant interest in the area of
biomedical applications.1-4
In addition to conventional dendrimers, Janus dendrimers have also become the focus
of intense research in the past two decades. These are dendrimers with well-defined but
asymmetric architectures of two chemically distinct dendrons on opposite sides with
different chemical compositions, peripheral groups, and/or polarities. They are also
known as ‘‘surface-block’’ dendrimers, diblock dendrimers, codendrimers, diblock codendrimers, or bow-tie dendrimers.5 In comparison with conventional dendrimers with
uniform chemical structures, the presence of two or more chemically distinct regions in
the backbone of Janus dendrimers can impart additional novel properties to these
molecules.
To develop dendrimer-based vehicles capable of encapsulating drugs and delivering
them to the organs of interest, amphiphilicity needs to be imparted to dendrimers. This
can be achieved by having both hydrophobic and hydrophilic dendrons in their
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backbones. Such dendrimers, commonly known as "Amphiphilic Janus dendrimers
(AJD)", are capable of undergoing phase segregation to form well-defined morphologies
owing to different phase behaviour of their dendritic blocks.5,6 To date, AJDs with a
variety of dendritic backbones have been synthesized. The first example of such AJD
synthesis dates back only to twenty years ago where Fréchet and coworkers synthesized
an asymmetric dendrimer based on 3,5-dihydroxybenzyl alcohol repeat unit, known as
Fréchet-type dendrimers, with phenyl and carboxy peripheral groups.7 Since then, many
examples of AJDs and their potential as drug delivery vehicles have been reported in the
literature. A few examples of these materials are discussed below.
As PAMAM dendrimers are leading dendrimer types in biomaterials, their
incorporation into AJD architectures has also been frequently reported.8 In an early work
by Okada and coworkers,9 PAMAM-based AJDs were prepared in which the periphery of
one wedge of the dendrimer was decorated with the hydrophilic maltono lactone
carbohydrate while the surface amine groups of the other wedge were reacted with
phthalic anhydride in order to impart the required hydrophobic properties. Although the
self-assembly behavior of this dendrimer was not investigated, its molecular recognition
potential was evaluated using concanavalin A lectin. In another study by the same group,
a library of third and fourth generation PAMAM-based AJDs with various surface
functionalities were prepared. These include dendrimers with amino and n-hexyl
(amino/hexyl) peripheral groups, hydroxyl and n-hexyl (hydroxyl/hexyl) peripheral
groups, and N-acetyl-D-glucosamine and n-hexyl (glucosamine/hexyl) peripheries.10 The
authors then studied the adlayer (the layer formed by the adsorption of AJDs on the solid
substrate) formation capabilities of these dendrimers on solid substrates. More recently,
effective synthesis of AJDs based on PAMAM and Fréchet-type dendrons have also been
reported.11 To efficiently construct such dendrimers, PAMAM dendrons (G1-4) with
alkyne functionalities at their focal point and Fréchet-type dendrons (G1-4) with azide
focal groups were ligated together employing the high-yielding Cu(I)-catalyzed alkyneazide click reaction to obtain various generations of such AJDs. In addition to PAMAMbased AJDs, amino acid-based AJDs,12-15 ones incorporating aliphatic polyethers,16-18
fullerene-containing AJDs,19,20 polymerized AJDs,21 and ones based on PEG have been
reported.22
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AJDs in which at least one dendritic block incorporates bis-MPA-based polyester
dendrons in its backbone are among the most widely reported dendrimers of this type.23-38
For instance, Fréchet and coworkers have developed "bow-tie" dendritic systems in
which both dendritic blocks are bis-MPA-based polyester dendrons.23,25,26 In these
examples, the periphery of one dendritic block was used for the conjugation of PEG
chains with varying MWs to enhance their water solubility and the other wedge of the
dendrimer was used for the conjugation of therapeutics.23,25,26 In another example,
Wegner and coworkers have synthesized a third generation AJD consisting of Fréchettype and polyester dendrons and studied its self-assembly behavior.30 It was shown that in
water-immiscible organic solvents containing water droplets this AJD undergoes a
topological transformation from sphere to button structures.
More recently, Percec and coworkers have synthesized a total number of 107
amphiphilic Janus dendrimers, with different backbones and generation numbers, and
screened their self-assembly behaviour in aqueous media.37,38 The authors showed that
when such materials are dispersed in water, they can undergo self-assembly to form a
wide range of morphologies including vesicles (named as dendrimersomes), cubosomes,
disks, tubular vesicles, and helical ribbons. Similar to polymersomes, dendrimersomes
are of significant interest as they can potentially be multifunctional by encapsulating both
hydrophilic and hydrophobic species. As a result, they were investigated in more depth in
these reports. The authors concluded that dendrimersomes not only exhibit stability and
mechanical strength of polymersomes, but also have the advantages of superior size
uniformity, ease of formation, and chemical modification.
The development of drug delivery vehicles that are responsive to specific stimuli is
also of significant interest as this can impart new properties and further expand their
scope of applications. To date, several types of nanomaterials responsive to a wide
variety of external stimuli have been developed.39-43 Among various stimuli, light is of
particular interest for the development of smart materials as it can be applied at a specific
time and location with control over its intensity and wavelength. In the context of
vesicular drug delivery systems that are capable of photolytic degradation, there are
limited number of reported examples.44-48 In these examples, which are mostly
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polymersome-based systems, a photodegradable moiety, often an o-nitrobenzyl ester
moiety, is placed at the junction between the hydrophilic and hydrophobic blocks of the
BCPs. Upon irradiation with UV light, the BCPs undergo degradation resulting in
disruption of the vesicular structure. However, as pointed out by other scientists, in these
cases there is a high chance for the released hydrophobic chains to either aggregate to
form macroscopic precipitates or undergo rearrangement to form other sorts of
assemblies.49 Both these events can potentially reduce their drug delivery efficiencies.
We have recently reported the synthesis and photodegradation behavior of dendrons
and dendrimers (G1-3) with an entire photodegradable backbone.50 We have shown that
these dendrimers are capable of undergoing complete photolytic backbone cleavage
without producing any macromolecular byproducts. In this chapter, the progress towards
the incorporation of these photodegradable dendrons into AJD structures, their selfassembly to nanomaterials including photodegradable dendrimersomes, and their
photolytic cargo release will be discussed. It is noteworthy that the photodegradable
dendrimersomes described in this chapter are the first example of any vesicular
architecture (including polymersomes, dendrimersomes, and small amphiphile-based
vesicles) that are capable of complete photolytic membrane degradation to release their
encapsulated model drugs.

6.2 Results and Discussion
6.2.1 Synthesis of Photodegradable Amphiphilic Janus Dendrimers
The synthetic strategy to incorporate our recently developed photodegradable dendrons50
into AJD structure involves the divergent growth of the dendrimers from the focal point
of the hydrophilic dendritic block (Scheme 6.1).
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Scheme 6.1. Synthesis of G1-3 AJDs.
For the hydrophilic block, a dendritic backbone based on triethylene glycol (TEG) and
gallic acid, 6.1, was synthesized with a benzyl alcohol focal point.51,52 As shown in
Scheme 6.1, the hydroxyl focal point was then reacted with our previously reported

141
photodegradable monomer 5.5 under EDC-coupling conditions to provide protected G1
dendrimer 6.2 in high yield. The acetonide protecting group was then removed under
acidic condition to obtain unprotected G1 AJD 6.3. Repetition of this coupling and
deprotection sequence provided protected G2, 6.4, and G3, 6.6, dendrimers in high
yields.
The resulting dendrimers were characterized by 1H and
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C NMR spectroscopy,

HRMS, IR spectroscopy, and SEC. SEC traces of the protected AJDs are depicted in
Figure 6.1a with their corresponding SEC data shown in Figure 6.1b.

Figure 6.1. a) SEC traces and b) MW and PDI characteristics of AJDs 6.2, 6.4, and 6.6. a
Molecular weight calculated based on chemical structures of the dendrimers,

b

Mn

obtained from SEC, and c PDI was determined from SEC.
As shown in the SEC traces (Figure 6.1a), the resulting dendrimers exhibit
monomodal MW distribution profiles with the expected increases in hydrodynamic
volume with each generation, as well as very narrow PDIs (Figure 6.1b).

6.2.2 Self-Assembly of Amphiphilic Janus Dendrimers in Aqueous
Media
Having the protected AJDs 6.2, 6.4, and 6.6 in hand, their self-assembly behaviors in
mixed organic-aqueous system were then investigated. For this purpose, an 8 mg/mL
solution of each dendrimer in THF (0.25 mL) was first prepared in a vial and distilled
water (1.25 mL) was then added dropwise with vigorous stirring. The samples were then
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stirred overnight with their caps left open to remove most of the THF. The samples were
dialyzed against distilled water to further remove the residual THF.
The samples were first analyzed by DLS measurements to gain insight into the sizes of
the materials obtained. In the case of the 1st generation dendrimer 6.2, no meaningful
DLS data was obtained. As a result, it was speculated that the hydrophobic block of this
AJD was too small compared to the hydrophilic block to induce any self-assembly events
and the molecule was essentially water-soluble. On the other hand, it was found that 2nd
and 3rd generation AJDs 6.4 and 6.6 were able to form assemblies with average sizes (zaverage) of about 270 nm and 450 nm, respectively (Figure 6.2).

Figure 6.2. Size distribution profiles measured by DLS for assemblies formed by a) 2nd
generation AJD 6.4 and b) 3rd generation AJD 6.6.
In addition to DLS, TEM imaging revealed additional information regarding the
morphologies of the resulting assemblies. As shown in Figure 6.3a, it was found that
particles formed by dendrimer 6.4 had a core-shell structure with a photodegradable
hydrophobic core and a shell of TEG chains. On the other hand, 3rd generation dendrimer
6.6 underwent self-assembly to form well-defined dendrimersomes in which the
photodegradable hydrophobic dendritic block constituted their membranes and the TEG
chains pointing towards the interior and exterior aqueous media (Figure 6.3b). Further
TEM analysis revealed that dendrimersomes have a membrane thickness of roughly 10
nm which is within the range of values obtained for other dendrimersomes formed by a
variety of other AJDs in the literature.37
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Figure 6.3. TEM images of a) particles prepared from AJD 6.4 and b) dendrimersomes
formed by AJD 6.6.

6.2.3 Photodegradation Study of the Dendrimersomes
As the main focus of this project was to develop dendrimersomes with photodegradable
membranes, photodegradation studies of the above-mentioned assemblies did not involve
the particles obtained from dendrimer 6.4.
Prior to the photolysis of the dendrimersomes, it was essential to study the
photodegradation behavior of AJD 6.6 in the solution state and compare the results to
those previously obtained for our photodegradable dendrimers.50 For this purpose, a ~30
µg/mL solution of G3 dendrimer 6.6 in THF was irradiated with 300 - 400 nm UV light
at with a receiving power of about 25 mW·cm-2 over a period of 30 min and the UVvisible absorption spectra of the solution were recorded in 2 min intervals. As shown in
Figure 6.4a, the result obtained is in accordance with our previously obtained data for
photodegradable hydrophobic dendrimers.50 A decrease in absorbance was observed for
the peaks at 225 and 265 nm while increases in absorbance were observed at 300 and 340
nm, along with corresponding red shifts in their absorption maxima. As mentioned
earlier, these observations are in accordance with the results obtained by other groups for
this photolabile group. The absorption band at 350 nm is attributed to onitrosobenzaldehyde, which is a product of o-nitrobenzyl ester photolysis, and exhibits a
weak absorption band at 350-360 nm that is solvent dependent. In addition, spectral
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change behavior of this dendrimer was also investigated when it was self-assembled into
vesicular structure in aqueous media. For the data to be consistent with the solution state,
the dendrimersome sample was prepared at the concentration of ~30 µg/mL and was
irradiated with the same lamp settings and time intervals described above. As shown in
Figure 6.4b, a general trend of decrease in the peak intensities was observed for the
dendrimersomes. It should be noted that as the chemical environments of dendrimer 6.6
in THF versus in self-assembled state in water are quite different and the suspension of
the dendrimersomes scatters light significantly, differences in their spectral profiles were
expected. Nevertheless, the change in the UV-visible spectra of the dendrimersomes upon
UV irradiation does suggest a change in the spectroscopic state of their photodegradable
hydrophobic membrane.

Figure 6.4. UV-visible spectra for G3 AJD 6.6 a) as THF solution and b) as selfassembled dendrimersomes in water upon irradiation with UV light for 30 min. Inset
shows the expanded region between 285-415 nm.
DLS analysis was also employed to study the photolysis of the dendrimersomes. For
this purpose, suspension of dendrimersomes with the concentration of 0.1 mg/mL were
placed in a quartz cuvette, irradiated with UV light, and DLS measurements were
performed at the given time points. As a result, there was no change in the overall
concentration of the dendrimer 6.6 throughout the experiment in the system. At each time
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point, three measurements of 150 s each were performed. As shown in Figure 6.5a, upon
irradiating dendrimersome for a course of 210 min, a dramatic decrease in the mean
count rate from about 240 to 9 kcps was observed. It has been demonstrated that a
decrease in the count rate (intensity of the scattered light) can stem from three factors: 1)
a decrease in the total concentration of particles in the system, 2) a decrease in the size of
the particles in the system, and 3) a combination of the former two factors.45 Taking into
account that no precipitation was observed during the photolysis of the dendrimersomes,
we conclude that the total concentration of particles did not change. As a result, the
observed decrease in the mean count rate can be explained by the decrease in the size of
the particles in the system. In fact, as shown in Figure 6.5b, it was demonstrated that after
irradiating the sample for 210 min, dendrimersomes were completely disrupted and new
objects with diameters of 2 nm were formed, likely small molecule degradation products.
However, due to the very low degree of light scattering, it should be noted that the quality
of DLS data obtained at this point was marginal.

Figure 6.5. DLS measurements for the photolysis of dendrimersomes: a) plot of mean
count rate versus irradiation time and b) size distribution profile of the dendrimersome
sample before and after UV irradiation.
As described above, while there was no precipitate formation during the experiment,
this decrease in the mean count rate can be attributed to very small size of the photolysis
byproducts which were out of the detection limit of the instrument. As a result, it was
concluded that, upon photolysis, the membranes of the dendrimersomes were completely
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fragmented to small molecules and the remaining hydrophilic dendritic blocks were
unable to undergo self-assembly to form any further meaningful morphologies. In fact,
this hypothesis was further supported by TEM imaging of the photodegraded sample. As
shown in Figure 6.6, no distinct self-assembled material was observed in these images. In
a similar observation by Zhao and coworkers, 60 nm polymeric micelles with a backbone
photodegradable hydrophobic core were shown to undergo photodegradation to a point
where no clear morphology was observable.53

Figure 6.6. TEM images of the UV-irradiated dendrimersome sample after 210 min.
As a result of this complete photolytic membrane degradation, this system offers
significant advantage over the currently reported photodegradable vesicular drug delivery
systems. As previously discussed, while it has been shown that photolysis of
polymersomes, comprised of BCPs with a single photodegradable group at the junction
between the hydrophilic and hydrophobic blocks, results either in the precipitation of the
detached hydrophobic block or morphological transformation to smaller size particles as
micelles, our photodegradable dendrimersome system represents the first example of this
class of drug delivery vehicles in which complete degradation of the hydrophobic block
is achieved. This is expected to result in significant enhancement in release efficiency of
vesicular drug delivery systems.
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6.3 Conclusion
In summary, a small library of AJDs (G1-3) with backbone photodegradable hydrophobic
dendritic blocks were successfully synthesized and fully characterized. 3rd generation
AJD 6.6 was shown to undergo self-assembly to form well-defined dendrimersomes with
an average size of about 450 nm. Upon irradiation with UV light (300-400 nm, 25
mW·cm-2), the dendrimersomes' membranes were effectively disrupted to disintegrate
these assemblies with no sign of precipitation or morphological change to smaller
assemblies. Studies are currently underway to evaluate the photolytic release behavior of
these smart dendrimersomes with regards to both hydrophilic and hydrophobic model
drug molecules.

6.4 Experimental
General Procedures and Materials
Compounds 6.151,52 and 5.550 were synthesized according to the previously published
procedures. All the other chemicals were purchased from Sigma-Aldrich or Alfa Aesar
and were used without further purification unless otherwise noted. Anhydrous DMF was
obtained from a solvent purification system using aluminum oxide columns.
Dichloromethane was distilled from calcium hydride. Unless otherwise stated, all
reactions were performed under a nitrogen atmosphere using flame or oven dried
glassware. For the reactions that were stirred in dark, aluminum foil was used to isolate
the reaction flasks from light. No special precautions regarding light, were taken during
purification or isolation of these compounds. For long term storage, the isolated materials
were stored in freezer. However no degradation issues were encountered when materials
were stored in the dark at ambient temperature. 1H NMR spectra were obtained at 400
MHz, and
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C NMR spectra were obtained at 100 MHz. NMR chemical shifts are

reported in ppm and are calibrated against the residual solvent signal of CDCl 3 (δ 7.26
and 77.16 ppm). J values are expressed in Hz. IR spectra were obtained as films from
CH2Cl2 on NaCl plates using a Bruker Tensor 27 instrument. HRMS was performed
using a Finnigan MAT 8400 electron impact mass spectrometer. ESI was performed
using a PE-Sciex API 365 mass spectrometer. UV–visible absorption spectroscopy was
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performed on a Varian Cary 300 Bio UV–visible spectrophotometer. Dialyses were
performed using Spectra/Por regenerated cellulose membranes with either a 2,000 g/mol
or 3500 g/mol MWCO. SEC instrument was equipped with a Viscotek GPC Max
VE2001 solvent module. Samples were analyzed using the Viscotek VE3580 RI detector
operating at 30 C. The separation technique employed a Polypore guard column (50 x
7.5mm) and two Agilent Polypore (300 x 7.5 mm) columns connected in series. Samples
were dissolved in THF (glass distilled grade) at approximately 5 mg/mL concentrations
and filtered through 0.22 µm syringe filters. Samples were injected using a 100 µL loop.
The THF eluent was filtered and eluted at 1 ml/min for a total of 30 minutes. A
calibration curve was obtained from polystyrene standards with molecular weights
ranging from 1,540-1,126,000 g/mol. The light source used for the photochemical
reactions was a Hanovia medium pressure mercury lamp (PC 451050/616750, 450 Wage)
with an emitting wavelength of 300-400 nm and a power of 25 mW·cm-2 at 10 cm from
the lamp where the samples were irradiate. DLS data were obtained using a Zetasizer
NanoZS instrument from Malvern Instruments.
Synthesis of Protected G1 AJD 6.2: Hydrophilic dendritic block 6.1 (0.55 g, 0.92
mmol, 1.0 equiv.) and monomer 5.5 (0.49 g, 1.4 mmol, 1.5 equiv.) were dissolved in
CH2Cl2 (30 mL). EDCHCl (0.40 g, 2.1 mmol, 2.2 equiv.) and DMAP (0.11 g, 0.92
mmol, 1.0 equiv.) were added in one portion and the resulting solution was stirred at
room temperature in dark for 18 h. At this point, CH2Cl2 was removed under reduced
pressure. The residue was dissolved in DMF and the product was purified by dialysis
against DMF using 2000 MWCO membrane for 24 h. The solvent was then removed
under reduced pressure to give dendrimer 6.2 (0.76 g, 0.82 mmol) in 89% yield. 1H NMR
(CDCl3) δ: 8.76 (d, J = 4.0, 1H), 8.30 (dd, J1 = 8.0, J2 = 4.0, 1H), 7.85 (d, J = 8.0, 1H),
6.67 (s, 2H), 5.66 (s, 2H), 5.27 (s, 2H), 4.28 (d, J = 12.0, 2H), 4.19-4.13 (m, 6H), 3.85 (t,
J = 4.0, 4H), 3.73 (t, J = 4.0, 2H), 3.75-3.69 (m, 8H), 3.68-3.62 (m, 12H), 3.56-3.52 (m,
6H), 3.37 (s, 9H), 1.47 (s, 3H), 1.40 (s, 3H), 1.17 (s, 3H).

13

C NMR (CDCl3) δ: 173.6,

163.9, 152.7, 147.1, 138.7, 137.1, 134.3, 130.8, 130.4, 128.9, 126.1, 108.3, 98.1, 72.2,
71.8, 71.8, 70.7, 70.6, 70.4, 70.4, 69.6, 68.9, 67.6, 66.1, 63.0, 58.9, 42.3, 26.5, 20.7, 18.2.
IR (cm-1, film from CH2Cl2): 3097, 2939, 2881, 1731, 1623, 1539, 1351, 1249, 1122.
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HRMS: calcd [M+Na]+ (C44H67NO20Na): 952.4154. Found: (ESI) 952.4114. SEC data:
Mn = 1200 gmol-1, PDI: 1.01.
Synthesis of Deprotected G1 AJD 6.3: Dendrimer 6.2 (0.26 g, 0.28 mmol) was
dissolved in methanol (25 mL) and CH2Cl2 (5 mL). Concentrated sulfuric acid (0.30 mL)
was added and the resulting solution was stirred at room temperature in dark for 2 h. At
this point, 1H NMR showed the completion of the reaction. The solution was diluted by
the addition of CH2Cl2 (50 mL). Organic solution was then washed with 1M Na2CO3
(2×100 mL) and brine (1×100 mL). The organic layer was dried over MgSO4, filtered,
and concentrated under reduced pressure to give dendrimer 6.3 (0.23 g, 0.26 mmol) in
93% yield. 1H NMR (CDCl3) δ: 8.75 (d, J = 4.0, 1H), 8.31 (dd, J1 = 8.0, J2 = 4.0, 1H),
7.83 (d, J = 8.0, 1H), 6.68 (s, 2H), 5.65 (s, 2H), 5.27 (s, 2H), 4.18-4.14 (m, 6H), 3.98 (d,
J = 8.0, 2H), 3.85 (t, J = 4.0, 4H), 3.80-3.77 (m, 4H), 3.73-3.70 (m, 6H), 3.66-3.62 (m,
12H), 3.55-3.52 (m, 6H), 3.36 (s, 9H), 2.81 (br s, 2H), 1.12 (s, 3H). 13C NMR (CDCl3) δ:
174.8, 163.8, 152.6, 147.1, 138.5, 136.8, 134.3, 130.8, 130.4, 129.0, 125.9, 108.2, 72.2,
71.7, 70.6, 70.5, 70.4, 70.3, 69.6, 68.8, 67.6, 66.9, 62.8, 58.8, 49.6, 17.1. IR (cm-1, film
from CH2Cl2): 3415, 3089, 2906, 2879, 1730, 1623, 1535, 1350, 1253, 1112. HRMS:
calcd [M+Na]+ (C41H63NO20Na): 912.3841. Found: (ESI) 912.3821. SEC data: Mn = 1200
gmol-1, PDI: 1.01.
Synthesis of Protected G2 AJD 6.4: Dendrimer 6.3 (0.21 g, 0.24 mmol, 1.0 equiv.) and
monomer 5.5 (0.26 g, 0.72 mmol, 3.0 equiv.) were dissolved in CH2Cl2 (45 mL).
EDC·HCl (0.21 g, 1.1 mmol, 4.5 equiv.) and DMAP (59 mg, 0.48 mmol, 2.0 equiv.) were
added in one portion and the resulting solution was stirred at room temperature in dark
for 18 h. At this point, CH2Cl2 was removed under reduced pressure. The residue was
dissolved in DMF and product was purified by dialysis against DMF using 3500 MWCO
membrane for 24 h. The solvent was then removed under reduced pressure to give
dendrimer 6.4 (0.31 g, 0.20 mmol) in 83% yield. 1H NMR (CDCl3) δ: 8.64-8.58 (m, 3H),
8.23-8.16 (m, 3H), 7.85 (d, J = 8.0, 2H), 7.63 (d, J = 8.0, 1H), 6.68 (s, 2H), 5.65 (s, 4H),
5.60 (s, 2H), 5.26 (s, 2H), 4.67-4.59 (m, 4H), 4.28 (d, J = 12.0, 4H), 4.19-4.13 (m, 6H),
3.85 (t, J = 4.0, 4H), 3.73 (t, J = 4.0, 2H), 3.75-3.69 (m, 10H), 3.67-3.61 (m, 12H), 3.563.51 (m, 6H), 3.36 (s, 9H), 1.49 (s, 3H), 1.47 (s, 6H), 1.39 (s, 6H), 1.18 (s, 6H). 13C NMR
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(CDCl3) δ: 173.6, 171.5, 163.6, 163.4, 152.7, 147.8, 147.1, 138.7, 137.6, 135.0, 134.2,
131.6, 130.4, 130.0, 129.0, 129.0, 126.1, 126.0, 126.0, 108.4, 98.2, 72.3, 71.9, 71.8, 70.7,
70.6, 70.4, 69.6, 68.9, 67.8, 66.4, 66.1, 63.8, 63.0, 58.9, 47.0, 42.4, 26.6, 20.6, 18.2, 17.9.
IR (cm-1, film from CH2Cl2): 3091, 2918, 2875, 1733, 1623, 1535, 1348, 1249, 1116.
HRMS: calcd [M+Na]+ (C73H97N3O34Na): 1582.5851. Found: (ESI) 1582.5857. SEC
data: Mn = 1900 gmol-1, PDI: 1.01.
Synthesis of Deprotected G2 AJD 6.5: Dendrimer 6.4 (0.20 g, 0.13 mmol) was
dissolved in methanol (50 mL) and CH2Cl2 (10 mL). Concentrated sulfuric acid (0.60
mL) was added and the resulting solution was stirred at room temperature in dark for 2 h.
At this point, 1H NMR showed the completion of the reaction. The solution was diluted
by the addition of CH2Cl2 (50 mL). Organic solution was then washed with 1M Na2CO3
(2×100 mL) and brine (1×100 mL). The organic layer was dried over MgSO4, filtered,
and concentrated under reduced pressure to give dendrimer 6.5 (0.18 g, 0.12 mmol) in
95% yield. 1H NMR (CDCl3) δ: 8.60-8.51 (m, 3H), 8.20- 8.09 (m ,3H), 7.79 (d, J = 8.0,
2H), 7.62 (d, J = 8.0, 1H), 6.68 (s, 2H), 5.61 (s, 6H), 5.25 (s, 2H), 4.63 (s, 4H), 4.21-4.12
(m, 6H), 4.02-3.94 (m, 4H), 3.85 (t, J = 4.0, 4H), 3.83-3.76 (m, 6H), 3.75-3.69 (m, 6H),
3.68-3.61 (m, 12H), 3.56-3.51 (m, 6H), 3.36 (s, 9H), 2.98 (t, J = 8.0, 4H), 1.49 (s, 3H),
1.13 (s, 6H). 13C NMR (CDCl3) δ: 175.0, 171.7, 163.8, 163.5, 152.7, 147.8, 147.1, 138.6,
137.4, 135.2, 134.2, 134.2, 131.5, 130.4, 130.2, 130.0, 129.2, 126.1, 125.9, 108.4, 72.3,
71.9 (2), 70.7, 70.6, 70.4, 69.7, 68.9, 67.9, 67.3, 67.3, 66.8, 63.8, 62.9, 59.0, 49.7, 47.0,
18.1, 17.2. IR (cm-1, film from CH2Cl2): 3394, 3082, 2927, 2883, 1726, 1625, 1537,
1350, 1255, 1114. HRMS: calcd [M+Na]+ (C67H89N3O34Na): 1502.5225. Found: (ESI)
1502.5205. SEC data: Mn = 1900 gmol-1, PDI: 1.02.
Synthesis of Protected G3 AJD 6.6: Dendrimer 6.5 (0.14 g, 0.10 mmol, 1.0 equiv.) and
monomer 5.5 (0.21 g, 0.60 mmol, 6.0 equiv.) were dissolved in CH2Cl2 (35 mL).
EDC·HCl (0.17 g, 0.90 mmol, 9.0 equiv.) and DMAP (49 mg, 0.40 mmol, 4.0 equiv.)
were added in one portion and the resulting solution was stirred at room temperature in
dark for 18 h. At this point, CH2Cl2 was removed under reduced pressure. The residue
was dissolved in DMF and product was purified by dialysis against DMF using 3500
MWCO membrane for 24 hrs. The solvent was then removed under reduced pressure to
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give dendrimer 6.6 (0.25 g, 90 µmol) in 90% yield. 1H NMR (CDCl3) δ: 8.61-8.57 (m,
5H), 8.51-8.48 (m ,2H), 8.22-8.16 (m, 5H), 8.12-8.08 (m, 2H), 7.85 (d, J = 8.0, 4H), 7.65
(d, J = 8.0, 3H), 6.67 (s, 2H), 5.64 (s, 8H), 5.61 (s, 4H), 5.59 (s, 2H), 5.25 (s, 2H), 4.674.58 (m, 12H), 4.27 (d, J = 12.0, 8H), 4.20-4.12 (m, 6H), 3.85 (t, J = 4.0, 4H), 3.73 (t, J
= 4.0, 2H), 3.75-3.68 (m, 14H), 3.67-3.61 (m, 12H), 3.56-3.51 (m, 6H), 3.36 (s, 9H),
1.50 (s, 6H), 1.48 (s, 3H), 1.46 (s, 12H), 1.38 (s, 12H), 1.17 (s, 12H). 13C NMR (CDCl3)
δ: 173.7, 171.6, 171.6, 163.8, 163.6, 163.3, 152.8, 147.9, 147.8, 147.2, 138.9, 137.7,
135.7, 135.2, 134.3, 134.1, 131.7, 130.9, 130.4, 130.3, 130.1, 129.1, 126.2, 126.1, 126.0,
114.8, 108.5, 98.3, 72.4, 72.0 (2), 70.8, 70.7, 70.6, 70.5, 69.8, 69.0, 67.9, 66.6, 66.5, 66.2,
64.0, 63.9, 63.9, 63.1, 59.0, 47.1, 47.0, 42.5, 26.7, 20.7, 18.3, 18.1, 18.0. IR (cm-1, film
from CH2Cl2): 3084, 2927, 2879, 1731, 1623, 1539, 1346, 1255, 1118. HRMS: calcd
[M+Na]+ (C131H157N7O62Na): 2842.9251. Found: (ESI) 2842.9245. SEC data: Mn = 3200
gmol-1, PDI: 1.01.
General Procedure for the Preparation of Dendrimer Assemblies: Dendrimer
assemblies were prepared by first dissolving each AJD dendrimer (2 mg) in spectroscopic
grade THF (0.25 mL) in a vial followed by dropwise addition of distilled water (1.25 mL)
with vigorous stirring. The resulting assembly samples were stirred overnight with their
vial caps left open to remove most of the THF. The residual THF was removed by
dialyzing the samples against distilled water using 3500 MWCO membrane for 24 h.
General Procedure for Monitoring Dendrimer Degradation by UV-visible
Spectroscopy: Dendrimer sample was prepared at the concentration of 30 µg/mL in
either spectroscopic grade THF or as dendrimersomes in distilled water. 3 mL of solution
was transferred to a quartz cuvette and irradiated with UV light for 30 min. UV-visible
absorption spectra were collected every 2 min.
General Procedure for Monitoring Dendrimersome Degradation by DLS analysis:
Dendrimesome sample was prepared at the concentration of 0.1 mg/mL of dendrimer 6.6
in distilled water. 2 mL of this sample was transfered to a quartz cuvette and irradiated
with UV light for 210 min. DLS measurements were performed at the given time points
on the same sample. For each time point three measurements each for 150 s were
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performed. Mean count rates reported in Figure 6.5a are the average values obtained for
each time point with their relevant error bars.
Transmission Electron Microscopy: The suspension of the dendrimer assemblies (5 μL,
0.05 mg/mL) was placed on a carbon formvar grid and was left to dry in air in dark for 6
h. Imaging was performed using a Phillips CM10 microscope operating at 80 kV with a
40 µm aperture.
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Chapter 7
Conclusions and Future Directions
The research described in this thesis demonstrated not only the application of dendronfunctionalized biodegradable and biocompatible PEO-PCL polymersome system as a
novel scaffold for various biomedical applications, but also took a significant step
towards the biomedical applications of photo-responsive materials by developing
backbone photodegradable dendrimers and dendrimer assemblies as potential drug
delivery vehicles. These contributions are of importance in the area of biomaterials as
researchers are always seeking materials with new and improved properties and
functions, as well as an enhanced understanding of the interactions of materials with
biological systems.
The initial focus of this research was to develop a biodegradable and biocompatible
polymersome-based system that could be used in different areas of biomedical research.
Work by our group had shown that dendritic surface functionalization of materials,
including polymersomes, is a highly promising approach for controlling their surface
functionalities and imparting specific biological properties. However, the polymersomes
used in these studies were micron-sized and were composed of nonbiodegradable PEOPBD BCPs with unknown biocompatibility. To address these limitations, and thus
provide a significant advancement toward biomedical applications, this work was
extended to nano-sized biodegradable and biocompatible polymer assemblies, namely
micelles and polymersomes, constructed by the self-assembly of PEO-PCL BCPs.
Having decorated their surfaces with azide groups, the conjugation of 3rd generation
polyester dendrons bearing alkyne functionalities at their focal points and either amine or
guanidine peripheral groups as well as a clickable small molecule rhodamine dye were
evaluated by performing Cu(I)-catalyzed alkyne-azide click reaction at the surfaces of the
assemblies. To demonstrate the applicability of the dendritic surface functionalization
approach, micelles with conjugated dendritic guanidines were shown to have enhanced
cell uptake by HeLa cancer cells relative to unfunctionalized micelles.
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To enhance the longitudinal relaxivity of clinically used MRI contrast agents, Gd(III)
complexes have been conjugated to a wide variety of macromolecular and material-based
scaffolds. Among such scaffolds, there are very few reports of polymersome-based MRI
contrast agents. Cheng et al. have investigated porous polymersomes containing Gd(III)labeled dendrimers within their aqueous cores, and have obtained an r1 of 7.5 mM-1 s-1
(60MHz, 40 °C) on a per Gd basis. More recently, Grull et al. incorporated Gd(III)labeled lipids into a polymersome membrane, resulting in an r1 of 22 mM-1 s-1 (20 MHz,
25 °C). To improve these values, in Chapter 3, we designed and synthesized dendritic and
non-dendritic polymersome-based MRI contrast agents. In this design, both alkynefunctionalized non-dendritic and dendritic Gd(III)-based contrast agents were first
synthesized and then installed onto the surface of azide-decorated PEO-PCL
polymersomes. The effects of the dendritic and polymersome components on the
relaxivities of the agents were elucidated. They were found to have an additive effect,
resulting in the highest currently reported r1 for a polymersome system. In addition, this
system possesses the advantage of being composed of PEO and biodegradable polyester
components. Therefore, this study not only enhanced the performance of the contrast
agents in terms of relaxivity, it also contributed to the fundamental understanding of the
contribution of different nano-scale components to enhancing this relaxivity.
To show the versatility of this functionalization approach and to demonstrate the
multifunctional potential of polymersomes, in Chapter 4, a multifunctional polymersome
system with the potential to interfere with the viral infection process at two levels was
developed. In this study, a 3rd generation polyester dendron decorated with Neu5Ac was
introduced to the surface of PEO-PCL polymersomes to inhibit the binding of influenza
virus hemagglutinin to Neu5Ac moieties on mammalian host cells. In addition, the
antiviral drug zanamivir was incorporated into the polymersome core with the aim of also
inhibiting influenza virus neuraminidase, thus preventing the release of progeny virus
from host cells. Using an enzyme-linked lectin inhibition assay, it was shown that
incorporation of the dendritic Neu5Ac onto the polymersome surface led to a nearly
2000-fold enhancement in binding affinity, showing the advantage of the polymersome
system for enhancing binding. Sustained release of the drug was also observed for this
system, with release occurring over a period of several days. This work represents the
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first multifunctional polymersome system with the potential to interfere with the viral
infection process.
The development of smart dendrimers that can respond to external stimuli is of
significant interest as this can impart new properties and further expand their scope of
applications. Among various stimuli, light is of particular interest as it can be applied at a
specific time and location with control over its intensity and wavelength. The examples
of photodegradable dendrimer systems in the literature have been limited to dendrimers
in which the photodegradable units were either at the core of the dendrimer or at the
junction between the hydrophobic and hydrophilic portions of amphiphilic dendrons. The
limitation of these approaches is that following photodegradation, in most cases residual
hydrophobic fragments may undergo aggregation in aqueous solutions. To address this
drawback, in Chapter 5, a new series of dendrons and dendrimers that are able for the
first time to undergo complete backbone photodegradation to small molecules was
designed and synthesized. This was done through the incorporation of photodegradable onitrobenzyl esters into a new dendrimer monomer based on bis-MPA. Dendrons were
synthesized using a divergent approach, and were subsequently coupled to a core
molecule in the final step via the microwave-assisted Cu(I)-catalyzed alkyne-azide click
reaction in high yields. Photolysis of these dendrimers were tracked using techniuqes
such as UV-visible and 1H NMR spectroscopy as well as SEC and it was demonstrated
that the dendrimers degrade to release the small molecule bis-MPA.
Incorporation of the photodegradable dendrons described in Chapter 5 into AJDs and
their self-assembly to different morphologies were discussed in Chapter 6. A small
library of AJDs (G1-3) with backbone photodegradable hydrophobic dendritic blocks and
hydrophilic blocks based on TEG and gallic acid were successfully synthesized. It was
shown that a 3rd generation AJD was able to undergo self-assembly to form well-defined
dendrimersomes with an average size of about 450 nm. Upon irradiation with UV light
(300-400 nm, 25 mWcm-2), the dendrimersomes' membranes were effectively disrupted
to disintegrate these assemblies with no sign of precipitation or morphological change to
smaller assemblies. This result is of significant interest because the photodegradable
dendrimersomes described in this chapter are the first example of any vesicular
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architecture (including polymersomes, dendrimersomes, and small amphiphile-based
vesicles) that are capable of complete photolytic membrane degradation to release their
encapsulated model drugs without creation of any smaller size micelles or precipitate.
Future investigations in the area of PEO-PCL polymersome-based biomaterials
involves evaluation of their actual antiviral potential against various strains of influenza
virus. This can be accomplished by initiating collaborative project with research groups
at the Department of Microbiology and Immunology at Western University. Moreover,
the concept of biodegradable and biocompatible polymersomes can be extended to
biodegradable and biocompatible dendrimersomes with activated azide surface groups by
synthesizing third or fourth generation AJDs constructed by bis-MBA-based hydrophobic
dendrons and TEG/gallic acid-based hydrophilic dendritic blocks. Given the higher order
of monodispersity that is offered by dendrimers compared to linear polymers, this can
potentially result in the development of the first example of a dendrimersome system
with activated surface groups that can readily be functionalized with various ligands of
interest.
In the context of backbone photodegradable dendrimers and dendrimer assemblies,
encapsulation and release behavior of these dendrimersomes with respect to both
hydrophilic and hydrophobic model drugs needs be investigated in a near future. In
longer term, tuning of their optical properties by changing the photochemically
responsive group or through the incorporation of other photophysical processes in such a
way that they can undergo photodegradation in the visible or NIR region can potentially
open up new opportunities to access materials with fully photodegradable hydrophobic
blocks suitable for biological or other applications. In addition, it would be interesting to
investigate to see whether or not it is possible to fine-tune the release rate of an
encapsulate model drug from photodegradable dendrimersomes. This can be done
through the selective incorporation of the photodegradable unit at specific generations
(G1, G2, or G3) of the AJDs. To accomplish this, a small library of three 3rd generation
AJDs with the photodegradable monomer unit incorporated at either the first, second, or
the third generation layer needs to be synthesized and their self-assembly to
dendrimersomes followed by their cargo release rates needs to be investigated.
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Appendix 2: Supporting Information for Chapter 2

Figure A2.1. 1H NMR spectrum of N3-PEO-OH (2.2) (400 MHz, CDCl3).

Figure A2.2. 1H NMR spectrum of copolymer 2.3 (400 MHz, CDCl3).
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Figure A2.3. 1H NMR spectrum of copolymer 2.4 (400 MHz, CDCl3).

Figure A2.4. 1H NMR spectrum of copolymer 2.5 (400 MHz, CDCl3).
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Figure A2.5. 1H NMR spectrum of copolymer 2.6 (400 MHz, CDCl3).

Figure A2.6. 1H NMR spectrum of rhodamine-labeled guanidine-functionalized dendron
2.8 (400 MHz, CD3OD).
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Figure A2.7. 1H NMR spectrum of rhodamine derivative 2.10 (400 MHz, CDCl3).

Figure A2.8. 1H NMR spectrum of rhodamine-labeled copolymer 2.11 (400 MHz,
CDCl3).
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Figure A2.9. 1H NMR spectrum of rhodamine-labeled copolymer 2.12 (400 MHz,
CDCl3).

Figure A2.10. 1H NMR spectrum of dendron 2.14 (400 MHz, (CD3)2SO).

172

Figure A2.11. MALDI-TOF mass spectrum of compound 2.2.
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Figure A2.12. Size distribution profiles following click reaction of rhodamine 2.10 on
vesicles.

Figure A2.13. Confocal microscopy of HeLa cells after incubation for 4 h with control
PEO-PCL micelles (rhodamine functionalization only): a) Differential interference
contrast image verifying the presence of cells in the field of view; b) Fluorescence image
taken using the same microscope settings used for the image in Figure 2.7 shows no
detectable uptake.
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Figure A3.1. IR spectra for: a) DTPA derivative 3.6; b) dendron 3.7; c) dendron 3.1.
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Figure A3.2. IR spectra for: a) DTPA derivative 3.6; b) compound 3.8; c) compound 3.2.
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Figure A3.3. Longitudinal relaxivity (r1) of dendron 3.1, polymersome 3.3, and
polymersome 3.4 in phosphate buffer (0.1 M, pH 7.4) as a function of field strength at
310 K.

Figure A3.4. Longitudinal relaxivity (r1) of unpurified 3.2 in phosphate buffer (0.1 M,
pH 7.4) as a function of field strength at 310 K. Note that the presence of excess Gd(III)
likely present as Gd(III)(H2O)8 increases the relaxivity.
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Table A3.1. NMRD data for 3.1, 3.3, and 3.4 at 298 K.
Dendron 3.1

Polymersome 3.3

Polymersome 3.4

Frequency
r1
± error
(MHz) (mM-1s-1) (mM-1s-1)

r1

± error

r1

± error

(mM-1s-1)

(mM-1s-1)

(mM-1s-1)

(mM-1s-1)

42.485
32.226
24.151
18.095
13.56
10.165
7.6177
5.7081
4.2784
3.2065
2.401
1.8005
1.3483
1.0104
0.75806
0.56802
0.42589
0.31839
0.23878
0.17926
0.13402
0.10033
0.07539
0.05663
0.04216
0.03178
0.02384
0.01787
0.01332
0.01005

29.1871
28.8367
27.3942
25.4439
24.2906
22.3345
20.4367
20.2217
19.4613
19.3263
19.5809
20.0514
20.4173
20.8922
21.3698
21.7274
22.0061
21.7189
22.1196
21.8339
22.4487
22.6929
22.6322
22.2902
22.4021
22.1639
23.2296
22.3151
22.7316
22.4915

1.42059
1.37637
1.3068
1.21532
1.23797
1.19751
0.98503
1.02722
0.98773
0.92909
0.93411
0.97972
0.9928
0.9895
1.01748
1.03445
1.04202
1.05168
1.09736
1.04392
1.08742
1.0932
1.09317
1.11094
1.11577
1.06491
1.14638
1.11062
1.1307
1.09679

13.9468
13.0277
12.5703
11.9149
11.5797
11.2655
10.6191
10.3709
10.2498
10.394
10.7171
10.849
10.9211
11.2019
11.4886
11.6184
11.5538
11.6476
11.6388
11.8268
11.8385
11.9043
11.821
11.8748
11.8676
11.819
11.8798
11.8476
11.8582
11.8228

0.35583
0.34114
0.35946
0.31532
0.37432
0.30497
0.26476
0.27915
0.24824
0.26049
0.25894
0.26617
0.26433
0.27076
0.27293
0.28249
0.27788
0.28257
0.28092
0.28324
0.29036
0.28695
0.31517
0.30641
0.29306
0.29499
0.28709
0.2852
0.28578
0.28582

11.2262
12.532
10.8241
10.4419
8.71823
7.61084
6.56897
7
7.42956
7.9399
7.23547
8.60099
8.75616
8.50837
8.40739
8.70394
8.6468
9.30443
9.38719
8.98621
9.65369
9.2335
9.44483
9.55961
9.57291
9.82512
10.3557
9.82217
9.86355
9.75123

0.4526
0.47005
0.39216
0.39374
0.36866
0.46985
0.3817
0.42405
0.41578
0.43684
0.39227
0.44634
0.44744
0.39931
0.38531
0.35741
0.36749
0.37775
0.3836
0.3988
0.36336
0.41176
0.38747
0.36876
0.3576
0.38554
0.42257
0.41358
0.39769
0.43025
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Table A3.2. NMRD data for 3.1, 3.3, and 3.4 at 298 K.
Dendron 3.1

Polymersome 3.3

Polymersome 3.4

Frequency
r1
(MHz) (mM-1s-1)

± error

r1

± error

r1

± error

(mM-1s-1)

(mM-1s-1)

(mM-1s-1)

(mM-1s-1)

(mM-1s-1)

42.485
32.226
24.151
18.095
13.56
10.165
7.6177
5.7081
4.2784
3.2065
2.401
1.8005
1.3483
1.0104
0.75806
0.56802
0.42589
0.31839
0.23878
0.17926
0.13402
0.10033
0.07539
0.05663
0.04216
0.03178
0.02384
0.01787
0.01332
0.01005

0.308419
0.297817
0.274025
0.27112
0.256736
0.278239
0.25443
0.23684
0.238939
0.244629
0.230666
0.243801
0.240478
0.248905
0.251679
0.25377
0.252389
0.256121
0.260583
0.259376
0.26436
0.271159
0.26105
0.261974
0.263527
0.269735
0.273295
0.26195
0.26032
0.257902

24.70432
24.32695
22.76779
22.62621
20.18495
18.49589
17.33842
17.1
16.54358
16.73642
17.21684
17.83
18.03611
18.38716
18.62432
18.94705
19.09358
19.66316
19.30158
19.65337
19.45042
19.16611
19.23768
19.69958
19.95242
19.43695
19.96768
19.37705
19.19758
18.79895

1.202339
1.155758
1.093878
1.143689
1.146539
0.994324
0.933652
0.829593
0.808106
0.863996
0.82571
0.867142
0.870415
0.890337
0.894888
0.902074
0.900006
0.993456
0.971088
1.000355
0.941913
0.964125
0.986247
0.963367
0.991791
0.970396
0.987754
0.942645
0.93875
0.949368

7.675889
8.508374
8.187685
8.252217
7.230542
7.226601
8.051232
8.232512
8.333005
8.324138
8.579803
8.837931
8.933498
9.749754
9.553202
9.370443
9.554187
9.399507
9.200985
10.14089
9.776355
8.791133
9.223645
9.727094
10.94581
9.330049
11.52217
10.90394
11.66059
9.871429

0.440764
0.430055
0.326891
0.299043
0.327636
0.373374
0.296329
0.332303
0.291729
0.299654
0.314226
0.308924
0.332639
0.369044
0.355386
0.363834
0.357284
0.317746
0.36774
0.408701
0.334029
0.312885
0.444246
0.362393
0.552264
0.466202
0.519033
0.478739
0.553324
0.493652

12.12974
11.57483
11.01165
10.7773
10.24124
9.982981
9.529907
9.277963
9.143037
9.123537
9.458981
9.874537
9.832926
10.1245
10.34187
10.38541
10.43285
10.40139
10.68167
10.60106
10.56869
10.71293
10.44635
10.56539
10.60959
10.62474
10.67987
10.6393
10.67291
10.57759
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Table A3.3. NMRD data for unpurified compound 3.2 at 298 and 310 K.
298 K
Frequency
r1
(MHz) (mM-1s-1)

310 K

± error

r1

(mM-1s-1)

(mM-1s-1)

± error
(mM-1s-1)

42.485 7.164357 0.239302 5.806553 0.198736
32.226
7.4717 0.26715 5.95605 0.215379
24.151
7.61 0.262536 6.12295 0.210226
18.095
7.84835 0.270608 6.39345 0.238233
13.56
7.81255 0.283246
6.5026 0.224501
10.165 7.442025 0.292533 5.94605 0.282405
7.6177
7.62545 0.265663 6.40275 0.239543
5.7081
7.9683 0.285034
6.863 0.251785
4.2784
8.0546 0.278805
6.9062 0.243733
3.2065
8.51975 0.290723 7.11605 0.247265
2.401
8.4612 0.286282
7.456 0.257229
1.8005
8.84115 0.296912 7.66125 0.268017
1.3483
8.9957 0.302398 7.78315 0.265708
1.0104
9.1258 0.306825
7.8839 0.261812
0.75806
9.1464 0.30944 7.87605 0.289503
0.56802
9.241 0.31658 7.83935 0.275286
0.42589
9.3689 0.317881 8.01545 0.269447
0.31839
9.29925 0.317361 7.88775 0.277594
0.23878
9.37455 0.320122
8.0635 0.278503
0.17926
9.46935 0.319043 7.95385 0.272022
0.13402
9.3859 0.315734
8.1297 0.274145
0.10033
9.3894 0.312762
8.0159 0.268276
0.075388
9.5268 0.314929 8.15365 0.276447
0.056625
9.3446 0.314749 8.15405 0.283728
0.042161
9.4225 0.32211
8.1109 0.272298
0.031778
9.4146 0.323253
7.9203 0.275189
0.023836
9.3698
0.3204 8.03265 0.276627
0.017874 9.43465 0.32513
8.1256 0.273448
0.013316 9.38825 0.319244
8.0661 0.279237
0.010053 9.32145 0.320652 8.10275 0.289865
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Figure A3.5. 1H NMR of dendron 3.7 (400 MHz , CD3OD).

Figure A3.6. 1H NMR of compound 3.8 (400 MHz , (CD3)2SO).
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Figure A4.1. Calibration curve for the determination of extinction coefficient of
rhodamine-labeled sialodendron 4.4.
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Figure A4.2. Size distribution profiles following functionalization of polymersomes
containing (a) 5 wt%; (b) 7 wt%; (c) 10 wt%; (d) 20 wt%; (e) 40 wt%; (f) 70 wt%; and
(g) 100 wt% azide copolymer 2.6 with the rhodamine-labeled sialodendron 4.4.
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Figure A4.3. Intensity-based size distribution profiles for polymersomes composed of a)
20% w/w azide-functionalized copolymer 2.6 and b) 40% w/w azide-functionalized
copolymer 2.6 following “click” conjugation of dendron 4.3.

Figure A4.4. Size distribution profiles for (a) zanamivir-loaded naked polymersomes
and (b) zanamivir loaded dendritic sialopolymersomes.
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Figure A4.5. a) Size distribution profile and b) TEM image of zanamivir-loaded naked
polymersomes after releasing the drug.

Figure A4.6. 1H NMR spectrum of compound 4.2 (400 MHz, CD3OD).
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Figure A4.7. 13C NMR spectrum of compound 4.2 (100 MHz, (CD3)2SO).

Figure A4.8. 1H NMR spectrum of sialodendron 4.3 (400 MHz, (CD3)2SO).
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Figure A4.9. 13C NMR spectrum of sialodendron 4.3 (100 MHz, (CD3)2SO).

Figure A4.10. 1H NMR spectrum of rhodamine-labeled sialodendron 4.4 (400 MHz,
(CD3)2SO).
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Figure A5.1. Evolution of UV-visible spectra for a) G1 dendrimer (5.14) and b) G2
dendrimer (5.15) upon irradiation with 350 nm light for 60 minutes.
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Figure A5.2. Evolution of 1H NMR spectra during the photolysis of G1 dendrimer (5.14)
in (CD3)2SO at 400 MHz.
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Figure A5.3. Evolution of 1H NMR spectra during the photolysis of G2 dendrimer (5.15)
in (CD3)2SO at 400 MHz.

190

Figure A5.4. Evolution of 1H NMR spectra during the photolysis of G3 dendrimer (5.16)
in (CD3)2SO at 400 MHz.
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Figure A5.5. SEC traces of a) G1 dendrimer 5.14, b) G2 dendrimer 5.15, and c) G3
dendirmer 5.16 before and after UV degradation.

Figure A5.6. MALDI-TOF spectra for a) G1 dendrimer 5.14, b) G2 dendrimer 5.15, and
c) G3 dendrimer 5.16. It should be noted that the laser used for MALDI-TOF
experiments operates at 360 nm and thus effectively photodegrades the dendrimers. As a
result, some photodegradation products were also observed in these spectra, which are
not shown.
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Figure A5.7. 1H NMR spectrum of compound 5.2 (400 MHz, CDCl3).

Figure A5.8. 13C NMR spectrum of compound 5.2 (100 MHz, CDCl3).
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Figure A5.9. 1H NMR spectrum of compound 5.4 (400 MHz, CDCl3).

Figure A5.10. 13C NMR spectrum of compound 5.4 (100 MHz, CDCl3).
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Figure A5.11. 1H NMR spectrum of compound 5.5 (400 MHz, CDCl3).

Figure A5.12. 13C NMR spectrum of compound 5.5 (100 MHz, CDCl3).
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Figure A5.13. 1H NMR spectrum of compound 5.6 (400 MHz, CDCl3).

Figure A5.14. 13C NMR spectrum of compound 5.6 (100 MHz, CDCl3).
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Figure A5.15. 1H NMR spectrum of compound 5.7 (400 MHz, CDCl3).

Figure A5.16. 13C NMR spectrum of compound 5.7 (100 MHz, CDCl3).
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Figure A5.17. 1H NMR spectrum of compound 5.8 (400 MHz, CDCl3).

Figure A5.18. 13C NMR spectrum of compound 5.8 (100 MHz, CDCl3).
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Figure A5.19. 1H NMR spectrum of compound 5.9 (400 MHz, CDCl3).

Figure A5.20. 13C NMR spectrum of compound 5.9 (100 MHz, CDCl3).
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Figure A5.21. 1H NMR spectrum of compound 5.10 (400 MHz, CDCl3).

Figure A5.22. 13C NMR spectrum of compound 5.10 (100 MHz, CDCl3).
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Figure A5.23. 1H NMR spectrum of compound 5.11 (400 MHz, CDCl3).

Figure A5.24. 13C NMR spectrum of compound 5.11 (100 MHz, CDCl3).
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Figure A5.25. 1H NMR spectrum of compound 5.12 (400 MHz, CDCl3).

Figure A5.26. 13C NMR spectrum of compound 5.12 (100 MHz, (CD3)2SO).
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Figure A5.27. 1H NMR spectrum of compound 5.14 (400 MHz, (CD3)2SO).

Figure A5.28. 13C NMR spectrum of compound 5.14 (100 MHz, (CD3)2SO).
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Figure A5.29. 1H NMR spectrum of compound 5.15 (400 MHz, (CD3)2SO).

Figure A5.30. 13C NMR spectrum of compound 5.15 (100 MHz, (CD3)2SO).
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Figure A5.31. 1H NMR spectrum of compound 5.16 (400 MHz, (CD3)2SO).

Figure A5.32. 13C NMR spectrum of compound 5.16 (100 MHz, (CD3)2SO).
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Figure A6.1. 1H NMR spectrum of compound 6.2 (400 MHz, CDCl3).

Figure A6.2. 13C NMR spectrum of compound 6.2 (100 MHz, CDCl3).
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Figure A6.3. 1H NMR spectrum of compound 6.3 (400 MHz, CDCl3).

Figure A6.4. 13C NMR spectrum of compound 6.3 (100 MHz, CDCl3).
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Figure A6.5. 1H NMR spectrum of compound 6.4 (400 MHz, CDCl3).

Figure A6.6. 13C NMR spectrum of compound 6.4 (100 MHz, CDCl3).
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Figure A6.7. 1H NMR spectrum of compound 6.5 (400 MHz, CDCl3).

Figure A6.8. 13C NMR spectrum of compound 6.5 (100 MHz, CDCl3).
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Figure A6.9. 1H NMR spectrum of compound 6.6 (400 MHz, CDCl3).

Figure A6.10. 13C NMR spectrum of compound 6.6 (100 MHz, CDCl3).
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